Application of BCMAP329G antibody and CAR-T cell in treatment of multiple myeloma
Through the molecular switching system that binds P329G mutant antibodies to CAR-T cells, the problems of toxicity and recurrence of traditional CAR-T cell therapy are solved, and safer and more effective multiple myeloma treatment is achieved, reducing treatment costs and increasing the cost of treatment Treatment versatility.
Patent Information
- Application Number
- CN202310524366.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-10
- Publication Date
- 2024-11-12
AI Technical Summary
Traditional CAR-T cell therapy has toxicity and recurrence problems in the treatment of multiple myeloma, making it difficult to effectively control the activity of CAR-T cells, resulting in acute and chronic side effects, and it is difficult to determine the correct time point for clearance, affecting long-term anti-tumor efficacy.
A molecular switch system is designed to bind to CAR-T cells through P329G mutant antibodies. It uses P329G to specifically bind BCMA antigen to regulate the activity of CAR-T cells, and regulate the frequency, dose and pathway of antibody administration. Amplify and survive in vivo, avoid toxic and side effects, and overcome tumor resistance and recurrence problems without changing CAR-T cells.
Effectively reduce the acute and chronic toxic and side effects of traditional CAR-T cell therapy, promote the long-lasting anti-tumor effect of CAR-T cells, improve the safety and flexibility of treatment, prolong the survival of CAR-T cells, and improve the The treatment versatility of different tumors and reduces the cost of treatment.
Smart Images

Figure SMS_4 
Figure SMS_7 
Figure SMS_8
Abstract
Description
Technical Field
[0001] The present invention generally relates to the fields of antibody engineering and cellular immunology. Specifically, the present invention relates to a combination of an antibody comprising a P329G mutation that specifically binds to a B-cell maturation antigen protein (BCMA) and an immune effector cell (e.g., T cell, NK cell) engineered to express a molecular switch-regulated chimeric antigen receptor, and a therapeutic method using the combination, and to the use of the combination in treating diseases associated with the expression of BCMA, such as cancers that express or overexpress BCMA. Background Art
[0002] B cell maturation antigen (BCMA, i.e. CD269, TNFRSF17) is a member of the tumor necrosis factor receptor superfamily (TNFRSF). BCMA is a type III transmembrane protein with a cysteine-rich domain (CRD) characteristic of TNFR family members in the extracellular domain (ECD), which forms a ligand binding motif. BCMA's ligands include B cell activating factor (BAFF) and B cell proliferation inducing ligand (APRIL), of which B cell proliferation inducing ligand (APRIL) binds to BCMA with higher affinity and promotes tumor cell proliferation.
[0003] BCMA is mainly expressed on the surface of mature B cells, i.e. plasma cells, and is not expressed in normal hematopoietic stem cells and non-hematopoietic tissues. BCMA signaling is essential for the survival of long-term bone marrow plasma cells, but is not necessary for overall B cell homeostasis. BCMA on the membrane surface can be cleaved and shed by γ-secretase, and the resulting soluble BCMA (sBCMA) may reduce the signal transduction of BCMA on the membrane surface by blocking BAFF / APRIL ligand binding. BCMA has been found to be overexpressed in multiple myeloma (MM) cells in preclinical models and human tumors. It upregulates classical and non-classical NF-κB signals, promotes MM cell growth, survival, adhesion, induces osteoclast activation, angiogenesis, metastasis and immunosuppression, etc. BCMA expression has become an important marker for the diagnosis of MM. In addition, the level of sBCMA in the serum of MM patients is increased, which is positively correlated with the number of MM cells in the bone marrow, and its concentration changes are closely related to MM prognosis and treatment response.
[0004] Multiple myeloma (MM) is the second most common malignant tumor in the blood system, which often occurs in the elderly. It is characterized by the uncontrollable progressive proliferation of plasma cell clones, which produce monoclonal immunoglobulins (Ig) or protein fragments (M proteins) that have lost their functions. The disease can reduce the patient's resistance to infection, cause severe bone deformation (accompanied by bone pain, pathological fractures and hypercalcemia), anemia, renal failure, neurological complications and hyperviscosity syndrome, and the progression of the disease will eventually lead to death.
[0005] Multiple myeloma has a high incidence and mortality rate. Research by the International Myeloma Working Group (IMWG) showed that the 5-year overall survival rates of patients in International Staging System (R-ISS) stages I, II, and III were 82%, 62%, and 40%, respectively, and the 5-year progression-free survival rates were 55%, 36%, and 24%, respectively. The treatment options for multiple myeloma depend on age, physical status, comorbidities, disease aggressiveness, and related prognostic factors. With the advent of new immunomodulators such as thalidomide and lenalidomide and the first-generation proteasome inhibitors (PIs), With the introduction of bortezomib, the treatment of multiple myeloma has undergone dramatic changes in the past 10 years. Some randomized controlled clinical studies have shown that new drug treatments for multiple myeloma have significantly increased the remission rate and improved progression-free survival (PFS) and overall survival (OS). In general, new treatments for multiple myeloma have significantly improved patient outcomes. However, due to the residual myeloma stem cells, changes in the cell microenvironment, activation of anti-apoptotic pathways, expression of drug-resistant genes, or clonal evolution, the vast majority of patients will eventually face disease recurrence or progression. The low remission rate and short median survival of relapsed / refractory multiple myeloma (RRMM) seriously endanger the health of patients.
[0006] Abecma is the first CAR-T cell therapy targeting BCMA. It recognizes and binds to the BCMA protein on multiple myeloma cancer cells, causing the death of cancer cells expressing the BCMA protein. That is, it directly targets the surface antigen BCMA protein of tumor cells through the chimeric antigen receptor (CAR) on the CAR-T cells, thereby achieving the purpose of identifying and killing tumor cells. The disadvantage of this traditional chimeric antigen receptor T cell is that there is a lack of control over the activity of CAR-T cells after infusion. After activation in vivo, these CAR-T cells will continue to recognize and kill cells expressing their targeted antigens. In some cases (such as large tumors in tumor patients), a large number of rapidly activated CAR-T cells will release massive inflammatory cytokines, causing patients to have cytokine release syndrome (CRS), neurotoxicity (NT) and other serious side effects. A meta-study of 84 clinical trials with 2,592 patients showed that the incidence of CRS and NT above grade 3 after receiving traditional CAR-T cell therapy was 29% and 28%, respectively. Although a large number of clinical trials have found that most patients who experience toxic reactions can recover quickly after receiving corresponding treatments and do not significantly affect the anti-tumor efficacy, the treatment of toxic and side effects takes up a lot of clinical resources and increases the physical, mental and economic burden on patients.
[0007] Since most CAR-T cells (e.g., Abecma) target antigens that are tumor-associated antigens (TAAs) rather than tumor-specific antigens (TSAs), these TAAs are often expressed at low levels in many normal tissues, especially important tissues and organs, in addition to being expressed on tumor cells. The recognition and killing of the normal tissues by CAR-T cells leads to "on-target / off tumor" toxicity, which the body may be able to tolerate in the short term, but if it cannot be recovered or alleviated for a long time, it may cause serious side effects. For example, CAR-T cells targeting CD19 are used clinically to treat CD19-positive blood tumors. In addition to clearing tumor cells, CD19 CAR-T cells also kill normal B cells. Although the continued presence of CAR-T cells in the body is closely related to the patient's long-term recurrence-free survival, it also leads to long-term B cell dysplasia and lack of humoral immunity in the body, which is prone to infection. Clinical trials have shown that 27-36% of lymphoma patients develop bacterial infections within 30 days after receiving CD19 CAR-T cell therapy, 9.2-28% develop viral infections one month later, and it takes a median of 6.7 months for B cells to recover. 31-64% of patients need to receive immunoglobulin replacement therapy. In addition, continuous activation of CAR-T cells in the body can easily lead to functional exhaustion, impairing their anti-tumor effects and reducing their persistence in the body, thereby reducing long-term treatment effects.
[0008] In order to reduce the "on-target / off tumor" toxicity of CAR-T cells, the following strategies are generally used in the prior art. One strategy is to design the antigen binding domain contained in the CAR to target the target antigen that is highly expressed on the tumor surface but not expressed or lowly expressed in normal tissues during CAR design. Another strategy is to strictly control the dose of T cells administered, because too many CAR-T cells will increase exponentially after being stimulated by antigens, which is more likely to cause on-target / off-tumor effects. Another strategy is to introduce an inducible suicide gene, such as the inducible Caspase-9 (iCasp9) suicide gene, when constructing CAR. When patients are observed to experience on-target / off-tumor toxicity, AP1903 (a dimerization chemical inducer that can activate iCasp9) is administered to induce apoptosis of CAR-T cells and reduce toxicity (Zhang Huihui et al., Preclinical study of suicide genes as a "safety switch" to control CAR-T cell toxicity, Chinese Journal of Oncology Biotherapy, 2021, 28(3): 225-231). There are also reports of using the herpes simplex virus thymidine kinase (HSV-TK) gene as a suicide gene to induce apoptosis of CAR-T cells by administering ganciclovir. In addition, there are also reports of using electroporation transfection methods to make T cells transiently express CAR, which exerts a therapeutic effect through transient killing function (Kenderian SS et al., CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia [J] Leukemia. 2015; 29 (8): 1637-1647). However, the above-mentioned regulatory methods are all carried out after toxicity occurs, and the toxicity alleviation effect depends on the effect and efficiency of drug clearance of CAR-T cells. Moreover, CAR-T cells cannot be restored after clearance, which affects the long-term anti-tumor efficacy.
[0009] However, these methods make it difficult to determine the correct time point for CAR-T cell clearance. In principle, there are two key time points where CAR-T cell activity needs to be adjusted or even terminated: (1) after CAR-T cell infusion, serious side effects occur; (2) after CAR-T cells eliminate all tumor cells and then continue to attack important healthy tissues. Because CAR-T cells are "living" drugs, it is difficult to predict how they will react in the body, making it difficult to determine the correct time point for clearance. Therefore, if CAR-T cells can be equipped with a certain switch with two "on and off" modes, the "switch" can be turned on when needed to release the anti-tumor activity of CAR-T cells; after CAR-T cells complete their tasks or in the event of serious side effects, the "switch" can be turned off, thereby controlling and regulating the activity of CAR-T cells, which will greatly improve the safety and flexibility of CAR-T cell use.
[0010] At present, a variety of "switch" strategies have been developed to control the activity of CAR-T cells, among which the strategy with significant clinical application prospects is "modular" universal CAR-T cells. Unlike traditional CAR-T cells, mod-uCAR-T cells do not directly target tumor cell antigens, but "match" CAR-T cells with tumor cells through intermediate bridging molecules (adaptors) to activate the anti-tumor effect of CAR-T cells. Once the adapter is cleared in the body, the CAR-T cells are inactivated, which can effectively prevent the "off-target" effect. Another benefit of using this adapter switch strategy is that by giving different or even dual-targeted adapter molecules simultaneously or sequentially, CAR-T cells can target different tumor cell antigens simultaneously or successively, thereby potentially overcoming problems such as tumor recurrence and drug resistance caused by tumor heterogeneity. In this case, only the adapter molecule needs to be changed, and the CAR molecule does not need to be changed. Therefore, this "conditionally activated" CAR-T cell has good versatility.
[0011] There is a need in the art for a therapeutic approach that can "conditionally activate" CAR-T cells while applying CAR-T cells and controlling their toxicity, particularly a therapeutic approach with a specific dose and / or dosing interval. SUMMARY OF THE INVENTION
[0013] Traditional CAR-T cells targeting BCMA still face toxicity and relapse problems in the treatment of MM. A meta-study showed that the incidence of CRS and NT after receiving traditional CAR-T cell therapy targeting BCMA was 74% (95% CI, 56–91%) and 34% (95% CI, 24–43%), of which the incidence of grade 3 and above events was 25% (95% CI, 7–43%) and 12% (95% CI, 4–20%), respectively. In addition, the humoral immunity of the treated patients was impaired due to the loss of plasma cells in the body, and the incidence of infection increased. Among the 128 patients with relapsed and refractory multiple myeloma (RRMM) treated with ide-cel, 69% had infection, and the incidence of grade 3 and above infection was 22%. Most patients needed to receive anti-infection, white blood cell growth factor and immunoglobulin replacement therapy. Similarly, among the 97 RRMM patients treated with Cilta-cel, 56% and 20% had infection and grade 3 and above infection. These clinical results suggest the need to develop a regulatable BCMA-targeted CAR-T cell therapy.
[0014] Based on the P329G mod-uCAR-T cell technology, the inventors have designed and constructed P329G CAR-T cells that target BCMA by binding to the Fc domain of an antibody that specifically binds to BCMA molecules containing the P329G mutation, and verified its specific and controllable anti-tumor effects in vivo and in vitro. Different from traditional BCMA-targeted CAR-T cells that directly recognize and kill MM cells, the drug combination of the present invention includes two components: BCMA-specific P329G antibody and P329GCAR-T cells. After the BCMA-specific P329G antibody recognizes tumor cells expressing BCMA, the P329G antibody acts as an adaptor molecule to bridge the P329GCAR-T cells and tumor cells together, and the P329G CAR-T cells are redirected to tumor cells by recognizing the Fc domain of the P329G antibody, producing target-specific tumor recognition and killing effects (see Figure 1B ). In the therapeutic method using the drug combination of the present invention, the P329G antibody acts as a bridge connecting the P329G CAR-T cells and tumor cells, plays a "molecular switch" role, and regulates the activity of the P329G CAR-T cells.
[0015] The CAR-T cell products developed by this technology have the following significant features: 1. By adjusting the frequency, dosage, route and function of antibody administration, the acute and chronic toxic effects of traditional CAR-T cell therapy can be effectively avoided, and the continuous proliferation and survival of CAR-T cells in vivo can be promoted to achieve a lasting anti-tumor effect; 2. By combining and sequentially administering antibodies, clinical pain points such as primary tumor resistance and recurrence after treatment can be effectively overcome without changing CAR-T cells; 3. By combining antibodies targeting different types of tumor antigens, the purpose of treating different tumors can be achieved without changing CAR-T cells. As the antibody drug market is mature and the cost is low, this therapy will help reduce treatment costs and improve the accessibility of CAR-T cell therapy.
[0016] Therefore, in a first aspect, the present invention provides P329G mutant antibodies capable of specifically binding to BCMA molecules as a "molecular switch" for immune effector cells (e.g., T cells, NK cells) expressing CAR polypeptides, including but not limited to ADI-38497 PG Ab (also referred to herein as "ADI-38497 PG antibody", "38497 PG Ab", "ADI-38497 PG IgG", "38497 PG IgG", "PG 38497 antibody").
[0017] In some embodiments, the present invention obtains an antibody or antigen-binding fragment that specifically binds to a BCMA molecule, comprising a heavy chain variable region and a light chain variable region, wherein:
[0018] The heavy chain variable region comprises a CDR H1 as shown in the amino acid sequence SSSYYWT (SEQ ID NO: 25) according to Kabat numbering, or a variant of the CDR H1 with no more than 2 amino acid changes or no more than 1 amino acid change; a CDR H2 as shown in the amino acid sequence SISIAGSTYYNPSLKS (SEQ ID NO: 26), or a variant of the CDR H2 with no more than 2 amino acid changes or no more than 1 amino acid change; and a CDRH3 as shown in the amino acid sequence DRGDQILDV (SEQ ID NO: 27), or a variant of the CDR H3 with no more than 2 amino acid changes or no more than 1 amino acid change; the light chain variable region comprises a CDR L1 as shown in the amino acid sequence RASQSISRYLN (SEQ ID NO: 28) according to Kabat numbering, or a variant of the CDR L1 with no more than 2 amino acid changes or no more than 1 amino acid change; a CDR L2 as shown in the amino acid sequence AASSLQS (SEQ ID NO: 29), or a variant of the CDR L2 with no more than 2 amino acid changes or no more than 1 amino acid change; and CDR L3 shown in the amino acid sequence QQKYFDIT (SEQ ID NO: 30), or a variant of the CDR L3 with no more than 2 amino acid changes or no more than 1 amino acid change; wherein the amino acid change is an addition, deletion or substitution of an amino acid.
[0019] In some embodiments, the present invention provides an antibody or antigen-binding fragment that specifically binds to a BCMA molecule, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a CDR H1 shown in the amino acid sequence SSSYYWT (SEQ ID NO:25) according to Kabat numbering; a CDR H2 shown in the amino acid sequence SISIAGSTYYNPSLKS (SEQ ID NO:26); and a CDR H3 shown in the amino acid sequence DRGDQILDV (SEQ ID NO:27); the light chain variable region comprises a CDR L1 shown in the amino acid sequence RASQSISRYLN (SEQ ID NO:28) according to Kabat numbering; a CDR L2 shown in the amino acid sequence AASSLQS (SEQ ID NO:29); and a CDRL3 shown in the amino acid sequence QQKYFDIT (SEQ ID NO:30).
[0020] In some embodiments, the present invention obtains an antibody or antigen-binding fragment that specifically binds to a BCMA molecule, which comprises a heavy chain variable region, wherein the heavy chain variable region comprises the sequence of SEQ ID NO: 2, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto.
[0021] In some embodiments, the present invention obtains an antibody or antigen-binding fragment that specifically binds to a BCMA molecule, which comprises a light chain variable region, wherein the light chain variable region comprises the sequence of SEQ ID NO: 3, or a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.
[0022] In some embodiments, the present invention obtains an antibody or antigen-binding fragment that specifically binds to a BCMA molecule, which comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises the sequence of SEQ ID NO:2, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity thereof; and the light chain variable region comprises the sequence of SEQ ID NO:3, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity thereof.
[0023] In some embodiments, the present invention obtains an antibody or antigen-binding fragment that specifically binds to a BCMA molecule, which comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises the sequence of SEQ ID NO: 2, and the light chain variable region comprises the sequence of SEQ ID NO: 3.
[0024] In some embodiments, the antibody of the present invention that specifically binds to a BCMA molecule is an IgG1, IgG2, IgG3, or IgG4 antibody; preferably, it is an IgG1 or IgG4 antibody; more preferably, it is an IgG1 antibody.
[0025] In some embodiments, the antigen-binding fragment of the antibody of the present invention that specifically binds to the BCMA molecule is Fab, Fab', F(ab')2, Fv, single-chain Fv, single-chain Fab, diabody.
[0026] For the antibody or antigen-binding fragment that specifically binds to the BCMA molecule, an antibody having a mutant Fc domain is obtained by mutating the amino acid at position P329 according to EU numbering to glycine (G), wherein the Fcγ receptor binding of the mutant Fc domain is reduced compared to the Fcγ receptor binding of the non-mutated parent antibody Fc domain.
[0027] In some embodiments, the mutant Fc domain is a mutant Fc domain of an IgG1, IgG2, IgG3 or IgG4 antibody, preferably, the mutant Fc domain is a mutant Fc domain of an IgG1 or IgG4 antibody; more preferably, the mutant Fc domain is a mutant Fc domain of an IgG1 antibody;
[0028] In some embodiments, the antibody or antigen-binding fragment that specifically binds to the BCMA molecule comprises the heavy chain constant region sequence shown in SEQ ID NO:5, or a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical thereto, and wherein the amino acid at position P329 according to EU numbering is mutated to G.
[0029] In some embodiments, the antibody or antigen-binding fragment that specifically binds to the BCMA molecule comprises a light chain constant region sequence shown in SEQ ID NO:6, or a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical thereto.
[0030] In some embodiments, the antibody or antigen-binding fragment that specifically binds to the BCMA molecule comprises a heavy chain constant region and a light chain constant region, wherein the heavy chain constant region comprises the amino acid sequence set forth in SEQ ID NO:5, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity thereof and wherein the amino acid at position P329 according to EU numbering is mutated to G; and the light chain constant region comprises the amino acid sequence set forth in SEQ ID NO:6, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity thereof.
[0031] In one embodiment, the antibody or antigen-binding fragment that specifically binds to the BCMA molecule comprises the heavy chain constant region sequence shown in SEQ ID NO:5 and the light chain constant region sequence shown in SEQ ID NO:6.
[0032] In some embodiments, the present invention obtains an antibody or antigen-binding fragment that specifically binds to a BCMA molecule, comprising a heavy chain, wherein the heavy chain comprises the sequence of SEQ ID NO: 34, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto and wherein the amino acid at position P329 according to EU numbering is mutated to G.
[0033] In some embodiments, the present invention obtains an antibody or antigen-binding fragment that specifically binds to a BCMA molecule, comprising a light chain, wherein the light chain comprises the sequence of SEQ ID NO: 35, or a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical thereto.
[0034] In some embodiments, the present invention obtains an antibody or antigen-binding fragment that specifically binds to a BCMA molecule, comprising a heavy chain and a light chain, wherein the heavy chain comprises the sequence of SEQ ID NO:34, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity thereof and wherein the amino acid at position P329 according to EU numbering is mutated to G; and the light chain comprises the sequence of SEQ ID NO:35, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity thereof.
[0035] In some embodiments, the present invention obtains an antibody or antigen-binding fragment that specifically binds to a BCMA molecule, which comprises a heavy chain and a light chain, wherein the heavy chain comprises the sequence of SEQ ID NO: 34, and the light chain comprises the sequence of SEQ ID NO: 35.
[0036] In a second aspect, the present invention provides a nucleic acid encoding the antibody of the first aspect of the present invention, a vector comprising the nucleic acid encoding the antibody, a cell comprising the nucleic acid molecule or vector, and a method for preparing the antibody, the method comprising culturing a host cell into which an expression vector encoding the nucleic acid encoding the antibody or antigen-binding fragment that specifically binds to the BCMA molecule of the first aspect of the present invention is introduced under conditions suitable for expressing the nucleic acid encoding the antibody or antigen-binding fragment that specifically binds to the BCMA molecule of the first aspect of the present invention, isolating the antibody or antigen-binding fragment that specifically binds to the BCMA molecule, and optionally the method further comprises recovering the antibody or antigen-binding fragment that specifically binds to the BCMA molecule from the host cell. Preferably, the host cell is prokaryotic or eukaryotic, more preferably selected from Escherichia coli cells, yeast cells, mammalian cells or other cells suitable for preparing antibodies or antigen-binding fragments thereof, and most preferably, the host cell is a HEK293 cell or a CHO cell.
[0037] In a third aspect, the present invention provides a pharmaceutical combination comprising
[0038] (i) a first component selected from immune effector cells (e.g., T cells, NK cells) expressing a molecular switch-regulated CAR polypeptide, a nucleic acid molecule encoding the CAR polypeptide, a vector comprising the nucleic acid molecule, and any combination thereof; and
[0039] (ii) a second component, which is an antibody or antigen-binding fragment that specifically binds to a BCMA molecule and comprises a P329G mutation (also referred to as a P329G mutant antibody), for example, the P329G mutant antibody of the first aspect of the invention, and
[0040] Optionally, pharmaceutically acceptable excipients;
[0041] Wherein, the molecular switch regulated CAR polypeptide comprises
[0042] (1) A humanized anti-P329G mutant scFv sequence, wherein the scFv sequence comprises the following sequence that can specifically bind to the Fc domain of an antibody comprising the P329G mutation, but cannot specifically bind to the Fc domain of an unmutated parent antibody:
[0043] (i) a heavy chain variable region comprising a
[0044] (a) a heavy chain complementary determining region CDR H1 represented by the amino acid sequence RYWMN (SEQ ID NO: 19), or a variant of said CDRH1 having no more than 2 amino acid changes or no more than 1 amino acid change;
[0045] (b) CDR H2 shown in the amino acid sequence EITPDSSTINYAPSLKG (SEQ ID NO: 20), or a variant of said CDR H2 with no more than 2 amino acid changes or no more than 1 amino acid change; and
[0046] (c) CDR H3 shown by the amino acid sequence PYDYGAWFAS (SEQ ID NO: 21), or a variant of said CDR H3 with no more than 2 amino acid changes or no more than 1 amino acid change; and
[0047] (ii) a light chain variable region comprising a
[0048] (d) a light chain complementary determining region (CDR L) 1 shown by the amino acid sequence RSSTGAVTTSNYAN (SEQ ID NO: 22), or a variant of said CDR L1 with no more than 2 amino acid changes or no more than 1 amino acid change;
[0049] (e) CDR L2 shown by the amino acid sequence GTNCRAP (SEQ ID NO: 23), or a variant of said CDR L2 with no more than 2 amino acid changes or no more than 1 amino acid change; and
[0050] (f) a CDR L3 represented by the amino acid sequence ALWYSNHWV (SEQ ID NO: 24), or a variant of said CDR L3 having no more than 2 amino acid changes or no more than 1 amino acid change;
[0051] wherein the amino acid change is an addition, deletion or substitution of an amino acid;
[0052] (2) a hinge region / spacer region selected from
[0053] (i)(G4S) n 、(SG4) n or G4(SG4) n A peptide linker, wherein "n" is an integer from 1 to 10, such as an integer from 1 to 4; for example, the sequence shown in SEQ ID NO: 14;
[0054] (ii) a CD8α hinge region or a variant thereof having 1-5 amino acid modifications, for example, the sequence shown in SEQ ID NO: 18 or a variant thereof having 1-2 amino acid modifications;
[0055] (3) a transmembrane region (TM), which is selected from the CD8 transmembrane domain or a variant thereof having 1-5 amino acid modifications, for example, the sequence shown in SEQ ID NO: 15 or a variant thereof having 1-2 amino acid modifications;
[0056] (4) a co-stimulatory signaling domain (CSD) selected from a 4-1BB co-stimulatory domain or a variant thereof having 1-5 amino acid modifications, for example, a sequence as shown in SEQ ID NO: 16 or a variant thereof having 1-2 amino acid modifications;
[0057] (5) a stimulatory signaling domain (SSD), which is a CD3δ signaling domain or a variant thereof having 1-10 amino acid modifications, for example, the sequence shown in SEQ ID NO: 17 or a variant thereof having 1-10 or 1-5 amino acid modifications;
[0058] The amino acid modification is the addition, deletion or substitution of amino acids.
[0059] In some embodiments, the molecular switch-regulated CAR polypeptide in the pharmaceutical combination of the present invention comprises
[0060] (1) A humanized anti-P329G mutant scFv sequence, wherein the scFv sequence comprises the following sequence that can specifically bind to the Fc domain of an antibody comprising the P329G mutation, but cannot specifically bind to the Fc domain of an unmutated parent antibody:
[0061] (i) a heavy chain variable region comprising a
[0062] (a) CDR H1 represented by the amino acid sequence RYWMN (SEQ ID NO: 19);
[0063] (b) CDR H2 represented by the amino acid sequence EITPDSSTINYAPSLKG (SEQ ID NO: 20); and
[0064] (c) CDR H3 represented by the amino acid sequence PYDYGAWFAS (SEQ ID NO: 21); and
[0065] (ii) a light chain variable region comprising a
[0066] (d) CDR L1 represented by the amino acid sequence RSSTGAVTTSNYAN (SEQ ID NO: 22);
[0067] (e) CDR L2 represented by the amino acid sequence GTNCRAP (SEQ ID NO: 23); and
[0068] (f) CDR L3 represented by the amino acid sequence ALWYSNHWV (SEQ ID NO: 24);
[0069] For example, (i) a heavy chain variable region comprising the sequence of SEQ ID NO: 12, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto, and
[0070] (ii) a light chain variable region comprising the sequence of SEQ ID NO: 13, or a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto;
[0071] For example, (i) a heavy chain variable region comprising the sequence of SEQ ID NO: 12, and (ii) a light chain variable region comprising the sequence of SEQ ID NO: 13;
[0072] (2) a hinge region / spacer region selected from
[0073] (i)(G4S) n 、(SG4) n or G4(SG4) n A peptide linker, wherein "n" is an integer from 1 to 4, such as the sequence shown in SEQ ID NO: 14;
[0074] (ii) the CD8α hinge region sequence shown in SEQ ID NO: 18 or a variant thereof having one amino acid modification;
[0075] (3) a transmembrane region (TM), which is selected from the CD8 transmembrane domain shown in SEQ ID NO: 15 or a variant thereof having one amino acid modification;
[0076] (4) a co-stimulatory signaling domain (CSD) selected from the 4-1BB co-stimulatory domain shown in SEQ ID NO: 16 or a variant thereof having one amino acid modification;
[0077] (5) a stimulatory signaling domain (SSD) selected from the CD3δ signaling domain shown in SEQ ID NO: 17 or a variant thereof having one amino acid modification;
[0078] The amino acid modification is the addition, deletion or substitution of amino acids.
[0079] In some embodiments, the molecular switch-regulated CAR polypeptide in the pharmaceutical combination of the present invention further comprises a signal peptide sequence at the N-terminus, for example, a signal peptide sequence as shown in SEQ ID NO: 11,
[0080] In some embodiments, the molecular switch-regulated CAR polypeptide described in the drug combination of the present invention has the amino acid sequence shown in SEQ ID NO: 1, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto.
[0081] In a fourth aspect, the present invention provides a nucleic acid encoding the molecular switch regulated CAR polypeptide described in the drug combination of the present invention, a vector comprising a nucleic acid encoding the CAR polypeptide, and a cell comprising the CAR nucleic acid molecule or vector, or a cell expressing the CAR polypeptide, preferably, the cell is an autologous T cell or an allogeneic T cell.
[0082] In some embodiments, the nucleic acid molecule encoding the molecular switch-regulated CAR polypeptide described in the drug combination of the present invention is a nucleic acid molecule encoding the amino acid sequence shown in SEQ ID NO: 1 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto.
[0083] In some embodiments, the vector comprising the nucleic acid molecule encoding the molecular switch-regulated CAR polypeptide described in the drug combination of the present invention is selected from a DNA vector, an RNA vector, a plasmid, a lentiviral vector, an adenoviral vector or a retroviral vector.
[0084] In some embodiments, the immune effector cells in the drug combination of the present invention are autologous T cells, NK cells or allogeneic T cells, NK cells prepared from T cells and NK cells expressing the molecular switch regulated CAR polypeptide of the present invention. For example, the immune effector cells are T cells and NK cells prepared from T cells and NK cells isolated from human peripheral blood mononuclear cells (PBMC) and expressing the molecular switch regulated CAR polypeptide of the present invention.
[0085] In some embodiments, the present invention utilizes primary P329G CAR-T cells prepared from human PBMCs from multiple different donor sources, and utilizes P329G mutated anti-BCMA humanized antibodies to evaluate the effector function of P329G CAR-T cells against BCMA-expressing tumor cells through antibodies in an in vitro co-culture system. Thus, the P329G mutated anti-BCMA antibody can act as a "molecular switch" to regulate the recognition and killing activity of P329G CAR-T cells against BCMA-positive tumor cells. This in vitro effector function is comparable to that of traditional CAR-T cells that directly target BCMA-positive tumor cells, but the activity of traditional CAR-T cells does not depend on the P329G mutated antibody.
[0086] In some embodiments, the present invention verifies the anti-tumor effect of P329G CAR-T cells combined with P329G mutant antibodies in immunodeficient mice inoculated with BCMA-positive human tumor cell line-derived tumors, and studies the dosage and interval of antibody administration.
[0087] In vitro and in vivo experiments have shown that only in the presence of P329G antibodies can the activity of P329G CAR-T cells be "turned on" to produce effector functions, identify and kill BCMA-positive tumor cells; by adjusting the dose and dosing interval of P329G antibodies, the degree of in vivo proliferation of P329G CAR-T cells and the intensity of their anti-tumor activity can be regulated. Given that BCMA transmits tumor-promoting signals after binding to its ligand, P329G antibodies can exert anti-tumor effects by blocking this signal. Therefore, BCMA-specific P329G antibodies and P329G CAR-T cells can also produce synergistic anti-tumor effects.
[0088] In some embodiments, for the pharmaceutical combination of the present invention, (i) the immune effector cells expressing the CAR polypeptide of the present invention are cultured at a rate of about 0.5×10 6 cells / kg body weight - approximately 5×10 6 cells / kg body weight, for example, approximately 0.75×10 6 cells / kg body weight, 1×10 6cells / kg body weight, 1.5×10 6 cells / kg body weight, 2×10 6 cells / kg body weight, 2.5×10 6 cells / kg body weight, 3×10 6 cells / kg body weight, 3.5×10 6 cells / kg body weight, 4×10 6 cells / kg body weight, 4.5×10 6 cells / kg body weight, 5×10 6 cells / kg body weight in a single or multiple intravenous administration to a subject; and
[0089] (ii) the P329G mutant antibody described in the pharmaceutical combination of the present invention is administered to the subject in the form of a dosage unit of about 0.1-3 mg / kg, preferably about 0.1 mg / kg, 0.2 mg / kg, 0.3 mg / kg, 0.4 mg / kg, 0.5 mg / kg, 1 mg / kg, 1.5 mg / kg, 2 mg / kg, 2.5 mg / kg, 3 mg / kg, preferably parenterally, more preferably intravenously.
[0090] In some embodiments, (i) and (ii) in the pharmaceutical combination of the present invention are administered separately, simultaneously or sequentially, for example, (ii) is administered on the first day, (i) is administered intravenously on the same day or the next day, and then (ii) is administered multiple times at a certain frequency.
[0091] In some preferred embodiments, (i) and (ii) in the pharmaceutical combination of the present invention are administered according to the following regimen:
[0092] On the first day, (ii) and (i) are sequentially administered, with an interval of about 1-5 hours (e.g., an interval of about 1, 2, 3, 4 or 5 hours). Preferably, (ii) is administered on the first day, and (i) is administered with an interval of about 1-5 hours (e.g., an interval of about 1, 2, 3, 4 or 5 hours); or (ii) is administered on the first day and (i) is administered on the second day, with an interval of about 24 hours.
[0093] Taking the first day as the starting day, administer (ii) every 1 week (QW), 2 weeks (Q2W) or every 3 weeks (Q3W) in the first cycle; and optionally
[0094] The second to nth cycles: (ii) is administered every three weeks (Q3W) in each cycle.
[0095] In some embodiments, each dosing cycle is 21 days or 28 days.
[0096] In some embodiments, at least 2-3 cycles are administered. In some embodiments, at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 cycles or more are administered.
[0097] In a fourth aspect, the present invention provides a drug combination of the present invention or use thereof for treating a BCMA-related disease in a subject, comprising administering to the subject a therapeutically effective amount of the drug combination defined in the aforementioned third aspect, wherein the BCMA-related disease is, for example, a cancer that expresses or overexpresses BCMA, the cancer is, for example, multiple myeloma, such as refractory multiple myeloma or relapsed multiple myeloma, for example, the multiple myeloma is relapsed / refractory multiple myeloma (RRMM).
[0098] In a fifth aspect, the present invention provides use of the drug combination of the present invention in the preparation of a medicament for treating a disease associated with BCMA, such as a cancer that expresses or overexpresses BCMA, such as multiple myeloma, such as refractory multiple myeloma or relapsed multiple myeloma, such as relapsed / refractory multiple myeloma (RRMM).
[0099] In a sixth aspect, the present invention provides a method for treating a disease associated with BCMA, the method comprising administering to a subject a therapeutically effective amount of the drug combination of the present invention, wherein the disease is, for example, a cancer that expresses or overexpresses BCMA, such as multiple myeloma, such as refractory multiple myeloma or relapsed multiple myeloma, for example, the multiple myeloma is relapsed / refractory multiple myeloma (RRMM).
[0100] In a seventh aspect, the present invention provides a kit of parts comprising the drug combination as defined in the third aspect above, preferably the kit is in the form of a drug dosage unit.
[0101] Thus, the present invention firstly obtains a high-affinity BCMA-specific P329G antibody in the first aspect through in vitro binding ability, affinity and Fc effector function detection, which can simultaneously bind to BCMA antigen and P329G CAR molecule to exert a bridging effect. Secondly, in the third aspect, the present invention uses the constructed P329G CAR structural molecule and combines the P329G CAR-T cells prepared by the CAR molecule with the BCMA-specific P329G antibody, and then co-cultures with BCMA-positive MM cells in vitro to construct an in vitro co-culture system, in which the effect of P329G antibody as a "molecular switch" to regulate the activity of P329G CAR-T cells is verified, that is, only in the presence of P329G mutant antibodies, P329G CAR-T cells can be activated, proliferated, secrete effector cytokines and produce killing effects, and these effects are P329G antibody dose-dependent, and as the antibody dose increases, the recognition and killing effects of P329G CAR-T cells are enhanced. However, WT antibodies without the P329G mutation could not stimulate the effector function of P329G CAR-T cells.
[0102] In addition, the in vitro experiments of the present invention showed that the soluble BCMA antigen did not affect the activity of P329G CAR-T cells when used in combination with the BCMA-specific P329G antibody, while the soluble BCMA antigen had a significant inhibitory effect on traditional CAR-T cells. In the subcutaneous and systemic tumor-bearing immunodeficient mouse models of MM cells with high and low BCMA expression, the P329G CAR-T cells of the present invention combined with the P329G antibody produced a good anti-tumor effect, which was at least equivalent to that of traditional CAR-T cells, but the degree of in vivo proliferation of P329G CAR-T cells was significantly lower than that of traditional CAR-T cells, suggesting that while producing a comparable anti-tumor effect, P329G CAR-T cells may induce lower acute toxic and side effects such as CRS and NT; further, by adjusting the dosage and interval of P329G antibody administration, the degree of in vivo proliferation of P329G CAR-T cells and the intensity of the anti-tumor effect can be adjusted. After the tumor is cleared, stopping the administration of P329G antibody can still maintain a sustained anti-tumor effect, which lays a foundation for "turning off" the activity of P329G CAR-T cells in clinical applications, while maintaining a sustained anti-tumor effect, restoring the number of normal plasma cells and humoral immunity to reduce long-term toxic and side effects such as infection.
[0103] The toxicological experiments of the present invention also showed that the combination of P329G CAR-T cells and P329G antibodies did not produce obvious toxicity, thus laying the foundation for clinical transformation.
[0104] In some embodiments, after administration of the therapy of the present invention, the probability of the subject developing CRS or ICANS is low, such as less than 50%, such as lower than existing BCMA-CAR-T products.
[0105] In some embodiments, the therapies of the invention have a good safety and / or tolerability profile.
[0106] In some embodiments, the second component (e.g., an anti-BCMA antibody) is capable of modulating the activity of the first component, in particular the cellular activity of CAR-T cells.
[0107] In some embodiments, the therapy of the present invention can partially relieve the disease in the subject. Clinical studies have shown that a total of 11 patients were enrolled, of which 5 patients achieved PR or above.
[0108] In some specific embodiments, the drug combination or therapy of the present invention achieves a relatively good effect in terms of safety (1) CRS: As of the data cutoff date, in the two studies, 5 of the 11 subjects developed CRS of varying degrees, and the CRS incidence rate was 45.5%, which is lower than that of existing BCMA-CART products. Under the current circumstances, the CRS that has occurred is relatively controllable. Most subjects have improved or been cured after treatment;
[0109] (2) ICANS: As of the data cutoff date, no neurological toxicity events were observed in the two studies. BRIEF DESCRIPTION OF THE DRAWINGS
[0111] The preferred embodiments of the present invention described in detail below will be better understood when read in conjunction with the following drawings. For the purpose of illustrating the present invention, the drawings show the currently preferred embodiments. However, it should be understood that the present invention is not limited to the precise arrangements and means of the embodiments shown in the drawings.
[0112] Figure 1A It shows that after T cells were transduced with HuR968B and Blue21 CAR constructed in Example 1-1, CD3 + cells, CD4 + 、CD8 + CAR expression in T cell subsets.
[0113] Figure 1BThe mechanism of action of P329G CAR-T cells in targeting BCMA-expressing target cells mediated by P329G antibodies is shown. The structures of 8 CAR constructs. In the figure, "SP" represents a signal peptide; "TMD" represents a transmembrane domain; "ICD" represents an intracellular domain; "CSD" represents a co-stimulatory domain; and "SSD" represents a stimulatory signaling domain. In the construct of PG CAR in the figure, the extracellular domain comprises an antigen binding portion that can specifically bind to a mutant Fc domain containing a P329G mutation, and the antigen binding portion comprises a heavy chain variable region (VH) and a light chain variable region (VHL).
[0114] Figure 2A A schematic diagram of a method for determining antibody affinity using surface plasmon resonance (SPR) is shown.
[0115] Figure 2B Representative affinity profiles of ADI-38497 PG antibody to recombinant human, cynomolgus monkey, mouse, rat, and rabbit BCMA proteins measured by SPR are shown.
[0116] Figure 2C The ability of P329G BCMA antibody to bind to CHO-GS cells stably expressing human, cynomolgus monkey, and mouse BCMA is shown.
[0117] Figure 2D The binding activity of P329G BCMA antibody to BCMA-expressing positive multiple myeloma cell lines MM.1s, RPMI8226, U266, H929, L363 and AMO1 is shown.
[0118] Figure 3A A schematic diagram of the detection of the affinity of the anti-P329G mutation specific single-chain antibody-rabbit Fc fusion protein and the ADI-38497 P329G mutation antibody using surface plasmon resonance (SPR) is shown.
[0119] Figure 3B Representative affinity profiles of ADI-38497 PG antibody and wild-type antibody binding to anti-PG scFv fusion protein using SPR are shown.
[0120] Figure 3C A schematic diagram of a method for measuring antibody affinity using surface plasmon resonance (SPR) is shown.
[0121] Figure 3D Representative affinity profiles of ADI-38497 PG antibody and wild-type antibody fused to anti-PG scFv (in the middle, the P329G CAR extracellular domain contained anti-PG scFv) measured by SPR are shown.
[0122] Figure 3E The binding ability of ADI-38497 WT antibody and ADI-38497 PG antibody to P329G CAR-T cells is shown.
[0123] Figure 4A The ability of ADI-38497 WT antibody and ADI-38497 PG antibody to mediate ADCC killing is shown.
[0124] Figure 4B The ability of ADI-38497 WT antibody and ADI-38497 PG antibody to mediate ADCP killing is shown.
[0125] Figure 4C The ability of ADI-38497 PG antibody to mediate target cell lysis is shown.
[0126] Figure 5A ADI-38497 PG antibody with P329G mutation specifically mediates CAR targeting H929 cells + -T activation.
[0127] Figure 5B The activation effect of different BCMA antibodies (ADI-38497 PG antibody, ADI-38497 WT antibody, GSK PG IgG) on HuR968B CAR-T cells induced by L363 target cells is shown.
[0128] Figure 5C Shown is the proliferation of HuR968B CAR-T cells stimulated by coated ADI-38497 WT antibody or ADI-38497 PG antibody.
[0129] Figure 5D The results show the release of effector cytokines secreted by HuR968B CAR-T cells after co-culture with H929 cells and RPMI8226 cells and the addition of different concentrations of BCMA antibodies (ADI-38497 PG antibody, ADI-38497 WT antibody, or GSK PG IgG as a positive control).
[0130] Figure 5EThe results show the release of effector cytokines secreted by HuR968B CAR-T cells after co-culture with different tumor cells and the addition of different concentrations of BCMA antibodies (ADI-38497 PG antibody, ADI-38497 WT antibody, or GSK PG IgG).
[0131] Fig. 5F The results show that different BCMA antibodies (ADI-38497 PG antibody, ADI-38497 WT antibody, or GSK PGIgG) induced HuR968B CAR-T cells to target tumor cells with different BCMA expression levels (H929 ++ Cells, RPMI8226 +++ Cells, AMO1 + Cells and L363 + cell) killing effect.
[0132] Figure 5G It shows that P329G BCMA antibody induces CAR-T to produce a killing effect on tumor cells.
[0133] Figure 6 The effects of different concentrations of free BCMA protein on the killing effects of HuR968B CAR-T and Blue21 CAR-T cells are shown.
[0134] Fig. 7A and Figure 7B Shown are the results of pharmacokinetic experiments of ADI-38497 PG antibody in mice.
[0135] Fig. 8A The therapeutic effects of different doses of PG antibody combined with PG CAR-T cells in immunodeficient tumor-bearing mice subcutaneously inoculated with human H929 tumor cells that highly express BCMA are shown. In the figure, "cCAR-T" represents traditional CAR-T, i.e., Blue21CAR-T.
[0136] Figure 8B The figure shows the changes in body weight of mice when they were treated with different doses of PG antibody combined with PG CAR-T cells in immunodeficient tumor-bearing mice subcutaneously inoculated with human H929 tumor cells that highly express BCMA.
[0137] Figure 8C The expansion of PG CAR-T cells in immunodeficient tumor-bearing mice subcutaneously inoculated with human H929 tumor cells that highly express BCMA was shown when different doses of PG antibody were combined with PG CAR-T cells for treatment.
[0138] Fig.9AThe therapeutic effects of different doses of PG antibody combined with PG CAR-T cells in immunodeficient tumor-bearing mice subcutaneously inoculated with human L363 low-expressing BCMA tumor cells are shown. In the figure, "cCAR-T" represents traditional CAR-T, i.e., Blue21CAR-T.
[0139] Fig. 9B The figure shows the changes in body weight of mice when treated with different doses of PG antibody combined with PG CAR-T cells in immunodeficient tumor-bearing mice subcutaneously inoculated with human L363 low-expressing BCMA tumor cells.
[0140] Fig. 9C The expansion of PG CAR-T cells in immunodeficient tumor-bearing mice subcutaneously inoculated with human L363 low-expressing BCMA tumor cells was shown when different doses of PG antibody were combined with PG CAR-T cells for treatment.
[0141] Fig. 10A The therapeutic effect of PG antibody combined with different doses of PG CAR-T cells was shown in immunodeficient tumor-bearing mice subcutaneously inoculated with human H929 tumor cells.
[0142] Fig. 10B The figure shows the expansion of PG CAR-T cells in immunodeficient tumor-bearing mice inoculated subcutaneously with human H929 tumor cells when PG antibody was combined with different doses of PG CAR-T cells for treatment.
[0143] Fig.11A The frequency of administration of PG antibody in the experiment of Example 11-1 is shown.
[0144] Fig. 11B The therapeutic effect of different dosing frequencies of PG antibody combined with PG CAR-T cells in immunodeficient tumor-bearing mice inoculated subcutaneously with human H929 tumor cells is shown.
[0145] Fig. 11C The expansion of PG CAR-T cells in mice in the experiment of Example 11-1 is shown.
[0146] Fig. 12A Fluorescence images showing the therapeutic effects of different doses of PG antibody combined with PG CAR-T cells in immunodeficient tumor-bearing mice inoculated with human H929-luc tumor cells via the tail vein.
[0147] Fig. 12B The therapeutic effects of different doses of PG antibody combined with PG CAR-T cells in immunodeficient tumor-bearing mice inoculated with human H929-luc tumor cells via the tail vein are shown.
[0148] Fig. 12CThe figure shows the changes in body weight of immunodeficient tumor-bearing mice inoculated with human H929-luc tumor cells via the tail vein and treated with different doses of PG antibody combined with PG CAR-T cells.
[0149] Fig.13A The therapeutic effect of PG antibody combined with PGCAR-T cells was shown in immunodeficient tumor-bearing mice subcutaneously inoculated with human H929 tumor cells.
[0150] Fig. 13B The figure shows the changes in body weight of mice when PG antibody combined with PGCAR-T cells were treated in immunodeficient tumor-bearing mice subcutaneously inoculated with human H929 tumor cells.
[0151] Fig. 13C and Fig.13D The results of hematological and blood biochemical tests of mice were shown when PG antibody was combined with PG CAR-T cells in immunodeficient tumor-bearing mice subcutaneously inoculated with human H929 tumor cells.
[0152] Fig.14 A swimmer showing the efficacy evaluation after administration of the C-BCMA-CAR-PG-01 regimen is shown.
[0153] Fig.15 A swimmer showing the efficacy evaluation after administration of the C-BCMA-CAR-PG-02 regimen is shown.
[0154] Fig.16 The CAR-T cell expansion diagram after administration of the C-BCMA-CAR-PG-01 regimen and the C-BCMA-CAR-PG-02 regimen is shown.
[0155] Fig.17 The graphs showing the changes in antibody concentrations after administration of the C-BCMA-CAR-PG-01 regimen and the C-BCMA-CAR-PG-02 regimen are shown.
[0156] Fig.18 The cell expansion diagram of a typical case 1 after administration of the C-BCMA-CAR-PG-02 regimen is shown.
[0157] Fig.19 A graph showing cytokine changes in typical case 1 after administration of the C-BCMA-CAR-PG-02 regimen is shown.
[0158] Fig. 20 The cell expansion diagram of typical case 2 after administration of C-BCMA-CAR-PG-01 regimen is shown.
[0159] Fig.21 The cytokine changes of typical case 2 after administration of C-BCMA-CAR-PG-01 regimen are shown. DETAILED DESCRIPTION OF THE INVENTION
[0161] Unless otherwise limited, all technical and scientific terms used herein have the same meaning as those of ordinary skill in the art to which the present invention belongs. All publications, patent applications, patents and other references mentioned herein are incorporated by reference in their entirety. In addition, the materials, methods and examples described herein are only illustrative and are not intended to be restrictive. Other features, purposes and advantages of the present invention will be apparent from this specification and the accompanying drawings and from the appended claims.
[0162] I. Definitions
[0163] To interpret this specification, the following definitions will apply, and wherever appropriate, terms used in the singular may also include the plural, and vice versa. It is to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.
[0164] The term "about" when used in conjunction with a numerical value is meant to encompass the numerical value within a range having a lower limit that is 5% less than the specified numerical value and an upper limit that is 5% greater than the specified numerical value.
[0165] As used herein, the term "and / or" means any one of the alternatives or two or more of the alternatives.
[0166] In this article, when the term "comprising" or "including" is used, unless otherwise specified, it also covers the situation consisting of the elements, integers or steps mentioned. For example, when referring to an antibody variable region "comprising" a specific sequence, it is also intended to cover the antibody variable region consisting of the specific sequence.
[0167] The terms "BCMA" and "B cell maturation antigen" are used interchangeably and include variants, isoforms, species homologs, and analogs of human BCMA that have at least one identical epitope with BCMA (e.g., human BCMA). BCMA protein may also include fragments of BCMA, such as the extracellular domain and fragments of the extracellular domain, such as fragments that retain the ability to bind to any of the antibodies of the present invention.
[0168] As used herein, the terms "BCMA antibody", "antibody against BCMA", "antibody that specifically binds to BCMA", "antibody that specifically targets BCMA", "antibody that specifically recognizes BCMA" are used interchangeably and refer to an antibody that can specifically bind to B cell maturation antigen (BCMA).
[0169] The term "antibody" is used in the broadest sense herein to refer to a protein comprising an antigen binding site, covering natural antibodies and artificial antibodies of various structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), single-chain antibodies, complete antibodies, and antibody fragments. Preferably, the antibody of the present invention is a single domain antibody or a heavy chain antibody.
[0170] "Antibody fragment" or "antigen-binding fragment" are used interchangeably herein and refer to a molecule different from an intact antibody, which comprises a portion of an intact antibody and binds to the antigen to which the intact antibody binds. Examples of antibody fragments include, but are not limited to, Fab, Fab', F(ab')2, Fv, single-chain Fv, single-chain Fab, diabody.
[0171] The term "scFv" refers to a fusion protein comprising at least one antibody fragment comprising a light chain variable region and at least one antibody fragment comprising a heavy chain variable region, wherein the light chain variable region and the heavy chain variable region are optionally continuously connected by means of a flexible short polypeptide linker and can be expressed as a single-chain polypeptide, and wherein the scFv retains the specificity of the complete antibody from which it is derived. Unless otherwise indicated, as used herein, scFv can have a VL variable region and a VH variable region in any order (e.g., relative to the N-terminus and C-terminus of the polypeptide), and the scFv can comprise VL-linker-VH or can comprise VH-linker-VL.
[0172] "Complementarity determining region" or "CDR region" or "CDR" or "hypervariable region" is a region in an antibody variable domain that is highly variable in sequence and forms structurally determined loops ("hypervariable loops") and / or contains antigen contact residues ("antigen contact points"). CDRs are primarily responsible for binding to antigen epitopes. The CDRs of the heavy and light chains are usually referred to as CDR1, CDR2, and CDR3, and are numbered sequentially from the N-terminus. The CDRs located in the antibody heavy chain variable domain are referred to as CDR H1, CDR H2, and CDR H3, while the CDRs located in the antibody light chain variable domain are referred to as CDR L1, CDR L2, and CDR L3. In a given light chain variable region or heavy chain variable region amino acid sequence, the precise amino acid sequence boundaries of each CDR can be determined using any one or a combination of a number of well-known antibody CDR assignment systems, including, for example, Chothia based on the three-dimensional structure of antibodies and the topology of the CDR loops (Chothia et al., (1989) Nature 342:877-883, Al-Lazikani et al., "Standard conformations for the canonical structures of immunoglobulins", Journal of Molecular Biology, 273, 927-948 (1997)), Kabat based on antibody sequence variability (Kabat et al., Sequences of Proteins of Immunological Interest, 4th Edition, US Department of Health and Human Services, National Institutes of Health (1987)), AbM (University of Bath), Contact (University College London), International ImMunoGeneTics database (IMGT) (World Wide Web at imgt.cines.fr / ), and the North CDR definition based on affinity propagation clustering using a large number of crystal structures.
[0173] Unless otherwise specified, in the present invention, the term "CDR" or "CDR sequence" encompasses a CDR sequence determined in any of the above-mentioned ways.
[0174] CDR can also be determined based on having the same Kabat numbering position as a reference CDR sequence (e.g., any of the CDRs exemplified in the present invention). In the present invention, when referring to antibody variable regions and specific CDR sequences (including heavy chain variable region residues), it refers to the numbering position according to the Kabat numbering system.
[0175] Although CDR is different from antibody to antibody, only a limited number of amino acid positions in CDR are directly involved in antigen binding. Using at least two of the Kabat, Chothia, AbM and Contact methods, the minimum overlapping region can be determined, thereby providing a "minimum binding unit" for antigen binding. The minimum binding unit can be a sub-portion of a CDR. As those skilled in the art will appreciate, the residues of the remainder of the CDR sequence can be determined by the structure and protein folding of the antibody. Therefore, the present invention also contemplates variants of any CDR given herein. For example, in a variant of a CDR, the amino acid residues of the minimum binding unit can remain unchanged, while the remaining CDR residues defined according to Kabat or Chothia or AbM can be replaced by conservative amino acid residues.
[0176] The term "chimeric antibody" is an antibody molecule in which (a) the constant region or a portion thereof is changed, replaced or exchanged so that the antigen binding site is linked to a constant region of a different or altered class and / or species or a completely different molecule (e.g., enzyme, toxin, hormone, growth factor, drug), etc. that imparts new properties to the chimeric antibody; or (b) the variable region or a portion thereof is changed, replaced or exchanged with a variable region having a different or altered antigen specificity. For example, a mouse antibody can be modified by replacing its constant region with a constant region from a human immunoglobulin. Due to the replacement with a human constant region, the chimeric antibody can retain its specificity in recognizing an antigen while having reduced antigenicity in humans as compared to the original mouse antibody.
[0177] "Humanized" antibody refers to a chimeric antibody comprising amino acid residues from non-human CDRs and amino acid residues from human FRs. In some embodiments, all or substantially all of the CDRs (e.g., CDRs) in the humanized antibody correspond to those of non-human antibodies, and all or substantially all of the FRs correspond to those of human antibodies. The humanized antibody optionally may comprise at least a portion of an antibody constant region derived from a human antibody. A "humanized form" of an antibody (e.g., a non-human antibody) refers to an antibody that has been humanized.
[0178] A "human antibody" refers to an antibody having an amino acid sequence that corresponds to the amino acid sequence of an antibody produced by a human or human cell or derived from a non-human source utilizing a human antibody library or other human antibody encoding sequence. This definition of a human antibody specifically excludes humanized antibodies comprising non-human antigen-binding residues.
[0179] The term "Fc region" refers to the C-terminal region of an immunoglobulin heavy chain, including a native sequence Fc region and a variant Fc region. The human IgG heavy chain Fc region is generally defined as a segment from the amino acid residue at the Cys226 or Pro230 position to the carboxyl terminus, and the lysine residue at position 447 at the C-terminus of the Fc region (according to the EU numbering system) may be present or absent. Thus, a complete antibody composition may include an antibody group in which all K447 residues are eliminated, an antibody group in which no K447 residue is eliminated, or an antibody group in which antibodies with K447 residues and antibodies without K447 residues are mixed.
[0180] In certain embodiments, the Fc region of an immunoglobulin comprises two constant domains, namely, CH2 and CH3, and in other embodiments, the Fc region of an immunoglobulin comprises three constant domains, namely, CH2, CH3, and CH4.
[0181] IgG binding to Fcγ receptors or C1q depends on residues located in the hinge region and the CH2 domain. Two regions of the CH2 domain are critical for FcγR and complement C1q binding and have unique sequences in IgG2 and IgG4. It has been shown that substitution of residues 233-236 in human IgG1 and IgG2 and substitution of residues 327, 330 and 331 in human IgG4 can significantly reduce ADCC and CDC activity (Armour et al., Eur. J. Immunol. 29 (8), 1999, 2613-2624; Shields et al., J. Biol. Chem. 276 (9), 2001, 6591-6604).
[0182] "Functional Fc region" and "functional Fc region" and similar terms are used interchangeably to refer to an Fc region having the effector function of a wild-type Fc region. In some embodiments, the Fc region comprises the amino acid sequence of SEQ ID NO: 9, or an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto.
[0183] "Variant Fc region", "Fc mutant", "Fc region carrying mutation", "mutant Fc region", "Fc region variant", "Fc variant", "variant Fc region" and "mutated Fc region" and similar terms are used interchangeably to refer to an Fc region that comprises at least one amino acid modification that is different from a native sequence Fc region / wild-type Fc region.
[0184] In some embodiments, the variant Fc region comprises an amino acid sequence that differs from the amino acid sequence of the native sequence Fc region by one or more amino acid substitutions, deletions or additions. In some embodiments, the variant Fc region has at least one amino acid substitution compared to the Fc region of wild-type IgG, and the at least one amino acid substitution is to replace the amino acid at the P329 position according to EU numbering with glycine (G). In some embodiments, the Fc region comprises the amino acid sequence described in SEQ ID NO: 10, or an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with the amino acid sequence and having a P329G mutation.
[0185] "Fc receptor" or "FcR" refers to a molecule that binds to the Fc region of an antibody. In some embodiments, the FcR is a natural human FcR. In some embodiments, the FcR is a receptor that binds to an IgG antibody, i.e., FcγR, including three receptors, FcγRI (CD64), FcγRII (CD32), and FcγRIII (CD16), as well as allelic variants and alternative splicing forms of these receptors. FcγRII receptors include FcγRIIA and FcγRIIB, and FcγRIII receptors include FcγRIIIA and FcγRIIIB.
[0186] The term "effector function" refers to those biological activities attributed to the Fc region of an immunoglobulin that vary with the immunoglobulin isotype. Examples of immunoglobulin effector functions include: Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), cytokine secretion, immune complex-mediated antigen uptake by antigen-presenting cells, C1q binding and complement-dependent cytotoxicity (CDC), downregulation of cell surface receptors (e.g., B cell receptor), and B cell activation.
[0187] The term "antibody-dependent cell-mediated cytotoxicity (ADCC)" is one of the main mechanisms by which certain cytotoxic effector cells (e.g., natural killer (NK) cells) mediate the killing of target cells and foreign host cells. In some embodiments, the chimeric antigen receptor of the present invention provides antibody-dependent cellular cytotoxicity of T lymphocytes and enhances the antibody-dependent cellular cytotoxicity of NK cells. The chimeric antigen receptor of the present invention binds to an antibody (or other anti-tumor molecule comprising an Fc portion) that binds to tumor cells, thereby inducing activation of T cells expressing the chimeric antigen receptor, continued proliferation, and exerting specific cytotoxicity to target cancer cells mediated by the antibody (or other anti-tumor molecule comprising an Fc portion).
[0188] The term "antibody-dependent cellular phagocytosis (ADCP)" refers to a cellular response in which antibodies that bind to target cells bind to FcγRIIIa on the surface of macrophages, inducing activation of macrophages, which in turn internalizes the target cells and causes them to be acidified and degraded by phagosomes. ADCP can also be mediated by FcγRIIa and FcγRI, but to a lesser extent.
[0189] The term "complement-dependent cytotoxicity (CDC)" refers to the lysis of target cells in the presence of complement. The complement system is part of the innate immune system composed of a series of proteins. The proteins of the complement system are called "complement", represented by the abbreviations C1, C2, C3, etc., which are a group of heat-labile proteins present in human or vertebrate serum and tissue fluid, which have enzymatic activity after activation. C1q is the first component of the complement-dependent cytotoxicity (CDC) pathway, which can bind to six antibodies, but binding to two IgGs is sufficient to activate the complement cascade. Activation of the classical complement pathway is initiated by the first component of the complement system (C1q) binding to antibodies (appropriate subclasses) that bind to the relevant antigen, activating a series of complement cascade reactions, forming holes in the target cell membrane, thereby causing target cell death. In order to assess complement activation, a CDC assay can be performed, for example, by the method described in Gazzano-Santoro et al., J. Immunol. Methods 202: 163 (1996).
[0190] The term "variable region" or "variable domain" refers to the domain of an antibody heavy chain or light chain that is involved in binding the antibody to an antigen. The variable domains of the heavy and light chains of natural antibodies generally have similar structures, wherein each domain comprises four conserved framework regions (FRs) and three complementary determining regions (CDRs). (See, e.g., Kindt et al., Kuby Immunology, 6 th ed., WH Freeman and Co. 91 pages (2007)). A single VH or VL domain may be sufficient to confer antigen-binding specificity.
[0191] As used herein, the term "binding" or "specific binding" means that the binding is selective for an antigen and can be distinguished from unwanted or non-specific interactions. The ability of an antibody to bind to a specific antigen can be determined by enzyme-linked immunosorbent assay (ELISA), SPR or biofilm interferometry or other conventional binding assays known in the art.
[0192] The term "stimulation" refers to a primary response induced by the binding of a stimulatory molecule (e.g., a TCR / CD3 complex) to its corresponding ligand, which thereby mediates a signal transduction event, such as, but not limited to, signal transduction via a TCR / CD3 complex. Stimulation may mediate the expression of certain molecular changes, such as downregulation of TGF-β and / or reorganization of cytoskeletal structure, etc.
[0193] The term "stimulatory molecule" refers to a molecule expressed by a T cell that provides a primary cytoplasmic signaling sequence that regulates the primary activation of the TCR complex in a stimulatory manner in at least some aspect of the T cell signaling pathway. In one embodiment, the primary signal is initiated, for example, by the binding of the TCR / CD3 complex to the MHC molecule loaded with a peptide and leads to mediating T cell responses, including but not limited to proliferation, activation, differentiation, etc. In the specific CAR of the present invention, the intracellular signaling domain in any one or more CARs of the present invention comprises an intracellular signaling sequence, for example, a primary signaling sequence of CD3δ.
[0194] The term "CD3 δ" is defined as a protein or its equivalent provided by GenBank Accession No. BAG36664.1, and a "CD3 δ stimulatory signal domain" is defined as amino acid residues from the cytoplasmic domain of the CD3 δ chain, which are sufficient to functionally propagate the initial signal necessary for T cell activation. In one embodiment, the cytoplasmic domain of CD3 δ comprises residues 52 to residue 164 of GenBank Accession No. BAG36664.1 or equivalent residues from non-human species (e.g., mice, rodents, monkeys, apes, etc.) as their functional homologs. In one embodiment, the "CD3 δ stimulatory signal domain" is a sequence provided in SEQ ID NO: 17 or a variant thereof.
[0195] The term "costimulatory molecule" refers to a corresponding binding partner on a cell that specifically binds to a costimulatory ligand to mediate a costimulatory response (such as but not limited to proliferation) of a cell. Costimulatory molecules are cell surface molecules that contribute to an effective immune response except for antigen receptors or their ligands. Costimulatory molecules include but are not limited to MHC class I molecules, TNF receptor proteins, immunoglobulin-like proteins, cytokine receptors, integrins, signaling lymphocyte activation molecules (SLAM proteins), activation of NK cell receptors, OX40, CD40, GITR, 4-1BB (i.e., CD137), CD27, and CD28. In some embodiments, "costimulatory molecule" is 4-1BB (i.e., CD137). Costimulatory signal domain refers to the intracellular portion of a costimulatory molecule.
[0196] The term "4-1BB" refers to a member of the TNFR superfamily having an amino acid sequence provided as GenBank Accession No. AAA62478.2 or equivalent residues from non-human species (e.g., mice, rodents, monkeys, apes, etc.); and "4-1BB costimulatory signaling domain" is defined as amino acid residues 214-255 of GenBank Accession No. AAA62478.2 or equivalent residues from non-human species (e.g., mice, rodents, monkeys, apes, etc.). In one embodiment, the "4-1BB costimulatory domain" is a sequence provided as SEQ ID NO: 16 or equivalent residues from non-human species (e.g., mice, rodents, monkeys, apes, etc.).
[0197] The term "signaling pathway" refers to the biochemical relationships between various signaling molecules that play a role in propagating a signal from one part of a cell to another part of the cell.
[0198] The term "cytokine" is a generic term for proteins released by one cell population that act as intercellular mediators on another cell. Examples of such cytokines include lymphokines, monokines, interleukins (ILs), such as IL-1, IL-1α, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-11, IL-12, IL-15; tumor necrosis factors, such as TNF-α or TNF-β; and other polypeptide factors, including gamma-interferon.
[0199] An "isolated" antibody is one that has been separated from the components of its natural environment. In some embodiments, the antibodies of the invention are purified to greater than 95% or 99% purity, as determined by, for example, electrophoresis (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatography (e.g., ion exchange or reversed-phase HPLC). For a review of methods for assessing antibody purity, see, e.g., Flatman et al., J. Chromatogr. B 848: 79-87 (2007).
[0200] An "isolated" nucleic acid refers to a nucleic acid molecule that has been separated from a component of its natural environment. An isolated nucleic acid includes a nucleic acid molecule contained in a cell that normally contains the nucleic acid molecule, but the nucleic acid molecule is present extrachromosomally or at a chromosomal location different from its natural chromosomal location. An "isolated nucleic acid encoding an antibody of the invention" refers to one or more nucleic acid molecules that encode a chain of an antibody of the invention or a fragment thereof, including such nucleic acid molecules in a single vector or separate vectors, as well as such nucleic acid molecules present at one or more locations in a host cell.
[0201] Calculation of sequence identity between sequences was performed as follows.
[0202] To determine the percent identity of two amino acid sequences or two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps may be introduced in one or both of the first and second amino acid sequences or nucleic acid sequences for optimal alignment or non-homologous sequences may be discarded for comparison purposes). In a preferred embodiment, for comparison purposes, the length of the reference sequence being aligned is at least 30%, preferably at least 40%, more preferably at least 50%, 60%, and even more preferably at least 70%, 80%, 90%, 100% of the length of the reference sequence. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide at the corresponding position in the second sequence, then the molecules are identical at this position.
[0203] Mathematical algorithms can be used to compare sequences and calculate percent identity between two sequences. In a preferred embodiment, the Needlema and Wunsch ((1970) J. Mol. Biol. 48: 444-453) algorithm (available at http: / / www.gcg.com) that has been integrated into the GAP program of the GCG software package is used, using a Blossum 62 matrix or a PAM250 matrix and a gap weight of 16, 14, 12, 10, 8, 6 or 4 and a length weight of 1, 2, 3, 4, 5 or 6 to determine the percent identity between two amino acid sequences. In another preferred embodiment, the GAP program in the GCG software package is used (available at http: / / www.gcg.com) to determine the percent identity between two nucleotide sequences using the NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70 or 80 and a length weight of 1, 2, 3, 4, 5 or 6. A particularly preferred parameter set (and the one that should be used unless otherwise stated) is the Blossum 62 scoring matrix with a gap penalty of 12, a gap extension penalty of 4, and a frameshift gap penalty of 5.
[0204] The percent identity between two amino acid or nucleotide sequences can also be determined using the algorithm of E. Meyers and W. Miller, ((1989) CABIOS, 4: 11-17), which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weighted remainder table, a gap length penalty of 12, a gap penalty of 4).
[0205] Additionally or alternatively, one can further use the nucleic acid sequences and protein sequences described herein as a "query sequence" to perform a search against public databases to, for example, identify other family member sequences or related sequences.
[0206] The terms "amino acid change" and "amino acid modification" are used interchangeably and refer to the addition, deletion, substitution and other modifications of amino acids. Any combination of the addition, deletion, substitution and other modifications of amino acids can be performed, provided that the final polypeptide sequence has the desired properties. In some embodiments, the amino acid substitution of the antibody results in reduced binding of the antibody to the Fc receptor. For the purpose of changing, for example, the binding characteristics of the Fc region, non-conservative amino acid substitutions are particularly preferred, i.e., replacing one amino acid with another amino acid having different structures and / or chemical properties. Amino acid substitutions include substitutions with non-naturally occurring amino acids or naturally occurring amino acid derivatives of twenty standard amino acids (e.g., 4-hydroxyproline, 3-methylhistidine, ornithine, homoserine, 5-hydroxylysine). Amino acid changes can be produced using genetic or chemical methods known in the art. Genetic methods may include site-directed mutagenesis, PCR, gene synthesis, etc. Methods for changing amino acid side chain groups by methods other than genetic engineering (such as chemical modification) may be useful. A variety of names may be used herein to represent the same amino acid changes. For example, a substitution from proline at position 329 of the Fc domain to glycine can be represented as 329G, G329, G 329 , P329GPro329Gly, or "PG" for short.
[0207] The terms "conservative sequence modifications" and "conservative sequence changes" refer to amino acid modifications or changes that do not significantly affect or change the binding characteristics of the antibody or antibody fragment containing the amino acid sequence. Such conservative modifications include amino acid substitutions, additions and deletions. Modifications can be introduced into the antibodies or antibody fragments of the present invention by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. Conservative substitutions are amino acid substitutions in which an amino acid residue is replaced by an amino acid residue with a similar side chain. Families of amino acid residues with similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), β-side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, one or more amino acid residues in the interior of the CAR of the present invention can be replaced with other amino acid residues from the same side chain family, and the functional assay described herein can be used to test the changed CAR.
[0208] The term "autologous" refers to any substance that is derived from the same individual into which the substance is later reintroduced.
[0209] The term "allogeneic" refers to any material that is derived from a different animal of the same species as the individual into which the material is introduced. Two or more individuals are said to be allogeneic to each other when the genes at one or more loci are not identical. In some aspects, allogeneic material from individuals of the same species can be genetically dissimilar enough to interact antigenically.
[0210] The term "xenogeneic" refers to a graft derived from an animal of a different species.
[0211] As used herein, the term "apheresis" refers to an art-recognized extracorporeal method by which blood from a donor or patient is removed from the donor or patient and passed through a device that separates selected specific components and returns the remainder to the donor's or patient's circulation, e.g., by retransfusion. Thus, in the context of an "apheresis sample," a sample obtained using apheresis is referred to.
[0212] The term "immune effector cell" refers to a cell that participates in an immune response, e.g., participates in promoting an immune effector reaction. Examples of immune effector cells include T cells, e.g., α / β T cells and γ / δ T cells, B cells, natural killer (NK) cells, natural killer T (NKT) cells, mast cells, and myeloid derived phagocytes.
[0213] "Immune effector function", "immune effector response" or "immune effector reaction" refers to, for example, a function or response of an immune effector cell that enhances or promotes immune attack on a target cell. For example, an immune effector function or response refers to a T cell or NK cell property that promotes killing of a target cell or inhibits growth or proliferation of a target cell. In the case of T cells, primary stimulation and co-stimulation are examples of immune effector functions or responses.
[0214] The term "effector function" refers to a specialized function of a cell. The effector function of a T cell may be, for example, cytolytic activity or helper activity, including the secretion of cytokines.
[0215] The term "T cell activation" refers to one or more cellular responses of T lymphocytes, particularly cytotoxic T lymphocytes, selected from the group consisting of proliferation, differentiation, cytokine secretion, cytotoxic effector molecule release, cytotoxic activity, and expression of activation markers. The chimeric antigen receptor of the present invention is capable of inducing T cell activation. Suitable assays for measuring T cell activation are described in the Examples and are known in the art.
[0216] The term "lentivirus" refers to a genus of the Retroviridae family. Lentiviruses are unique among retroviruses in their ability to infect non-dividing cells; they can deliver significant amounts of genetic information to host cells, making them one of the most efficient methods of gene delivery vectors. HIV, SIV, and FIV are all examples of lentiviruses.
[0217] The term "lentiviral vector" refers to a vector derived from at least a portion of a lentiviral genome, and particularly includes self-inactivating lentiviral vectors as provided in Milone et al., Mol. Ther. 17(8): 1453–1464 (2009). Other examples of lentiviral vectors that can be used clinically include, but are not limited to, those from Oxford BioMedica. Gene delivery technology, LENTIMAX from Lentigen TM Vector Systems, etc. Non-clinical types of lentiviral vectors are also available and known to those skilled in the art.
[0218] The term "BCMA-associated disease" refers to any condition caused by, exacerbated by, or otherwise associated with increased expression or activity of BCMA.
[0219] The terms "individual" or "subject" are used interchangeably and include mammals. Mammals include, but are not limited to, domesticated animals (e.g., cattle, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In particular, the individual or subject is a human.
[0220] The terms "tumor" and "cancer" are used interchangeably herein and encompass both solid tumors and liquid tumors.
[0221] The terms "cancer" and "cancerous" refer to the physiological condition in mammals in which cell growth is unregulated.
[0222] The term "tumor" refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all precancerous and cancerous cells and tissues. The terms "cancer," "cancerous," and "tumor" are not mutually exclusive when referred to herein.
[0223] "Tumor immune escape" refers to the process by which a tumor evades immune recognition and clearance. Thus, as a therapeutic concept, tumor immunity is "treated" when such escape is weakened and the tumor is recognized and attacked by the immune system. Examples of tumor recognition include tumor binding, tumor shrinkage, and tumor clearance.
[0224] The term “median effective concentration (EC 50)” refers to the concentration of a drug, antibody or toxic agent that induces a response that is 50% between baseline and maximum after a specified exposure time.
[0225] The term "fluorescence activated cell sorting" or "FACS" refers to a specialized type of flow cytometry. It provides a method for sorting a heterogeneous mixture of biological cells into two or more containers one cell at a time, based on the specific light scattering and fluorescence characteristics of each cell (FlowMetric. "Sorting Out Fluorescence Activated Cell Sorting". 2017-11-09). Instruments for performing FACS are known to those skilled in the art and are commercially available to the public. Examples of such instruments include the FACS StarPlus, FACScan, and FACSort instruments from Becton Dickinson (Foster City, CA), the Epics C from Coulter Epics Division (Hialeah, FL), and the MoFlo from Cytomation (Colorado Springs, Colorado).
[0226] The term "pharmaceutically acceptable excipient" refers to a diluent, adjuvant (eg, Freund's adjuvant (complete and incomplete)), excipient, buffer or stabilizer, etc., which is administered together with the active substance.
[0227] As used herein, "treat" refers to slowing, interrupting, blocking, alleviating, stopping, reducing, or reversing the progression or severity of an existing symptom, disorder, condition, or disease. The desired therapeutic effect includes, but is not limited to, preventing the occurrence or recurrence of the disease, alleviating symptoms, reducing any direct or indirect pathological consequences of the disease, preventing metastasis, reducing the rate of disease progression, improving or alleviating the disease state, and alleviating or improving prognosis. In some embodiments, the antibody molecules of the present invention are used to delay the development of the disease or to slow the progression of the disease.
[0228] The term "effective amount" refers to an amount or dosage of an antibody or composition of the invention that produces the desired effect in a patient in need of treatment or prevention after being administered to the patient in a single or multiple doses. The effective amount can be readily determined by the attending physician, who is a person skilled in the art, by considering a variety of factors such as the species of the mammal; body weight, age, and general health; the specific disease involved; the extent or severity of the disease; the response of the individual patient; the specific antibody administered; the mode of administration; the bioavailability characteristics of the administered formulation; the selected dosing regimen; and the use of any concomitant therapy.
[0229] A "therapeutically effective amount" refers to an amount effective to achieve the desired therapeutic outcome at the desired dosage and for the desired period of time. The therapeutically effective amount of an antibody or antibody fragment or composition thereof may vary according to factors such as the disease state, age, sex and weight of the individual and the ability of the antibody or antibody portion to stimulate the desired response in the individual. A therapeutically effective amount is also an amount in which any toxic or deleterious effects of the antibody or antibody fragment or composition thereof are outweighed by the therapeutically beneficial effects. Relative to untreated subjects, a "therapeutically effective amount" preferably inhibits a measurable parameter (e.g., tumor growth rate, tumor volume, etc.) by at least about 20%, more preferably at least about 40%, even more preferably at least about 50%, 60% or 70%, and still more preferably at least about 80% or 90%. The ability of a compound to inhibit a measurable parameter (e.g., cancer) can be evaluated in an animal model system that is predictive of efficacy in human tumors.
[0230] The term "drug combination" or "drug combination product" refers to a non-fixed combination (product) or a fixed combination (product), including but not limited to a drug box. The term "non-fixed combination" means that the active ingredients (e.g., (i) P329G CAR-T cells and (ii) P329G mutant antibodies for BCMA) are applied to subjects in sequence as separate entities simultaneously, without specific time limits or at the same or different time intervals, wherein such administration provides effective treatment in the subject. The term "fixed combination" refers to the combination of P329G mutant antibodies for BCMA and P329G CAR-T cells of the present invention, each of which is simultaneously applied to the patient in the form of a specific single dose. The term "non-fixed combination" means that the combination of 329G mutant antibodies for BCMA and P329G CAR-T cells of the present invention is applied to the patient simultaneously, in parallel or sequentially as separate entities, without specific dosage and time limits, wherein such administration provides a therapeutically effective level of the drug combination of the present invention in the patient. In a preferred embodiment, the drug combination is a non-fixed combination.
[0231] The term "vector" as used herein when referring to nucleic acids refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is attached. The term includes vectors that are self-replicating nucleic acid structures as well as vectors that are incorporated into the genome of a host cell into which they have been introduced. Some vectors are capable of directing the expression of nucleic acids to which they are operatively attached. Such vectors are referred to herein as "expression vectors."
[0232] The term "host cell" refers to a cell into which an exogenous polynucleotide has been introduced, including the offspring of such cells. Host cells include "transformants" and "transformed cells", which include primary transformed cells and offspring derived therefrom, without considering the number of passages. Offspring may not be completely identical to parent cells in nucleic acid content, but may contain mutations. Included herein are mutant offspring with the same function or biological activity screened or selected in the initially transformed cells. Host cells are any type of cell system that can be used to produce antibody molecules of the present invention, including eukaryotic cells, for example, mammalian cells, insect cells, yeast cells; and prokaryotic cells, for example, Escherichia coli cells. Host cells include cultured cells, and also include cells inside transgenic animals, transgenic plants, or cultured plant tissues or animal tissues.
[0233] "Subject / patient sample" refers to a collection of cells, tissues or body fluids obtained from a patient or subject. The source of the tissue or cell sample can be solid tissue, such as from fresh, frozen and / or preserved organ or tissue samples or biopsy samples or puncture samples; blood or any blood component; body fluids, such as cerebrospinal fluid, amniotic fluid (amniotic fluid), peritoneal fluid (ascites), or interstitial fluid; cells from any time of pregnancy or development of the subject. Tissue samples may contain compounds that are naturally not mixed with tissues in nature, such as preservatives, anticoagulants, buffers, fixatives, nutrients, antibiotics, etc. Examples of tumor samples include, but are not limited to, tumor biopsies, fine needle aspirates, bronchial lavage fluid, pleural fluid (pleural effusion), sputum, urine, surgical specimens, circulating tumor cells, serum, plasma, circulating plasma proteins, ascites, primary cell cultures or cell lines derived from tumors or exhibiting tumor-like properties, and preserved tumor samples, such as formalin-fixed, paraffin-embedded tumor samples or frozen tumor samples.
[0234] The term "treat" or "treating" with reference to a disease means to alleviate the disease (ie, slow or arrest or reduce the development of the disease or at least one clinical symptom thereof), prevent or delay the onset or development or progression of the disease.
[0235] II. Molecular switch regulated chimeric antigen receptor (CAR) of the present invention
[0236] The present invention relates to a chimeric antigen receptor polypeptide capable of specifically binding to a mutant Fc domain of an antibody against a BCMA molecule. Specifically, the chimeric antigen receptor of the present invention comprises a humanized anti-P329G mutant scFv sequence, and the scFv sequence is capable of specifically binding to an antibody Fc domain comprising a P329G mutation, but is not specifically binding to an unmutated parent antibody Fc domain. Compared to the binding of an unmutated parent antibody Fc domain to an Fc receptor, the binding of an antibody Fc domain comprising a P329G mutation to an Fc receptor (e.g., an Fcγ receptor) is reduced.
[0237] The recombinant CAR construct of the present invention comprises a sequence encoding CAR, wherein CAR comprises a humanized anti-P329G mutation scFv sequence, and the scFv sequence specifically binds to the antibody Fc domain of the P329G mutation.
[0238] In one embodiment, the scFv sequence in the CAR construct of the present invention comprises the following sequence:
[0239] (i) a heavy chain variable region comprising a
[0240] (a) a heavy chain complementary determining region CDR H1 represented by the amino acid sequence RYWMN (SEQ ID NO: 19), or a variant of said CDRH1 having no more than 2 amino acid changes or no more than 1 amino acid change;
[0241] (b) CDR H2 shown in the amino acid sequence EITPDSSTINYAPSLKG (SEQ ID NO: 20), or a variant of said CDR H2 with no more than 2 amino acid changes or no more than 1 amino acid change; and
[0242] (c) CDR H3 shown by the amino acid sequence PYDYGAWFAS (SEQ ID NO: 21), or a variant of said CDR H3 with no more than 2 amino acid changes or no more than 1 amino acid change; and
[0243] (ii) a light chain variable region comprising a
[0244] (d) a light chain complementary determining region (CDR L) 1 shown by the amino acid sequence RSSTGAVTTSNYAN (SEQ ID NO: 22), or a variant of said CDR L1 with no more than 2 amino acid changes or no more than 1 amino acid change;
[0245] (e) CDR L2 shown by the amino acid sequence GTNCRAP (SEQ ID NO: 23), or a variant of said CDR L2 with no more than 2 amino acid changes or no more than 1 amino acid change; and
[0246] (f) a CDR L3 represented by the amino acid sequence ALWYSNHWV (SEQ ID NO: 24), or a variant of said CDR L3 having no more than 2 amino acid changes or no more than 1 amino acid change;
[0247] The amino acid change is an addition, deletion or substitution of an amino acid.
[0248] Further, the scFv can be linked to a signal peptide sequence at the N-terminus, for example, a signal peptide sequence as shown in SEQ ID NO: 11, and the scFv can be linked to an optional hinge region / spacer sequence as provided in SEQ ID NO: 14 or SEQ ID NO: 18, a transmembrane region as provided in SEQ ID NO: 15, a co-stimulatory signal domain as provided in SEQ ID NO: 16, and an intracellular stimulatory signal domain comprising SEQ ID NO: 17 or a variant thereof at the C-terminus, for example, wherein the respective domains are adjacent to each other and are in the same open reading frame to form a single fusion protein.
[0249] In some embodiments, the scFv domain comprises (i) a heavy chain variable region comprising a sequence of SEQ ID NO: 12, or a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical thereto, and (ii) a light chain variable region comprising a sequence of SEQ ID NO: 13, or a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical thereto;
[0250] In some embodiments, the scFv domain comprises (i) a heavy chain variable region set forth in SEQ ID NO: 12 and (ii) a light chain variable region set forth in SEQ ID NO: 13. In one embodiment, the scFv domain further comprises a (Gly4-Ser)n linker, wherein n is 1, 2, 3, 4, 5 or 6, preferably 3 or 4. The light chain variable region and the heavy chain variable region of the scFv can be, for example, in any of the following orientations: light chain variable region-linker-heavy chain variable region or heavy chain variable region-linker-light chain variable region.
[0251] In some embodiments, an exemplary CAR construct of the present invention comprises a signal peptide sequence, a humanized anti-P329G mutant scFv sequence, a hinge region / spacer, a transmembrane domain, an intracellular co-stimulatory signaling domain, and an intracellular stimulatory signaling domain.
[0252] In one embodiment, the present invention provides the amino acid sequence of the full-length CAR polypeptide as SEQ ID NO: 1, as shown in the sequence listing.
[0253] In some embodiments, the present invention provides a recombinant nucleic acid construct comprising a nucleic acid molecule encoding a CAR of the present invention, for example, a nucleic acid molecule encoding an amino acid sequence shown in SEQ ID NO: 1 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with SEQ ID NO: 1. The CAR construct encoding the present invention can be obtained using recombinant methods known in the art. Alternatively, the target nucleic acid can be produced synthetically rather than by a genetic recombination method.
[0254] The present invention includes retroviral and lentiviral vector constructs that express CARs that can be directly transduced into cells.
[0255] In some embodiments, the nucleic acid sequence of the CAR construct of the present invention is cloned into a lentiviral vector to generate a full-length CAR construct in a single coding frame, and the EF1α promoter is used for expression.
[0256] It will be understood by those of ordinary skill in the art that the CAR polypeptides of the present invention can also be modified so as to change in the amino acid sequence, but not in terms of the desired activity. For example, additional nucleotide substitutions that result in amino acid substitutions at "non-essential" amino acid residues can be made to the CAR polypeptide. For example, a non-essential amino acid residue in a molecule can be replaced with another amino acid residue from the same side chain family. In another embodiment, an amino acid fragment can be replaced with a structurally similar fragment that differs in the order and composition of the side chain family members, for example, a conservative substitution can be made in which an amino acid residue is replaced with an amino acid residue having a similar side chain.
[0257] Families of amino acid residues having similar side chains have been defined in the art, including basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).
[0258] In some embodiments, the present invention contemplates the generation of functionally equivalent CAR polypeptide molecules, for example, the VH or VL of the humanized anti-P329G mutant scFv sequence contained in the CAR can be modified to obtain a VH having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with SEQ ID NO: 12 and a VL having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with SEQ ID NO: 13.
[0259] The transmembrane domain included in the CAR of the present invention is an anchored transmembrane domain, which is a component of a polypeptide chain that can be integrated into a cell membrane. The transmembrane domain can be fused with other extracellular and / or intracellular polypeptide domains, wherein these extracellular and / or intracellular polypeptide domains will also be restricted to the cell membrane. In the chimeric antigen receptor (CAR) polypeptide of the present invention, the transmembrane domain confers membrane attachment to the CAR polypeptide of the present invention. The CAR polypeptide of the present invention includes at least one transmembrane domain, which may be derived from a natural source or a recombinant source, comprising dominant hydrophobic residues such as leucine and valine. In the case where the source is natural, the domain may be derived from a membrane-bound protein or a transmembrane protein such as CD28, CD8 (e.g., CD8α, CD8β) transmembrane domain. In one embodiment, the transmembrane domain comprises SEQ ID NO:15 amino acid sequence.
[0260] In some embodiments, the transmembrane domain in the CAR of the present invention is connected to the extracellular region of CAR (ie, humanized anti-P329G mutant scFv sequence) by means of a hinge region / spacer. For example, in one embodiment, the hinge can be a hinge region of CD8α, a hinge region of CD28. In some embodiments, the hinge region or the spacer sequence comprises the amino acid sequence of SEQ ID NO: 18.
[0261] Additionally, glycine-serine doublets also provide particularly suitable linkers as hinge / spacer regions. For example, in one embodiment, the linker comprises the amino acid sequence of GGGGS (SEQ ID NO: 14).
[0262] The cytoplasmic domain included in the CAR of the present invention includes an intracellular signaling domain. The intracellular signaling domain can activate at least one effector function of the immune cell introduced with the CAR of the present invention.
[0263] Examples of intracellular signaling domains for use in the CAR of the present invention include cytoplasmic sequences of T cell receptors (TCRs) and co-receptors that act synergistically to initiate signal transduction after the extracellular domain binds to the P329G mutated antibody Fc domain, as well as any derivatives or variants of these sequences and any recombinant sequences with the same functional capacity.
[0264] Considering that the signal generated by TCR alone is not enough to fully activate T cells, the CAR of the present invention is also designed to generate a costimulatory signal domain (CSD). The activation of T cells is mediated by two different cytoplasmic signaling sequences: those sequences that initiate antigen-dependent primary activation through TCR (primary intracellular signaling domains) and those sequences that act in an antigen-independent manner to provide costimulatory signals (secondary cytoplasmic domains, e.g., costimulatory domains).
[0265] In one embodiment, the CAR of the present invention comprises a primary intracellular signaling domain, e.g., a primary signaling domain of CD3δ, e.g., a CD3δ signaling domain set forth in SEQ ID NO: 17.
[0266] The intracellular signaling domain in the CAR of the present invention also includes a secondary signaling domain (ie, a co-stimulatory signaling domain). The co-stimulatory signaling domain refers to the CAR portion of the intracellular domain comprising a co-stimulatory molecule. Co-stimulatory molecules are cell surface molecules required for lymphocytes to effectively respond to antigens in addition to antigen receptors or their ligands. In some embodiments, co-stimulatory molecules include but are not limited to CD28, 4-1BB (CD137), and the co-stimulatory effect caused by them enhances the proliferation, effector function and survival of human CART cells in vitro and enhances the anti-tumor activity of human T cells in vivo.
[0267] Intracellular signaling sequences of the CAR of the present invention can be connected to each other in a random order or in a specified order. Optionally, short oligopeptide linkers or polypeptide linkers can form bonds between intracellular signaling sequences. In one embodiment, a glycine-serine doublet can be used as a suitable linker. In one embodiment, a single amino acid, for example, alanine, glycine, can be used as a suitable linker.
[0268] In one embodiment, the intracellular signaling domain of the CAR of the present invention is designed to include the costimulatory signaling domain of 4-1BB and the stimulatory signaling domain of CD3δ.
[0269] III. Nucleic acid molecules encoding the CAR of the present invention, vectors, and cells expressing the CAR of the present invention
[0270] The present invention provides nucleic acid molecules encoding CAR constructs described herein.In one embodiment, the nucleic acid molecule is provided as a DNA construct.
[0271] The present invention also provides a vector inserted with a CAR construct of the present invention. By effectively connecting a nucleic acid encoding a CAR polypeptide to a promoter and incorporating the construct into an expression vector, expression of a natural or synthetic nucleic acid encoding CAR is achieved. The vector may be suitable for replication and integration in eukaryotic organisms. Common cloning vectors contain transcription and translation terminators, initiation sequences, and promoters for regulating the expression of the desired nucleic acid sequence.
[0272] Numerous virus-based systems have been developed for transferring genes into mammalian cells. For example, retroviruses provide a convenient platform for gene delivery systems. The selected gene can be inserted into a vector and packaged in retroviral particles using techniques known in the art. The recombinant virus can then be isolated and delivered to the subject's cells in vivo or ex vivo. Numerous retroviral systems are known in the art. In some embodiments, a lentiviral vector is used.
[0273] Vectors derived from retroviruses (such as lentiviruses) are suitable tools for achieving long-term gene transfer because they allow long-term, stable integration of transgenics and their propagation in daughter cells. Lentiviral vectors have the additional advantage of being superior to vectors derived from cancer-retroviruses (such as murine leukemia viruses) because they can transduce non-proliferative cells, such as hepatocytes. They also have additional low immunogenicity advantages. Retroviral vectors can also be, for example, γ retroviral vectors. γ retroviral vectors can, for example, include promoters, packaging signals (ψ), primer binding sites (PBS), one or more (e.g., two) long terminal repeats (LTR) and target transgenics, for example, genes encoding CAR. γ retroviral vectors can lack viral structural genes such as gag, pol and env.
[0274] An example of a promoter capable of expressing a CAR transgene in mammalian T cells is the EF1a promoter. The natural EF1a promoter drives the expression of the α subunit of the elongation factor-1 complex, which is responsible for enzymatic delivery of aminoacyl tRNA to the ribosome. The EF1a promoter has been widely used in mammalian expression plasmids and has been shown to effectively drive the expression of CAR from a transgene cloned into a lentiviral vector. See, for example, Milone et al., Mol. Ther. 17 (8): 1453–1464 (2009).
[0275] Another example of a promoter is the immediate early cytomegalovirus (CMV) promoter sequence. This promoter sequence is a constitutive strong promoter sequence that can drive any polynucleotide sequence effectively connected thereto to express at a high level. However, other constitutive promoter sequences may also be used, including but not limited to simian virus 40 (SV40) early promoter, mouse mammary tumor virus (MMTV), human immunodeficiency virus (HIV) long terminal repeat (LTR) promoter, MoMuLV promoter, avian leukemia virus promoter, Epstein-Barr virus immediate early promoter, Rous sarcoma virus promoter and human gene promoter, such as but not limited to actin promoter, myosin promoter, elongation factor-1α promoter, hemoglobin promoter and creatine kinase promoter. In addition, the present invention should not be limited to the use of constitutive promoters. Inducible promoters are also contemplated as part of the present invention.
[0276] In some embodiments, the present invention provides methods for expressing a CAR construct of the present invention in a mammalian immune effector cell (e.g., a mammalian T cell or a mammalian NK cell) and the immune effector cells produced thereby.
[0277] A cell source (e.g., immune effector cells, e.g., T cells or NK cells) is obtained from a subject. The term "subject" is intended to include living organisms (e.g., mammals) that can stimulate an immune response. T cells can be obtained from numerous sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, umbilical cord blood, thymus tissue, tissue from an infection site, ascites, pleural effusion, spleen tissue, and tumors.
[0278] Any technique known to those skilled in the art (such as Ficoll TM In one preferred aspect, cells from circulating blood of an individual are obtained by apheresis. The apheresis product generally contains lymphocytes, including T cells, monocytes, granulocytes, B cells, other nucleated leukocytes, erythrocytes, and platelets. In one embodiment, the cells collected by apheresis can be washed to remove the plasma fraction and to place the cells in a suitable buffer or culture medium for subsequent processing steps. In one aspect of the invention, the cells are washed with phosphate buffered saline (PBS).
[0279] Specific T cell subsets, such as CD3+, CD28+, CD4+, CD8+, CD45RA+, and CD45RO+ T cells, can be further isolated by positive or negative selection techniques. For example, in one embodiment, by using beads conjugated with anti-CD3 / anti-CD28 (e.g. In some embodiments, the time period is between about 30 minutes and 36 hours or longer. Longer incubation time can be used to separate T cells in any case where there is a small amount of T cells, such as for separating tumor infiltrating lymphocytes (TIL) from tumor tissue or from immunocompromised individuals. In addition, the efficiency of capturing CD8+T cells can be increased using longer incubation time. Therefore, by simply shortening or extending the time, allowing T cells to combine with CD3 / CD28 beads and / or by increasing or reducing the ratio of beads to T cells, T cell subsets can be selected preferentially at the beginning of cultivation or at other time points during the culture process.
[0280] Enrichment of T cell populations can be accomplished by a negative selection process using a combination of antibodies directed against surface markers unique to the negatively selected cells. One approach is to sort and / or select cells using negative magnetic immunoadhesion or flow cytometry using a mixture of monoclonal antibodies directed against cell surface markers present on the negatively selected cells.
[0281] In some embodiments, immune effector cell can be an allogeneic immune effector cell, for example, a T cell or a NK cell. For example, the cell can be an allogeneic T cell, for example, an allogeneic T cell lacking a functional T cell receptor (TCR) and / or human leukocyte antigen (HLA) (for example, HLA class I and / or HLA class II) expression.
[0282] A T cell lacking a functional TCR can, for example, be engineered so that it does not express any functional TCR on its surface; engineered so that it does not express one or more subunits that make up a functional TCR (e.g., engineered so that it does not express or shows reduced expression of TCRα, TCRβ, TCRγ, TCRδ, TCRε and / or TCRδ); or engineered so that it produces very few functional TCRs on its surface.
[0283] The T cells described herein can be engineered, for example, so that it does not express functional HLA on its surface. For example, the T cells described herein can be engineered so that the cell surface expression of HLA (e.g., HLA class I and / or HLA class II) is downregulated. In some aspects, downregulation of HLA can be achieved by reducing or eliminating beta-2 microglobulin (B2M) expression.
[0284] In some embodiments, the T cell may lack a functional TCR and a functional HLA, e.g., HLA class I and / or HLA class II.
[0285] In one embodiment, cells transduced with a nucleic acid encoding a CAR described herein are proliferated, for example, the cells are proliferated in culture for 2 hours to about 14 days.
[0286] The CAR-expressing immune effector cells obtained after in vitro proliferation can be tested for effector function as described in the examples.
[0287] In a specific embodiment, the first component suitable for use in the pharmaceutical combination of the present invention is a CAR-T cell comprising the CAR of the present invention.
[0288] IV. Antibodies that specifically bind to BCMA molecules and antibodies comprising mutant Fc domains thereof
[0289] The present invention provides an antibody that binds to BCMA with high target specificity and high affinity, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a CDR H1 shown in the amino acid sequence SSSYYWT (SEQ ID NO: 25) according to Kabat numbering, or a variant of the CDR H1 with no more than 2 amino acid changes or no more than 1 amino acid change; a CDR H2 shown in the amino acid sequence SISIAGSTYYNPSLKS (SEQ ID NO: 26), or a variant of the CDR H2 with no more than 2 amino acid changes or no more than 1 amino acid change; and a CDR H3 shown in the amino acid sequence DRGDQILDV (SEQ ID NO: 27), or a variant of the CDR H3 with no more than 2 amino acid changes or no more than 1 amino acid change; the light chain variable region comprises a CDR L1 shown in the amino acid sequence RASQSISRYLN (SEQ ID NO: 28) according to Kabat numbering, or a variant of the CDR L1 with no more than 2 amino acid changes or no more than 1 amino acid change; a CDR L2, or a variant of said CDR L2 with no more than 2 amino acid changes or no more than 1 amino acid change; and CDR L3 shown in the amino acid sequence QQKYFDIT (SEQ ID NO: 30), or a variant of said CDR L3 with no more than 2 amino acid changes or no more than 1 amino acid change;
[0290] The amino acid changes are amino acid additions, deletions or conservative amino acid substitutions.
[0291] In some embodiments, the antibodies of the invention that bind to BCMA molecules bind to mammalian BCMA, such as human, cynomolgus monkey, mouse, rat, and rabbit BCMA.
[0292] In some embodiments, the antibodies of the invention that bind to BCMA molecules have one or more of the following properties:
[0293] (1) Specific binding to BCMA;
[0294] (2) binds to human BCMA and cross-reacts with cynomolgus monkey, mouse, rat, and rabbit BCMA;
[0295] (3) In the absence of a mutant Fc domain, for example, in the case of having an unmutated parent antibody Fc domain, BCMA-positive cancer cells can be killed by antibody-dependent cellular cytotoxicity and / or antibody-dependent cellular phagocytosis (ADCP).
[0296] In some embodiments, the antibody that binds to the BCMA molecule of the present invention comprises a heavy chain variable region, wherein the heavy chain variable region comprises the sequence of SEQ ID NO: 2, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto, wherein the amino acid changes in the sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity are preferably amino acid substitutions, more preferably conservative amino acid substitutions, and preferably, the amino acid changes do not occur in the CDR regions.
[0297] In some embodiments, the antibody that binds to the BCMA molecule of the present invention comprises a light chain variable region, wherein the light chain variable region comprises the sequence of SEQ ID NO:3, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto, wherein the amino acid changes in the sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity are preferably amino acid substitutions, more preferably conservative amino acid substitutions, and preferably, the amino acid changes do not occur in the CDR regions.
[0298] In some embodiments, an antibody that binds to a BCMA molecule of the present invention comprises a heavy chain variable region and a light chain variable region, wherein:
[0299] the heavy chain variable region comprises a sequence of SEQ ID NO:2, or a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical thereto, and the light chain variable region comprises a sequence of SEQ ID NO:3, or a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical thereto;
[0300] The amino acid changes in the sequences with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity are preferably amino acid substitutions, more preferably conservative amino acid substitutions, and preferably, the amino acid changes do not occur in the CDR regions.
[0301] In some embodiments, an antibody that binds to a BCMA molecule of the present invention comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises or consists of the sequence of SEQ ID NO: 2, and the light chain variable region comprises or consists of the sequence of SEQ ID NO: 3.
[0302] In some embodiments, the antibody that binds to a BCMA molecule of the present invention is an IgG1, IgG2, IgG3, or IgG4 antibody; preferably, it is an IgG1 or IgG4 antibody; more preferably, it is an IgG1 antibody, for example, a human IgG1 antibody.
[0303] In some embodiments, the antibody that binds to the BCMA molecule provided herein comprises a mutant Fc domain, wherein the amino acid at position P329 according to EU numbering is mutated to glycine (G), and the Fcγ receptor binding of the mutant Fc domain is reduced compared to the Fcγ receptor binding of the unmutated parent antibody Fc domain; for example, the mutant Fc domain is a mutant Fc domain of an IgG1, IgG2, IgG3 or IgG4 antibody, preferably, the mutant Fc domain is a mutant Fc domain of an IgG1 or IgG4 antibody; more preferably, the mutant Fc domain is a mutant Fc domain of an IgG1 antibody, for example, the mutant Fc domain is a mutant Fc domain of a human IgG1 antibody. In some embodiments, the mutant Fc domain comprises an amino acid sequence of SEQ ID NO: 10, or has at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, and comprises a P329G mutation.
[0304] In some embodiments, the antibody that binds to the BCMA molecule comprising a P329G mutant Fc domain is incapable of antibody-dependent cellular cytotoxicity by binding to an Fcγ receptor, and is incapable of antibody-dependent cellular phagocytosis (ADCP).
[0305] In some embodiments, an antibody that binds to a BCMA molecule of the invention comprises a heavy chain, wherein the heavy chain variable region comprises a sequence of SEQ ID NO: 34, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto and comprises P329G (EU numbering), wherein the amino acid change in the sequence of at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity is preferably an amino acid substitution, more preferably an amino acid conservative substitution, preferably, the amino acid change does not occur in the CDR region or in the variable region.
[0306] In some embodiments, the antibody that binds to the BCMA molecule of the present invention comprises a light chain, wherein the light chain variable region comprises the sequence of SEQ ID NO: 35, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto, wherein the amino acid changes in the sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity are preferably amino acid substitutions, more preferably conservative amino acid substitutions, and preferably, the amino acid changes do not occur in the CDR regions or in the variable regions.
[0307] In some embodiments, an antibody that binds to a BCMA molecule of the present invention comprises a heavy chain and a light chain, wherein:
[0308] the heavy chain comprises the sequence of SEQ ID NO:34, or a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical thereto, and the light chain comprises the sequence of SEQ ID NO:35, or a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical thereto;
[0309] The amino acid changes in the sequences with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity are preferably amino acid substitutions, more preferably conservative amino acid substitutions, and preferably, the amino acid changes do not occur in the CDR regions or in the variable regions.
[0310] In some embodiments, an antibody that binds to a BCMA molecule of the present invention comprises a heavy chain and a light chain, wherein the heavy chain comprises or consists of the sequence of SEQ ID NO: 34, and the light chain comprises or consists of the sequence of SEQ ID NO: 35.
[0311] In some embodiments, the present invention provides nucleic acids encoding any of the above antibodies or fragments thereof or any of their chains that bind to BCMA molecules. In one embodiment, a vector comprising the nucleic acid is provided. In one embodiment, the vector is an expression vector. In one embodiment, a host cell comprising the nucleic acid or the vector is provided. In one embodiment, the host cell is eukaryotic. In another embodiment, the host cell is selected from yeast cells, mammalian cells (e.g., CHO cells or 293 cells), or other cells suitable for preparing antibodies or antigen-binding fragments thereof. In another embodiment, the host cell is prokaryotic.
[0312] For example, the nucleic acid of the present invention comprises a nucleic acid encoding an antibody that binds to a BCMA molecule of the present invention. In some embodiments, one or more vectors comprising the nucleic acid are provided. In one embodiment, the vector is an expression vector, such as a eukaryotic expression vector. The vector includes, but is not limited to, a virus, a plasmid, a cosmid, a lambda phage, or a yeast artificial chromosome (YAC). In one embodiment, the vector is a pcDNA3.4 expression vector.
[0313] Once an expression vector or DNA sequence for expression has been prepared, the expression vector can be transfected or introduced into a suitable host cell. A variety of techniques can be used to achieve this purpose, for example, protoplast fusion, calcium phosphate precipitation, electroporation, retroviral transduction, viral transfection, gene gun, lipid-based transfection or other conventional techniques. In the case of protoplast fusion, the cells are cultivated in a culture medium and screened for suitable activity. Methods and conditions for culturing the transfected cells produced and for recovering the antibody molecules produced are known to those skilled in the art and can be based on this specification and methods known in the prior art, depending on the specific expression vector and mammalian host cell used. Variation or optimization.
[0314] In addition, one or more markers of the host cell that allows to select transfected can be introduced to select the cell that has stably incorporated DNA into its chromosome. The marker can for example provide prototrophy, biocidal resistance (for example, antibiotic) or heavy metal (such as copper) resistance etc. to the auxotrophic host. The selectable marker gene can be directly connected to the DNA sequence to be expressed or introduced into the same cell by co-transformation. Additional elements may also be needed so that the best synthetic mRNA can be obtained. These elements can include splicing signals, as well as transcription promoters, enhancers and termination signals.
[0315] In one embodiment, a host cell comprising a polynucleotide of the present invention is provided. In some embodiments, a host cell comprising an expression vector of the present invention is provided. In some embodiments, the host cell is selected from yeast cells, mammalian cells or other cells suitable for preparing antibodies. Suitable host cells include prokaryotic microorganisms, such as Escherichia coli. The host cell can also be a eukaryotic microorganism such as a filamentous fungus or yeast, or various eukaryotic cells, such as insect cells, etc. Vertebrate cells can also be used as hosts. For example, a mammalian cell line modified to be suitable for suspension growth can be used. Examples of useful mammalian host cell lines include SV40 transformed monkey kidney CV1 line (COS-7); human embryonic kidney line (HEK293 or 293F cells), 293 cells, baby hamster kidney cells (BHK), monkey kidney cells (CV1), African green monkey kidney cells (VERO-76), human cervical cancer cells (HELA), canine kidney cells (MDCK), Buffalo rat liver cells (BRL 3A), human lung cells (W138), human liver cells (HepG2), Chinese hamster ovary cells (CHO cells), CHO-S cells, NSO cells, myeloma cell lines such as Y0, NS0, P3X63 and Sp2 / 0, etc. For a review of mammalian host cell lines suitable for producing proteins, see, for example, Yazaki and Wu, Methods in Molecular Biology, Vol. 248 (BKCLo ed., Humana Press, Totowa, NJ), pp. 255-268 (2003). In a preferred embodiment, the host cell is a CHO cell or a HEK293 cell.
[0316] In one embodiment, the present invention provides a method for preparing an antibody that binds to a BCMA molecule (including a P329G mutant antibody), wherein the method comprises culturing a host cell comprising a nucleic acid encoding the antibody that binds to a BCMA molecule (including a P329G mutant antibody) or an expression vector comprising the nucleic acid under conditions suitable for expressing the nucleic acid encoding the antibody that binds to a BCMA molecule (including a P329G mutant antibody), and optionally isolating the antibody that binds to a BCMA molecule (including a P329G mutant antibody). In a certain embodiment, the method further comprises recovering the antibody that binds to a BCMA molecule (including a P329G mutant antibody) from the host cell (or host cell culture medium).
[0317] The antibodies (including P329G mutant antibodies) of the present invention that bind to BCMA molecules prepared as described herein can be purified by known prior art techniques such as high performance liquid chromatography, ion exchange chromatography, gel electrophoresis, affinity chromatography, size exclusion chromatography, etc. The actual conditions used to purify a particular protein also depend on factors such as net charge, hydrophobicity, hydrophilicity, etc., and these are obvious to those skilled in the art. The purity of the antibodies (including P329G mutant antibodies) that bind to BCMA molecules of the present invention can be determined by any of a variety of well-known analytical methods, including size exclusion chromatography, gel electrophoresis, high performance liquid chromatography, etc.
[0318] The antibodies (including P329G mutant antibodies) that bind to BCMA molecules provided herein can be identified, screened or characterized for their physical / chemical properties and / or biological activity by a variety of assays known in the art. On the one hand, the antibodies (including P329G mutant antibodies) that bind to BCMA molecules of the present invention are tested for their antigen binding activity, for example, by known methods such as FACS, ELISA or Western blotting. Binding to BCMA can be determined using methods known in the art, and exemplary methods are disclosed herein. In some embodiments, FACS is used to determine the binding of antibodies (including P329G mutant antibodies) that bind to BCMA molecules of the present invention to cell surface BCMA (eg, human BCMA).
[0319] The present invention also provides an assay for identifying antibodies (including P329G mutant antibodies) that bind to BCMA molecules and have biological activity. The biological activity may include, for example, ADCC effect, CDC effect, etc.
[0320] Cells used in any of the above in vitro assays include cell lines that naturally express BCMA or are engineered to express BCMA. The cell lines engineered to express BCMA are cell lines that do not normally express BCMA but express BCMA after transfection of BCMA-encoding DNA into the cells.
[0321] V. Pharmaceutical Combinations of the Present Invention
[0322] For the optimization of the safety and efficacy of CAR therapy, the molecular switch regulated chimeric antigen receptor of the present invention is a regulatable CAR that can control the activity of CAR. The present invention uses the Pro329Gly (antibody Fc segment according to the EU numbering of the 329th proline mutated to glycine, abbreviated as P329G) mutant antibody as a safety switch in the CAR treatment of the present invention. In the absence of the P329G mutant antibody, the CAR activity of the present invention is turned off; in the presence of the P329G mutant antibody, the CAR activity of the present invention is turned on; thus, the opening and closing of the CAR molecule activity of the present invention is regulated by the P329G mutant antibody.
[0323] In some embodiments, the present invention provides a drug combination, which includes (i) immune effector cells (e.g., T cells, NK cells) expressing the molecular switch regulated CAR polypeptides of the present invention;And (ii) P329G mutant antibodies specifically binding BCMA molecules.For example, the immune effector cells are T cells expressing the molecular switch regulated CAR polypeptides of the present invention prepared from autologous T cells or allogeneic T cells, for example, the immune effector cells are T cells expressing the molecular switch regulated CAR polypeptides of the present invention prepared from T cells separated from human PBMC.In some embodiments, the P329G mutant antibody is ADI-38497 PG Ab.
[0324] In some embodiments, the present invention provides a drug combination comprising (i) a nucleic acid molecule encoding a molecular switch-regulated CAR polypeptide of the present invention or a vector comprising the nucleic acid component; and (ii) a P329G mutant antibody that specifically binds to a BCMA molecule.
[0325] In some embodiments, the pharmaceutical combination of the present invention optionally further comprises a pharmaceutically acceptable excipient for a suitable formulation. For example, (ii) in the pharmaceutical combination can be formulated according to conventional methods (eg, Remington's Pharmaceutical Science, latest edition, Mark Publishing Company, Easton, USA).
[0326] In some embodiments, the drug combination of the present invention is used to treat a disease associated with BCMA, such as a cancer that expresses or overexpresses BCMA, such as multiple myeloma, wherein the multiple myeloma is refractory multiple myeloma or relapsed multiple myeloma, such as relapsed / refractory multiple myeloma (RRMM).
[0327] VI. Uses of the pharmaceutical combination of the present invention and methods of treatment using the pharmaceutical combination of the present invention
[0328] The present invention provides the aforementioned drug combination of the present invention for treating a disease associated with BCMA in a subject, such as a cancer expressing or overexpressing BCMA, such as relapsed / refractory multiple myeloma (RRMM).
[0329] In one embodiment, the pharmaceutical combination of the present invention is used to treat a cancer that expresses or overexpresses BCMA in a subject and is capable of reducing the severity of at least one symptom or indication of the cancer or inhibiting the growth of cancer cells, wherein the cancer is multiple myeloma, such as refractory multiple myeloma or relapsed multiple myeloma, such as relapsed / refractory multiple myeloma.
[0330] The present invention provides a method for treating a BCMA-related disease (e.g., a cancer that expresses or overexpresses BCMA, such as multiple myeloma, such as refractory multiple myeloma or relapsed multiple myeloma, such as relapsed / refractory multiple myeloma) in a subject, comprising administering a therapeutically effective amount of a pharmaceutical combination of the present invention to an individual in need thereof.
[0331] The present invention provides use of the aforementioned drug combination of the present invention in the preparation of a medicament for treating a disease associated with BCMA (e.g., a cancer that expresses or overexpresses BCMA, such as multiple myeloma, such as refractory multiple myeloma or relapsed multiple myeloma, such as relapsed / refractory multiple myeloma).
[0332] The drug combination of the present invention can also be applied to individuals who have been treated with at least three previous therapies for cancer but have subsequently relapsed or metastasized, for example, the cancer is multiple myeloma, for example, refractory multiple myeloma or relapsed multiple myeloma, such as relapsed / refractory multiple myeloma (RRMM). In some embodiments, the previous therapy includes treatment with a proteasome inhibitor and an immunomodulator.
[0333] In some embodiments, the multiple myeloma is refractory multiple myeloma. In some embodiments, wherein the multiple myeloma is relapsed multiple myeloma. In some embodiments, the multiple myeloma is refractory and relapsed multiple myeloma relapsed / refractory multiple myeloma (RRMM). In some embodiments, the subject has received at least three prior therapies for the treatment of multiple myeloma. In some embodiments, the prior therapy includes treatment with a proteasome inhibitor and an immunomodulator.
[0334] In some embodiments, the drug combination of the present invention (i) expresses the immune effector cells (e.g., T cells, NK cells) of the molecular switch regulated CAR polypeptide of the present invention and (ii) the P329G mutant antibody that specifically binds to the BCMA molecule is used for parenteral, percutaneous, intracavitary, intraarterial, intravenous, intrathecal administration, or directly injected into a tissue or tumor. In some embodiments, the drug combination of the present invention (ii) specifically binds to the P329G mutant antibody of the BCMA molecule before (i) expressing the immune effector cells (e.g., T cells, NK cells) of the molecular switch regulated CAR polypeptide of the present invention.
[0335] In some embodiments, the immune effector cells (i) expressing the molecular switch-regulated CAR polypeptide of the present invention in the drug combination of the present invention are T cells expressing the CAR polypeptide of the present invention prepared from autologous T cells or allogeneic T cells; the P329G mutant antibody (ii) specifically binding to the BCMA molecule in the drug combination of the present invention is any antibody that specifically binds to the BCMA molecule, which comprises a P329G mutation. Preferably, the P329G mutant antibody is ADI-38497 PG Ab.
[0336] In some embodiments, administering the drug combination of the present invention to an individual suffering from cancer results in the complete disappearance of a tumor. In some embodiments, administering the drug combination of the present invention to an individual suffering from cancer results in a reduction of tumor cells or tumor size by at least 85% or more. The reduction of a tumor can be measured by any method known in the art, such as X-rays, positron emission tomography (PET), computed tomography (CT), magnetic resonance imaging (MRI), cytology, histology, or molecular genetic analysis.
[0337] In some embodiments, the drug combination of the present invention can reduce the "on-target / off tumor" toxicity of CAR-T cells.
[0338] VII. Therapy of the Invention
[0339] In some specific embodiments, the present invention relates to a method of treating multiple myeloma in an individual, comprising administering to the individual a drug combination comprising
[0340] (i) The first component, for example, is a T cell expressing a molecular switch-regulated CAR polypeptide, i.e., a CAR-T cell.
[0341] (ii) a second component, e.g., an antibody or antigen-binding fragment that specifically binds to a BCMA molecule comprising a P329G mutation, wherein the P329G mutant antibody comprises a mutant Fc domain, wherein the amino acid at position P329 according to EU numbering is mutated to glycine (G).
[0342] In some embodiments, the method comprises administering the first component at a dose of about 0.5×10 6 cells / kg body weight - approximately 5×10 6 cells / kg body weight, for example, approximately 0.75×10 6 cells / kg body weight, 1×10 6 cells / kg body weight, 1.5×10 6 cells / kg body weight, 2×10 6 cells / kg body weight, 2.5×10 6 cells / kg body weight, 3×10 6 cells / kg body weight, 3.5×10 6 cells / kg body weight, 4×10 6 cells / kg body weight, 4.5×10 6 cells / kg body weight, 5×10 6 In some embodiments, the administration is a single administration or multiple administrations, preferably a single administration. In some embodiments, the administration is intravenous administration.
[0343] In some embodiments, the method comprises administering the second component at a dose of about 0.1-3 mg / kg, preferably about 0.1 mg / kg, 0.2 mg / kg, 0.3 mg / kg, 0.4 mg / kg, 0.5 mg / kg, 1 mg / kg, 1.5 mg / kg, 2 mg / kg, 2.5 mg / kg, 3 mg / kg. In some embodiments, the administration is parenteral, more preferably intravenous.
[0344] In some embodiments, the first component and the second component are administered in the following regimen:
[0345] The second component is applied on the first day, and the first component is applied at an interval of about 1-5 hours (e.g., at an interval of about 1, 2, 3, 4 or 5); or the second component is applied on the first day, and the first component is applied on the second day, with an interval of about 24 hours;
[0346] Taking the first day as the starting date, the second component is administered every 1 week (QW), 2 weeks (Q2W) or every 3 weeks (Q3W) in the first cycle;
[0347] Cycle 2 to Cycle n: Administer the second component every three weeks (Q3W) in each cycle.
[0348] In some embodiments, each dosing cycle is 21 days or 28 days.
[0349] In some embodiments, at least 2-3 cycles are administered. In some embodiments, at least 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 cycles or more are administered.
[0350] In some embodiments, a lymphodepletion (LD) regimen is administered to the individual. In some embodiments, a lymphodepletion (LD) regimen is administered to the individual prior to administration of the second component. In some embodiments, the lymphodepletion regimen is administered prior to administration of the second component, for example, 1, 2, 3, 4, 5, or 6 days prior to administration. In some embodiments, the duration of LD is about 1 to 5 days, for example, about 3 days. In some embodiments, the time window between the end of LD and the start of administration of the second component, such as a BCMA antibody, is 2 days or 3 days or 4 days. In some embodiments, LD is started about 3 to 5 days prior to administration of a dose of a second component, such as a BCMA antibody.
[0351] In some embodiments, LD is initiated about 3, 4, or 5 days prior to administration of a dose of a second component, e.g., an anti-BCMA antibody. In some embodiments, a dose of a second component, e.g., an anti-BCMA antibody, is administered about 1, 2, or 3 days after the end of LD.
[0352] In some embodiments, LD comprises fudarapane and cyclophosphamide.
[0353] In some embodiments, the first component, such as CAR-T cells, is prepared within about 20-40 days before the second component of the present invention is administered. In some embodiments, the first component, such as CAR-T cells, is prepared within about 25-35 days. In some embodiments, the first component comprises T cells. In some embodiments, T cells are autologous T cells, such as T cells obtained from blood components collected from the subject.
[0354] In some embodiments, the present invention relates to a pharmaceutical combination for use in the methods of treatment of the present invention.
[0355] In some embodiments, after administration of the therapy of the present invention, the probability of the subject developing CRS or ICANS is low, such as less than 50%, such as lower than existing BCMA-CAR-T products.
[0356] In some embodiments, the therapies of the invention have a good safety and / or tolerability profile.
[0357] In some embodiments, the second component (e.g., an anti-BCMA antibody) is capable of modulating the activity of the first component, in particular the cellular activity of CAR-T cells.
[0358] In some embodiments, the therapy of the present invention can partially relieve the disease in the subject. Clinical studies have shown that a total of 11 patients were enrolled, of which 5 patients achieved PR or above.
[0359] VIII. Kit of the Invention
[0360] The present invention provides a kit comprising the drug combination of the present invention, preferably the kit is in the form of a drug dosage unit, so that the dosage unit can be provided according to the dosage regimen or the drug administration interval.
[0361] In one embodiment, the kit of parts of the present invention comprises in the same package:
[0362] (i) an immune effector cell (e.g., T cell, NK cell) expressing a molecular switch-regulated CAR polypeptide of the present invention, a nucleic acid molecule encoding a molecular switch-regulated CAR polypeptide of the present invention, a vector comprising the nucleic acid, and any combination thereof;
[0363] (ii) P329G mutant antibody that specifically binds to BCMA molecules.
[0364] The various embodiments / technical solutions described in the present invention and the features in each embodiment / technical solution should be understood to be able to be combined with each other arbitrarily, and the various solutions obtained by these combinations are included in the scope of the present invention, just as the solutions obtained by these combinations are specifically and one by one listed in this document, unless the context clearly shows otherwise.
[0365] The following examples are described to assist understanding of the present invention. The examples are not intended to and should not be interpreted in any way as limiting the scope of protection of the present invention. Example
[0366] Example 1. CAR gene synthesis, construction of viral expression vector, preparation of P329G CAR-T cells and detection of CAR expression
[0367] (1-1) CAR gene synthesis and construction of viral expression vector
[0368] A P329G CAR molecule (SEQ ID NO: 1), also known as HuR968B CAR, was constructed, which was fused with a signal peptide (SP) as shown in SEQ ID NO: 11, a specific single-chain antibody fragment recognizing the P329G antibody (VH-linker-VL, having the VH shown in SEQ ID NO: 12, the linker sequence shown in SEQ ID NO: 33, and the VL shown in SEQ ID NO: 13), a G4S hinge region as shown in SEQ ID NO: 14, a CD8 transmembrane domain (CD8TM) as shown in SEQ ID NO: 15, a 41BB co-stimulatory domain (41BB-CSD) as shown in SEQ ID NO: 16, and a CD3δ molecule intracellular activation domain (CD3δSSD) as shown in SEQ ID NO: 17.
[0369] In addition, a Blue21 CAR (SEQ ID NO: 8) directly targeting BCMA was constructed and used as a control. Blue21 CAR contains a signal peptide shown in SEQ ID NO: 11, an anti-BCMA single-chain antibody (from 11D53 clone), a hinge region of the CD8α molecule shown in SEQ ID NO: 18, and a CD8 transmembrane domain shown in SEQ ID NO: 15, a 4-1BB costimulatory domain shown in SEQ ID NO: 16, and a CD3δ chain intracellular activation domain shown in SEQ ID NO: 17 from the N-terminus to the C-terminus.
[0370] The above-mentioned DNA fragments encoding the CAR polypeptide were respectively inserted into the downstream of the EF1α promoter of the pRK lentiviral expression vector (which was modified by replacing the promoter and the resistance gene of the pRRLSIN.cPPT.PGK-GFP.WPRE vector (Addgene, 12252, purchased from BioWind)), replacing the EGFR sequence in the vector, and obtaining the CAR expression plasmids pRK-HuR968B and pRK-Blue21.
[0371] (1-2) Preparation of lentiviral concentrate
[0372] The CAR expression plasmid prepared in Example 1-1 was transfected into Lenti-X-293T cells (Takara) at a mass ratio of 3:3:2:2 using the PEI transfection method with the structural plasmid pMDLg / pRRE (Addgene, 12251, purchased from Biowind), the regulatory plasmid pRSV-rev (Addgene, 12253, purchased from Biowind) and the envelope plasmid pMD2G (Addgene, 12259, purchased from Biowind). After 16 hours of transfection, it was replaced with fresh DEME medium containing 2% fetal bovine serum (FBS). After continued culture for 48 hours, the cell supernatant was collected, the cell debris was removed by centrifugation, PEG8000 was added and incubated at 4°C for 16-64 hours for lentivirus concentration, the supernatant was removed after centrifugation again, and the lentivirus precipitate was resuspended in T cell culture medium to obtain a lentivirus concentrate, which was packaged and frozen at -80°C.
[0373] (1-3) Preparation of P329G CAR-T cells and detection of CAR expression:
[0374] Recombinant human interleukin-2 for injection (National Medicine Standard No. S20040020) was added to TexMACS GMP Medium (Miltenyi Biotec, 170-076-309) to prepare a T cell culture medium with an IL-2 concentration of 200 IU / ml.
[0375] PBMC cells from multiple donors were obtained from ORiCELLS, and the specific information is shown in Table 1 below:
[0376] Table 1. Related information of donor PBMC cells
[0377]
[0378]
[0379] On day 0, the resuscitated PBMCs of each donor were sorted using the Pan T Cell Isolation Kit (human) (Miltenyi, 130-096-535) to obtain T cells, which were resuspended to a certain density using T cell culture medium and activated by adding TransAct (Miltenyi, 130-111-160).
[0380] On the first day, a certain amount of T cells were separated and cultured without adding lentiviral concentrate. These cells were untransduced cells (UNT, un-transduced T cells), and the remaining T cells were added with lentiviral concentrate obtained from Example 1-2 at MOI = 1 to 5 (the lentivirus was a lentivirus encoding P329G CAR (SEQ ID NO: 1) or a control traditional CAR (SEQ ID NO: 8)) and the T cells were blown evenly; the viral supernatant was removed by centrifugation on the second day, and the cells were resuspended in fresh T cell culture medium. On the third day, all cells were transferred to G-Rex (WILSONWOLF, item number 80040S), and an appropriate amount of fresh T cell culture medium was added, and placed in a 37°C CO2 incubator for static culture; every 2 to 3 days, the cells were replaced with fresh culture medium or IL-2 was directly added with half the amount of culture medium, wherein IL-2 was added to the cell culture medium at a concentration of 200 IU / ml. When the number of cells is expanded to about 20-80 times, the demand is met (generally reaching 2-8x10 8 After centrifugation to remove the culture medium, CAR-T cells were used CS10 (Stemcell, 07930) was resuspended and aliquoted, and then programmed to cool to -80°C for cryopreservation.
[0381] Take an appropriate amount of CAR-T cells, wash once with FACS buffer (PBS + 2% FBS), resuspend and add FACS buffer containing LIVE / DEADFixable Dead Cell Stain, stain at room temperature for 10-15 minutes, wash twice, add PerCP-Cy5.5-CD3, BUV805-CD, Biotin-F(ab')2Fragment goat anti-human IgG (Jackson ImmunoResearch, 109-066-006; PG CAR detection) or Biotin-F(ab')2Fragment goat anti-mouse IgG (Jackson ImmunoResearch, 115-066-006; Blue 21CAR detection) antibody combination, stain at 4°C for 30-45 minutes, wash twice, add APC-Streptavidin, and stain at 4°C for 30-45 minutes; wash the cells twice, resuspend them in FACS buffer, and detect them by flow cytometry.
[0382] Figure 1A The results show that after T cells were transduced with the two CARs constructed in Example 1-1, CD3 + cells, CD4 + 、CD8 +The expression of CAR in T cell subsets showed that the positive rate of CAR expression in these transduced T cells was approximately 18% to 29%.
[0383] Example 2. Detection of BCMA-specific P329G mutant antibody binding activity to antigen
[0384] (2-1) Synthesis of BCMA-specific antibodies
[0385] The heavy and light chain variable region sequences of the BCMA parent antibody ADI-34861 (VH shown in SEQ ID NO: 31 and VL shown in SEQ ID NO: 32, respectively) were obtained from the international application number PCT / CN2019 / 074419 (BCMA antibody related patent), and the heavy and light chain variable region sequences of ADI-38497 (SEQID NO: 2, SEQ ID NO: 3) were obtained by performing CDR region mutations on the basis of the parent antibody ADI-34861. Compared with the corresponding parent antibody, the affinity of the mutated antibody was significantly improved, and the specific experimental data are shown in Table 2 below.
[0386] Table 2 Binding affinity of parental and mutant antibodies to BCMA
[0387]
[0388] The light and heavy chain variable region sequences of the BCMA antibody clone J6M0 of GSK were obtained from patent US9273141B2 and used as a control antibody (GSK IgG).
[0389] The light and heavy chain variable region sequences of GSK IgG and ADI-38497 antibodies were synthesized by whole gene and loaded into pcDNA3.4 expression vectors (purchased from Shanghai Boying) containing WT human IgG1 heavy chain constant region (SEQ ID NO: 4) or human IgG1 heavy chain constant region (SEQ ID NO: 5) containing P329G point mutation and κ light chain constant region (SEQ ID NO: 6). The light and heavy chain expression vectors were co-transfected into HEK293 cells by PEI at a molar ratio of 2:3, and the culture supernatant was collected after 5-7 days of culture. The supernatant culture medium containing the antibody was purified by a Protein A column in one step, and then dialyzed with PBS. The concentration was detected by reading the absorbance value at 280nm using a NanoDrop instrument, and the sample purity was detected by SDS-PAGE and SEC-HPLC methods. GSK WT antibody, GSK PG antibody; ADI-38497 WT antibody, ADI-38497 PG antibody were obtained. Antibodies having the sequences of the heavy chain variable region (SEQ ID NO: 2) and light chain variable region (SEQ ID NO: 3) of the BCMA antibody clone ADI-38497 are also referred to in the present application as ADI-38497 antibodies, including ADI-38497 PG antibodies (comprising a P329G mutation) and ADI-38497 WT antibodies.
[0390] (2-2) Antibody affinity testing
[0391] The affinity of ADI-38497 PG antibody to BCMA of different species was determined by Biacore T200. Figure 2A A schematic diagram of a method for determining antibody affinity using surface plasmon resonance (SPR) is shown.
[0392] The specific method is as follows: After anti-human Fc IgG (Ab97221, Abcam) is coupled to the surface of a CM5 chip (29149603, Cytiva), the ADI-38497 PG antibody is captured on the chip surface, and the affinity and kinetic constants are obtained by detecting the binding and dissociation between the antibody on the chip surface and the BCMA antigen in the mobile phase. The determination process uses 10×HBS-EP+ (BR-1006-69, Cytiva) diluted 10 times as the experimental buffer. Each cycle in the affinity test includes capturing the ADI-38497 PG antibody, binding to a concentration of antigen, and chip regeneration. The gradient diluted antigen (antigen concentration gradient is 1.25-40nM, 2-fold dilution) flows through the chip surface from low concentration to high concentration at a flow rate of 30μl / min, the binding time is 180s, and the appropriate dissociation time (900s or 600s or 60s) is set. Finally, the chip was regenerated using 10 mM glycine-HCl, pH 1.5 (BR-1003-54, Cytiva).
[0393] The data results were analyzed by Biacore T200 analysis software (version 3.1) using a 1:1 binding model.
[0394] Figure 2B The representative affinity profiles of ADI-38497 PG antibody and recombinant human, cynomolgus monkey, mouse, rat and rabbit BCMA proteins measured by SPR are shown. The results show that ADI-38497 PG antibody can bind to BCMA proteins from the above different species, and the order of binding activity is human BCMA> monkey BCMA> mouse BCMA> rat BCMA> rabbit BCMA.
[0395] Table 3 Binding affinity of ADI-38497 PG antibody to BCMA proteins from different species
[0396]
[0397] (2-3) Detection of the binding activity of P329G BCMA antibody with BCMA antigens from different species
[0398] First, CHO GS cells expressing BCMA antigens from different species were prepared. Specifically, BCMA genes from humans, mice, and cynomolgus monkeys were synthesized and cloned into lentiviral vectors, and then lentiviruses containing BCMA genes from different species were packaged and used to infect CHO GS cells. Subsequently, CHO GS cell lines expressing BCMA antigens from different species were obtained by flow cytometry sorting, namely hBCMA-CHO GS, mBCMA-CHO GS, and cynoBCMA-CHO GS cells.
[0399] Then, ADI-38497 PG antibody and GSK-derived BCMA antibody (i.e., GSK PG IgG was used as a benchmark) were prepared into antibody solutions of different concentrations with 10-fold gradient dilutions using FACS buffer, and incubated with 1E5 prepared CHO GS cells expressing BCMA antigens of different species at 4°C for 30 minutes, washed with FACS buffer, and then incubated with Fcγ fragment-specific APC-goat anti-human IgG (Jackson ImmunoResearch, 109-136-098) at 4°C for 30 minutes. P329G antibody bound to cells was detected by flow cytometry, APC channel MFI was analyzed, and the antibody concentration was used as the X-axis and the APC channel MFI was used as the Y-axis to plot and calculate the EC50 of binding.
[0400] Figure 2C The binding ability of different concentrations of P329G BCMA antibody to CHO-GS cells stably expressing human, cynomolgus monkey and mouse BCMA is shown. Figure 2C It can be seen that the ADI-38497 PG IgG antibody can bind to different species of BCMA expressed on the cell surface, while the GSK-derived BCMA antibody (Benchmark) has a higher species specificity for BCMA and does not recognize mouse BCMA. This result is consistent with the SPR detection result.
[0401] Table 4 EC50 values of the binding of P329G BCMA antibody to CHO-GS cells expressing BCMA of different species
[0402]
[0403] (2-4) Detection of the binding activity of P329G BCMA antibody to BCMA antigen on the surface of tumor cells
[0404] Take an appropriate amount of tumor cells in the logarithmic growth phase, wash twice with FACS buffer, add ADI-38497 PG antibody and GSK PGIgG used as a benchmark, add isotype hIgG1 antibody to the cells as staining control, stain at 4°C for 30 minutes, wash twice, add goat anti-human IgG antibody with APC-F(ab')2 fragment, stain at 4°C for 30 minutes, wash twice, resuspend the cells in FACS buffer, and detect by flow cytometry.
[0405] Figure 2DThe data show the binding activity of different concentrations of P329G BCMA antibody with BCMA-expressing positive multiple myeloma cell lines MM.1s, RPMI8226, U266, H929, L363 and AMO1 (MM.1s was purchased from Nanjing Kebai Biotechnology Co., Ltd., CBP60239; RPMI8226 was purchased from Nanjing Kebai Biotechnology Co., Ltd., CBP60244; U266 was purchased from Wuhan Pronosai Life Science Co., Ltd., CL-0510; H929 was purchased from Nanjing Kebai Biotechnology Co., Ltd., CBP60243; L363 was purchased from Nanjing Kebai Biotechnology Co., Ltd., CBP6024; AMO1 was purchased from Nanjing Kebai Biotechnology Co., Ltd., CBP60242). The ADI-38497 PG antibody can bind to BCMA-expressing positive tumor cells in a concentration-dependent manner. Among the BCMA-expressing positive tumor cells, MM.1s cells expressed BCMA at the highest level, RPMI8226, U266 and H929 cells expressed BCMA at a moderate level, and L363 and AMO1 cells expressed BCMA at a low level.
[0406] Table 5 EC50 values of the binding of P329G BCMA antibody to BCMA-positive tumor cells
[0407]
[0408]
[0409] Example 3. Binding activity detection of BCMA-specific P329G mutant antibody and P329G CAR extracellular domain
[0410] (3-1) Affinity detection of the binding between the P329G mutant antibody and the extracellular domain of the P329G CAR
[0411] The binding affinity of ADI-38497 molecules (P329G mutant antibody or wild-type antibody) to anti-P329G mutation-specific single-chain antibody-rabbit Fc fusion protein (also called "anti-PG scFv fusion protein" or simply "anti-PG scFv") was determined by Biacore T200. Figure 3A Schematic diagram showing the detection of affinity between anti-P329G mutation specific single-chain antibody-rabbit Fc fusion protein and ADI-38497 P329G mutation antibody using surface plasmon resonance (SPR).
[0412] The specific method is as follows: After the synthetic anti-PG scFv fusion protein (SEQ ID NO: 7) is coupled to the surface of the C1 chip (BR100535, Cytiva), the affinity and kinetic constants are obtained by detecting the binding and dissociation of the antibody on the chip surface with the ADI-38497 molecule in the mobile phase. The determination process uses 10×HBS-EP+ (BR-1006-69, Cytiva) diluted 10 times as the experimental buffer. Each cycle of affinity detection includes binding to one concentration of antibody and chip regeneration. The gradient diluted ADI-38497 molecules (concentration gradient of 3.125nM-100nM, 2-fold dilution) are flowed from low concentration to high concentration over the chip surface at a flow rate of 30μl / min, with a binding time of 180s and a dissociation time of 300s. Finally, 10mM Glycine-HCl, pH 1.5 (BR-1003-54, Cytiva) is used to regenerate the chip.
[0413] The data results were analyzed by Biacore T200 analysis software (version 3.1) using a 1:1 binding model.
[0414] Figure 3B Representative affinity profiles of ADI-38497 PG antibody and wild-type antibody binding to anti-PG scFv fusion protein using SPR are shown. The results show that only ADI-38497 PG antibody can specifically bind to anti-PG scFv as the extracellular domain of P329G CAR.
[0415] Table 6 Affinity of P329G BCMA antibody and wild-type antibody to anti-PG scFv determined by SPR
[0416]
[0417] (3-2) Binding affinity test of ADI-38497 molecule and anti-PG scFv fusion protein
[0418] The binding affinity of ADI-38497 molecules (P329G mutant antibody or wild-type antibody) to anti-PG scFv fusion protein was determined by Biacore T200. Figure 3C A schematic diagram showing a method for measuring antibody affinity using surface plasmon resonance (SPR).
[0419] The specific method is as follows: After anti-Fab IgG (I5260, Sigma) is coupled to the surface of HLC chip (HLC30M, Xantec), ADI-38497 molecules are captured on the chip surface, and the affinity and kinetic constants are obtained by detecting the binding and dissociation of the antibody on the chip surface with the anti-PG scFv fusion protein in the mobile phase. The determination process uses 10×HBS-EP+ (BR-1006-69, Cytiva) diluted 10 times as the experimental buffer. Each cycle of affinity detection includes capturing ADI-38497 molecules, binding to a concentration of anti-PG scFv and chip regeneration. The gradient diluted anti-PG scFv (concentration gradient of 1.25nM-40nM, 2-fold dilution) is flowed over the chip surface from low concentration to high concentration at a flow rate of 30μl / min, with a binding time of 180s and a dissociation time of 300s. Finally, the chip was regenerated using 10 mM glycine-HCl, pH 1.5 (BR-1003-54, Cytiva).
[0420] The data results were analyzed by Biacore T200 analysis software (version 3.1) using a 1:1 binding model.
[0421] Figure 3D Representative affinity profiles of ADI-38497 PG antibody and wild-type antibody with anti-PG scFv as the extracellular domain of P329G CAR are shown using SPR. The results show that only ADI-38497 PG antibody can specifically bind to P329G CAR.
[0422] Table 7 Affinity of P329G BCMA antibody and wild-type antibody with anti-PG scFv determined by SPR
[0423]
[0424] (3-3) Detection of the binding activity of P329G BCMA antibody and P329 CAR
[0425] The P329G CAR-T cells prepared in Example 1 were resuspensed with RPMI 1640 medium containing 10% FBS and cultured at 37°C for 24 hours. ADI-38497 PG antibody and wild-type ADI-38497 WT antibody were prepared into antibody solutions of different concentrations with 5-fold gradient dilutions using FACS buffer, and incubated with 1E5 CAR-positive cells at 4°C for 30 minutes, washed with FACS buffer, and then incubated with Fcγ fragment-specific APC goat anti-human IgG (Jackson ImmunoResearch, 109-136-098) at 4°C for 30 minutes. Antibodies bound to cells were detected by flow cytometry, and the APC channel MFI was analyzed. The antibody concentration was used as the X-axis and the APC channel MFI was used as the Y-axis to draw a plot and calculate the EC50 of binding.
[0426] Figure 3E The binding ability of ADI-38497 WT antibody and ADI-38497 PG antibody to P329G CAR-T cells was shown. The results showed that only the P329G mutant antibody showed binding to CAR, while the WT antibody did not bind to CAR, which was consistent with the SPR results.
[0427] Table 8 summarizes the EC50 and EC90 values of the binding of ADI-38497 PG antibody and WT antibody to P329G CAR-T cells from different donors.
[0428] Table 8 EC50 and EC90 values of BCMA IgG antibody binding to CAR-T cells
[0429]
[0430] Example 4. Fc domain function detection of BCMA-specific P329G mutant antibody
[0431] (4-1) ADCC effector function test of ADI-38497 PG antibody
[0432] The PBMC cells (Peripheral Blood Mononuclear Cells) of donor 3 were resuscitated, resuspended in RPMI 1640 medium, and stabilized at 37°C for 1-2 hours. PBMC and target cells were mixed at an effector-target ratio of 25:1, and mixed with different concentrations of BCMA antibodies, and cultured at 37°C for 4 hours and 24 hours, respectively. The antibody-mediated killing effect of PBMC on target cells was detected using an LDH detection kit (Promega, G1780), and the antibody concentration was used as the X-axis and the cell lysis ratio was used as the Y-axis for plotting and analysis. At the same time, the cells were collected, washed twice with FACS buffer, and CD3, CD56, CD16 and CD107a antibodies were added, of which CD107a antibodies needed to be added in advance and incubated with the cells at 37°C for 1 hour. The above cell antibody mixture was stained at 4°C for 30 minutes, washed twice, resuspended in FACS buffer, and detected by flow cytometry.
[0433] Figure 4A The ability of ADI-38497 WT antibody and ADI-38497 PG antibody to mediate ADCC killing was shown. The results showed that when different incubation times (4 hours, 24 hours) and different detection indicators (cytotoxicity to target cells, effects on the expression of CD3, CD56, CD16 and CD107a) were tested, only the WT antibody mediated the ADCC cytotoxic killing effect on BCMA-expressing positive H929 tumor cells, while the P329G mutant antibody lacked the ability to induce ADCC effect.
[0434] (4-2) ADCP effector function test of ADI-38497 PG antibody
[0435] ADCP reporter cell lines (Promega, G9871) and H929 cells in the logarithmic growth phase were taken, and the ADCP reporter cells and H929 target cells were mixed at effector-target ratios of 2:1 and 5:1, and mixed with different concentrations of BCMA antibodies, and cultured at 37°C for 20 hours. The antibody-mediated target cell-dependent reporter cell activation effect was detected using a luciferase assay kit (Promega, E2620), and the antibody concentration was used as the X-axis and the fluorescence reading change was used as the Y-axis for plotting and analysis.
[0436] Figure 4BThe results showed that when different effector-target ratios (2:1 or 5:1) were tested, only the ADI-38497 WT antibody mediated the ADCP killing effect on BCMA-positive H929 tumor cells, while the P329G mutant antibody lacked the ability to induce ADCP killing effect on BCMA-positive H929 tumor cells.
[0437] (4-3) Functional test of whether ADI-38497 PG antibody alone mediates target cell lysis
[0438] H929 cells and L363 cells in logarithmic growth phase were taken and plated in a certain number in a well plate; a portion of H929 cells and L363 cells in logarithmic growth phase were treated with mitomycin C as target cells and used as negative controls. Subsequently, different concentrations of ADI-38497 PG antibody were added and mixed, and cultured at 37°C for 48 hours, 72 hours and 120 hours respectively. The proportion of live cells was detected using CellTiter-Glo (Promega, G9242), and the co-incubation time was used as the X-axis and the fluorescence reading was used as the Y-axis for plotting and analysis.
[0439] Figure 4C The ability of ADI-38497 PG antibody to mediate target cell lysis was demonstrated, and the results showed that when different incubation times (48 hours, 72 hours, and 120 hours) and different ADI-38497 PG antibody concentrations (5 μg / ml, 50 μg / ml) were tested, all showed that ADI-38497 PG antibody alone lacked the ability to induce target cell lysis.
[0440] Example 5. In vitro functional study of P329G CAR-T
[0441] (5-1) CAR-T cell activation detection
[0442] The CAR-T cells prepared by donor 5 in Example 1 were resuscitated and cultured stably overnight at 37°C. H929 or L363 tumor target cells and CAR-T cells were mixed at an E:T ratio of 2:1, and 5-fold or 10-fold gradient dilutions of different concentrations of ADI-38497 PG antibody solution were added to a total volume of 200 μL, cultured at 37°C for about 24 hours, centrifuged, and the cells were collected, washed twice with FACS buffer, and resuspended and added with FACS buffer containing LIVE / DEAD Fixable Dead Cell Stain and Biotin-F(ab')2Fragment goat anti-human IgG (Jackson ImmunoResearch, 109-066-006), stained at 4°C for 30 minutes, washed twice, and CD4, CD8, CD25, CD69 and APC-Streptavidin antibody combinations were added. The above cell antibody mixture was stained at 4°C for 30 minutes, washed twice, resuspended in FACS buffer, and detected by flow cytometry.
[0443] Figure 5A It showed that only ADI-38497 PG antibody with P329G mutation could specifically mediate CAR against H929 cells + -T activation, upregulating the expression levels of CD25 and CD69, and + CAR + and CD8 + CAR + Cells were activated in an indifferent manner and in a concentration-dependent manner according to the ADI-38497 PG antibody.
[0444] Figure 5B Shows the activation effect of different BCMA antibodies (ADI-38497 PG antibody, ADI-38497 WT antibody, GSK PG IgG) on HuR968B CAR-T cells induced by L363 target cells. Figure 5B It can be seen that BCMA antibodies containing the P329G mutation (ADI-38497 PG antibody, GSK PG IgG) can specifically mediate the activation of CAR+ T cells and significantly upregulate the expression levels of CD25 and CD69. The expression of CD25 and CD69 in the CAR-negative cell population was also slightly upregulated, indicating a lower level of activation, but the degree of activation was not significant and could be ignored.
[0445] Therefore, whether in H929 cells that highly express BCMA ( Figure 5A ) or in L363 cells with low BCMA expression ( Figure 5B) as target cells, only BCMA antibodies containing P329G mutation (ADI-38497 PG antibody, GSK PG IgG) can specifically mediate CAR + -T activation significantly upregulated the expression levels of CD25 and CD69, and was dependent on the concentration gradient of BCMA antibodies with the P329G mutation.
[0446] (5-2) CAR-T cell proliferation assay
[0447] The UNT cells and CAR-T cells prepared by donor 4 in Example 1 were resuscitated and cultured stably overnight at 37°C. ADI-38497 WT antibody or ADI-38497 PG antibody was diluted with PBS, added to a 96-well plate and incubated overnight at 4°C to coat the plate. The CAR-T cells recovered after overnight culture were added to the 96-well plate coated with antibodies. As a positive control, CD3 / CD28-coupled magnetic beads (magnetic beads: cell ratio 3:1) were directly added to the CAR-T cells; they were incubated at 37°C for 72 hours and 120 hours, respectively, and the cells were coated with CellTiter- Luminescent Cell Viability Assay (Promega, G7572) was used to detect the luminescence value of cells.
[0448] Figure 5C The proliferation of HuR968B CAR-T cells after stimulation with coated ADI-38497 WT antibody or ADI-38497 PG antibody is shown. HuR968B CAR-T cells proliferate under the stimulation of coated ADI-38497 P329G antibody. Compared with the stimulation with ADI-38497 WT antibody, ADI-38497 PG antibody causes HuR968BCAR-T cells to proliferate by about 7 times or 43.5 times after 3 or 5 days of stimulation, respectively; while UNT cells do not proliferate significantly under the stimulation with ADI-38497 PG antibody compared with the stimulation with ADI-38497 WT antibody. Both HuR968B CAR-T cells and UNT cells proliferate significantly under the stimulation with CD3 / CD28 antibody-coupled magnetic beads.
[0449] (5-3) Cytokine detection
[0450] The CAR-T cells prepared in Example 1 were revived and cultured at 37°C overnight. The tumor target cells and CAR-T cells were mixed at an E:T ratio of 2:1, and 5-fold or 10-fold gradient dilutions of different concentrations of BCMA antibody (ADI-38497PG antibody, ADI-38497 WT antibody, or GSK PG IgG as a benchmark) were added to a total volume of 200 μL, cultured at 37°C for about 24 hours, and centrifuged to collect the supernatant. Using BD TM Cytokines were detected using the Cytometric Bead Array (CBA) Human Th1 / Th2 Cytokine Kit II (BD, 551809). After mixing equal volumes of Capture Beads in the kit, plate them at 25 μL / well. Add an equal volume of supernatant or supernatant dilution or standard. After mixing, add 25 μL of human Th1 / Th2 PE detection reagent and incubate at room temperature in the dark for 3 hours. Wash twice with wash buffer and resuspend, detect using a flow cytometer, and calculate the cytokine concentration using the MFI value of the PE channel.
[0451] Figure 5D The results show the release of effector cytokines secreted by CAR-T cells after the HuR968B CAR-T cells from donor 4 in Example 1 were co-cultured with H929 cells and RPMI8226 cells and the addition of different concentrations of BCMA antibodies (ADI-38497 PG antibody, ADI-38497 WT antibody, or GSK PG IgG as a positive control).
[0452] Figure 5E The results show that HuR968B CAR-T cells from donor 5 (purchased from ORiCELLS, Cat NO.: FPB004F-C, Lot NO.: PCH20210100004, Donor ID: Z0086) were co-cultured with different tumor cells, and the release results of effector cytokines secreted by CAR-T cells after the addition of different concentrations of BCMA antibodies (ADI-38497 PG antibody, ADI-38497 WT antibody, or Benchmark GSK PG IgG).
[0453] from Figure 5D and Figure 5EIt can be seen that when WT BCMA antibody (ADI-38497 WT antibody) is added, HuR968B CAR-T cells are not activated and do not secrete effector cytokines such as IL-2, IFN-γ, and TNFα. Only when BCMA antibody containing P329G mutation (ADI-38497 PG antibody, or GSK PG IgG as a positive control) is added, HuR968B CAR-T cells are activated and secrete effector cytokines. And according to the results of cytokine secretion under different target cell conditions, there is no obvious correlation between the level of cytokine secretion by effector cells and the BCMA expression level of target cells.
[0454] (5-4) Killing efficiency test
[0455] The CAR-T cells prepared in Example 1 were revived and cultured stably at 37°C overnight. The tumor target cells and CAR-T cells were mixed at an E:T of 2:1, and 10-fold gradient dilutions of different concentrations of BCMA antibody (ADI-38497 PG antibody, ADI-38497 WT antibody, or Benchmark GSK PG IgG) solution were added to a total volume of 200 μL, cultured at 37°C for about 24 hours, and centrifuged, and the cell supernatant was transferred to a 96-well white-bottom ELISA plate. The LDH value in the supernatant was measured using CytoTox 96Non-RadioactiveCytotoxicity Assay (Promega, G1780) and an ELISA reader (Molecular Devices, SpectraMax i3x) to calculate the killing efficiency.
[0456] Fig. 5F The results show that different BCMA antibodies (ADI-38497 PG antibody, ADI-38497 WT antibody, or BenchmarkGSK PG IgG) induced HuR968B CAR-T cells to target tumor cells with different BCMA expression levels (H929 ++ Cells, RPMI8226 +++ Cells, AMO1 + Cells and L363 +In the case of adding WT BCMA antibody, HuR968B cells are not activated and do not produce a killing effect on tumor cells. Only when adding BCMA antibody containing P329G mutation, P329G CAR-T cells are activated to kill target cells, and have antibody concentration dependence, which is consistent with the above-mentioned CAR-T cell activation and effector cytokine results in this embodiment. In addition, in the case of H929 and RPMI8226 cells with high BCMA expression as target cells, the killing effect of P329G BCMA antibody-mediated HuR968B CAR-T cells is higher than that of AMO1 and L363 target cells with low BCMA expression.
[0457] Figure 5G It was shown that neither P329G BCMA antibody nor WT BCMA antibody mediated the killing effect of CAR-T on BCMA-negative target cells (such as BCMA-KO-H929 cells), and WT BCMA antibody was also unable to mediate the killing effect on H929 cells (H929) expressing BCMA. Only P329G BCMA antibody could induce CAR-T to produce a killing effect on tumor cells.
[0458] Table 9 EC50 values of the killing effect of HuR968B CAR-T cells mediated by P329G BCMA antibody on H929 target cells
[0459] Antibody EC50(nM) ADI-38497 PG 0.3502 to 0.7433 ADI-38497 WT Very wide
[0460] Example 6: Effect of free BCMA protein on PG CAR-T function
[0461] (6-1) Killing efficiency test
[0462] The CAR-T cells prepared by donor 6 in Example 1 were revived and cultured stably at 37°C overnight. The tumor target cells and CAR-T cells were mixed at an E:T ratio of 2:1, and a certain concentration of PG BCMA antibody was added. For traditional Blue21 CAR-T, BCMA antibody was not required. 10-fold gradient dilutions of different concentrations of BCMA protein solutions were added as free BCMA protein to a total volume of 200 μL, cultured at 37°C for about 24 hours, and centrifuged, and the cell supernatant was transferred to a 96-well white-bottom ELISA plate. The LDH value in the supernatant was measured using CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega, G1780) and an ELISA reader (Molecular Devices, SpectraMax i3x) to calculate the killing efficiency.
[0463] Figure 6 The effect of different concentrations of free BCMA protein on the killing effect of HuR968B CAR-T and Blue21 CAR-T cells is shown. When different concentrations of free BCMA protein are added, once the traditional CAR T cells bind to the free BCMA protein, their function will be blocked (due to the high affinity of traditional CAR molecules for BCMA), while when the PG BCMA antibody binds to the soluble BCMA, the PG CAR-T can still exert a normal killing effect. Therefore, the advantage of PG CAR-T cells is that their function is less affected by soluble ligands (such as soluble BCMA).
[0464] Example 7: In vivo pharmacokinetic study of ADI-38497 PG antibody
[0465] (7-1) Antibody injection and sampling
[0466] BALB / c mice (aged 4-6 weeks, body weight 15-17g, female) were divided into 3 groups, namely ADI-38497 PG antibody, 1mg / kg antibody group; ADI-38497 PG antibody, 10mg / kg antibody group; and ADI-38497 PG antibody, 200mg / kg antibody group, 9 mice in each group; the antibody was diluted to 0.1mg / mL, 1mg / mL and 20mg / mL with 1×PBS, and the administration volume for each mouse was 10mL / kg, that is, the antibody dosage was 1mg / kg, 10mg / mL and 200mg / mL respectively; the administration method was intravenous injection, and the administration frequency was single. 100μL of blood samples were collected from the retro-orbital venous plexus of mice at 5 minutes, 30 minutes, 2h, 6h, 24h, 48h, 96h, 168h, 336h and 504h after antibody administration, centrifuged at 3000g, and the supernatant was aspirated for blood drug concentration determination.
[0467] (7-2) ADI-38497 PG antibody detection
[0468] Coat the 96-well ELISA plate one day in advance. Use coating solution (take a pack of carbonate (Thermo, 28382) powder, dissolve in 400mL ultrapure water, dilute to 500mL, mix to make coating solution) to dilute BCMA antigen to 1μg / ml, 100μL per well, seal the plate with a sealing film, and incubate at room temperature overnight. Pour out the coating solution, pat dry on absorbent paper, then add 300μL of washing solution to each well, shake and mix for 10 seconds, pat dry the washing solution, and repeat washing 3 times. Use a spray gun to add blocking solution, 200μL per well, seal the plate with a sealing film, and incubate at room temperature for 2h. Then wash the plate once. Add 100 μL of the diluted standard curve (prepared by gradient dilution of BCMA antibody with known concentration (for example, using ADI-38497 PG antibody with known concentration to prepare the standard curve), quality control samples and samples to be tested to each well and incubate at room temperature for 2 hours. Pour off the pre-coating solution, pat dry on absorbent paper, then add 300 μL of wash solution to each well, shake and mix for 10 seconds, pat dry the wash solution, and repeat washing 3 times. Repeat once. Dilute goat anti-human IgG-Fc-HRP antibody (BETHYL) 1:100,000, add 100 μL to each well, and incubate at room temperature in the dark for 1 hour. Then wash the plate once. Add TMB substrate to a 96-well ELISA plate, 100 μL per well, and color at room temperature in the dark for 5 minutes. Add 50 μL of ELISA stop solution to each well, shake for 10 seconds, and read OD450 nm and OD620 nm values within 30 minutes.
[0469] Fig. 7A and 7BThe pharmacokinetic results of ADI-38497 PG antibody (hereinafter referred to as PG Ab in the mouse in vivo experiments) in mice are shown. After intravenous injection of 1 mg / kg, 10 mg / kg, and 200 mg / kg of ADI-38497 PG antibody in mice, the exposure (Cmax and AUClast) of ADI-38497 PG antibody in serum showed a dose-dependent effect, and there was no significant difference in other pharmacokinetic parameters. As shown in Table 10, ADI-38497 PG antibody 1 mg / kg: AUC0-inf, Cmax, CL, T1 / 2 were 2480 μg×h / mL, 30 ug / ml, 0.40 ml / kg / h, 145 h, respectively; ADI-38497 PG antibody 10 mg / kg: AUC0-inf, Cmax, CL, T1 / 2 were 24720 μg×h / mL, 187 ug / ml, 0.32 ml / kg / h, 219 h, respectively; PG antibody 200 mg / kg: AUC0-inf, Cmax, CL, T1 / 2 were 397734 μg×h / mL, 3895 ug / ml, 0.43 ml / kg / h, 197 h, respectively. The half-life of ADI-38497 PG antibody 1 mg / kg was slightly shorter than that of ADI-38497 PG antibody 10 mg / kg and 200 mg / kg.
[0470] Table 10 ADI-38497 PG antibody pharmacokinetic experimental results
[0471]
[0472] Example 8. Effect of PG CAR-T cells combined with different doses of PG antibodies against BCMA-highly expressed tumors in vivo
[0473] (8-1) Mouse tumor inoculation and treatment
[0474] Resuspend H929 cells in 1× PBS to prepare a cell concentration of 5×10 6 NOG mice (aged 4-6 weeks, weighing 15-17 g, female) were shaved on the right back and injected subcutaneously with H929 cell suspension at a volume of 0.2 mL / mouse, i.e., an inoculum of 1×10 6 cells / mouse. Seven days after tumor cell inoculation, the tumor volume of mice ranged from 50.82 to 104.36 mm 3The mice were divided into 7 groups, namely PBS vehicle group, PG Ab group, PG CAR-T group only, traditional CAR-T group, PG Ab + PG CAR-T, 3mg / kg antibody group, PG Ab + PG CAR-T, 1mg / kg antibody group and PG Ab + PG CAR-T, 0.3mg / kg antibody group, with 7 mice in each group. Antibodies were prepared at concentrations of 0.3mg / mL, 0.1mg / mL and 0.03mg / mL, respectively. After grouping, antibodies were administered on the 7th day. The volume of each mouse was 10mL / kg. The frequency of administration was once a week, and the administration method was intraperitoneal injection. The CAR-T cells prepared by donor 4 were resuspended in 1×PBS to prepare CAR + The cells are 25×10 6 On the 7th day, 0.2 mL of cell suspension was injected into the tail vein of each animal, and CAR was then infused. + Cells 5×10 6 The body weight of mice, the maximum long axis (L) and the maximum wide axis (W) of tumor tissue were monitored twice a week.
[0475] Fig. 8A The therapeutic effects of different doses of PG antibody combined with PG CAR-T cells were shown in immunodeficient tumor-bearing mice subcutaneously inoculated with human H929 high-expression BCMA tumor cells. The results showed that in the BCMA high-expression tumor model, the administration of PGCAR-T cells alone did not produce obvious anti-tumor effects, and the administration of PG antibodies alone produced certain anti-tumor effects. Only mice treated with PGCAR-T cells and PG antibodies at the same time produced significant anti-tumor effects, and showed antibody dose-dependent effects. Treatment with PG CAR-T cells combined with 0.3mg / kg antibody, 1mg / kg antibody, and 3mg / kg antibody resulted in tumor growth inhibition rates (TGI) of 92%, 88%, and 101%, respectively, while the anti-tumor efficacy TGIs in mice treated with only PG CAR-T cells or only PG antibodies were 25% and 53%, respectively. In addition, the anti-tumor effect of PG CAR-T cells combined with PG antibody 3mg / kg was comparable to the anti-tumor effect of traditional Blue21 CAR-T cells at the same dose, with TGIs of 101% and 102%, respectively.
[0476] Figure 8B The weight changes of mice in this experiment are shown. The results showed that the weight of mice treated with PG CAR-T cells combined with PG antibodies remained stable after treatment, and the average weight increased by 5.2%, 3.0%, and 7.6% after treatment with 0.3mg / kg, 1mg / kg, and 3mg / kg of PG antibodies. The results showed that PG CAR-T cells combined with PG antibody treatment produced a significant anti-tumor effect without obvious toxic side effects.
[0477] (8-2) Detection of CAR-T cells in mice:
[0478] Take 30 μL of the mouse blood sample of Example 8-1 and add it to a 96-well V-well plate, marked as a sample test well; take 10 μL of the mouse blood sample and add it to a 96-well V-well plate, marked as a control well. Add 100 μL of LIVE / DEAD FixableDead Cell Stain and TruStain FcX to all wells. TM (anti-mouse CD16 / 32) (Biolegend) FACS buffer, gently mix, incubate at 4°C in the dark for 15 minutes; then add Biotin-F(ab')2 fragment Fragment goat anti-human IgG antibody to the sample detection wells, incubate at 4°C in the dark for 30 minutes; then add 100 μL FACS buffer to each sample detection well, centrifuge at 400g, and discard the supernatant; add 100 μL FACS buffer containing APC-Cy7 anti-human CD45 (Biolegend), PerCP-Cy5.5-CD3 (BD Biosciences) and APC-streptavidin (Biolegend) to each well, mix gently, incubate at 4°C in the dark for 30 minutes; then add 200 μL / well FACS buffer to all wells, centrifuge at 400g, and discard the supernatant; add 250 μL / well 1×RBC Lysis / Fixation solution (Biolegend), mix well, incubate at room temperature in the dark for 20 minutes; centrifuge at 400g and discard the supernatant; resuspend the cells in 100 μL FACS buffer, add 10 μL 123count ebeads to each well, and detect using flow cytometer.
[0479] Figure 8CThe expansion of PG CAR-T cells in mice in the experiment of Example 8-1 is shown. The results showed that the expansion of PGCAR-T cells in vivo depends on PG antibodies, showing a certain antibody dose dependence, and mice in the higher dose group have a higher level of PG CAR-T cell expansion. Only PG CAR-T cells were administered, and they began to expand in the mice one week after being reinfused into the mice. After 2 weeks, they expanded to 466 cells / 100μL peripheral blood. After 3 weeks, the expansion reached a higher level (3644 cells / 100μL peripheral blood), and it remained at a high level after 4 weeks (3214 cells / 100μL peripheral blood); when PG CAR-T cells were used in combination, different doses of PG antibodies were given at 0.3mg / kg, 1mg / kg, and 3mg / kg. After 2 weeks, PG The peak expansion levels of CAR-T cells in vivo reached 11428 cells / 100μL peripheral blood, 19299 cells / 100μL peripheral blood, and 35368 cells / 100μL peripheral blood, respectively. They remained at a high level after 4 weeks, reaching 15486 cells / 100μL peripheral blood, 25073 cells / 100μL peripheral blood, and 27666 cells / 100μL peripheral blood, respectively, which were much higher than the group not given antibodies in the same period. In addition, the traditional Blue21 CAR-T cells used as positive controls showed similar expansion dynamics. They also began to expand in the body of mice 1 week after being reinfused, and reached a peak level (174769 cells / 100μL peripheral blood) 2 weeks later, and remained at an extremely high level (131963 cells / 100μL peripheral blood) 4 weeks later.
[0480] Example 9. Effect of PG CAR-T cells combined with different doses of PG antibodies against BCMA low-expressing tumors in vivo
[0481] (9-1) Mouse tumor inoculation and treatment
[0482] Resuspend L363 cells in 1× PBS to prepare a cell concentration of 5×10 6 NOG mice (aged 4-6 weeks, weighing 15-17 g, female) were shaved on the right back and injected subcutaneously with L363 cell suspension at a volume of 0.2 mL / mouse, i.e., an inoculum of 1×10 6 cells / mouse. Nine days after tumor cell inoculation, the tumor volume of mice ranged from 74.14 to 110.29 mm 3The mice were divided into 7 groups, namely vehicle group, PG Ab group, PG CAR-T group, traditional CAR-T group, PG Ab + PG CAR-T, 3mg / kg antibody group, PG Ab + PG CAR-T, 1mg / kg antibody group and PG Ab + PG CAR-T, 0.3mg / kg antibody group, with 7 mice in each group. Antibodies were prepared at concentrations of 0.3mg / mL, 0.1mg / mL and 0.03mg / mL, respectively. After grouping, antibodies were administered on the 9th day. The volume of each mouse was 10mL / kg, the frequency of administration was once a week, and the administration method was intraperitoneal injection. The CAR-T cells prepared by donor 4 were resuspended in 1×PBS to prepare CAR + The cells are 25×10 6 On the 9th day, 0.2 mL of cell suspension was injected into the tail vein of each animal, and CAR was then infused. + Cells 5×10 6 The body weight of mice, the maximum long axis (L) and the maximum wide axis (W) of tumor tissue were monitored twice a week.
[0483] Fig.9A The therapeutic effects of different doses of PG antibody combined with PG CAR-T cells were shown in immunodeficient tumor-bearing mice subcutaneously inoculated with human L363 low-expressing BCMA tumor cells. The results showed that in the BCMA low-expressing tumor model, the administration of PGCAR-T alone did not produce anti-tumor effects, while the anti-tumor effect of the administration of PG antibody alone was not obvious, with a TGI of 21%. Only mice treated with PGCAR-T cells and PG antibodies at the same time produced significant anti-tumor effects, and showed an antibody dose-dependent effect. When PGCAR-T cells were combined with 0.3mg / kg dose of PG antibody, PG CAR-T cells induced significant anti-tumor effects with a TGI of 87%. When the combination increased the PG antibody dose to 1mg / kg and 3mg / kg, the maximum anti-tumor effect induced by PG CAR-T cells increased significantly, with TGIs of 103% and 103%, respectively, showing the same anti-tumor effect as traditional Blue21 CAR-T cells.
[0484] Fig. 9B The weight changes of mice in this experiment are shown. The results showed that the weight of mice treated with PG CAR-T cells combined with PG antibodies remained steadily increased after treatment, and the average weight increase after combined use of PG antibodies at 0.3 mg / kg, 1 mg / kg, and 3 mg / kg was 18.2%, 10.5%, and 8.5%, respectively. The results showed that PG CAR-T cells combined with PG antibodies produced a significant anti-tumor effect and did not induce significant toxicity.
[0485] (9-2) Detection of CAR-T cells in mice: The method is the same as Example 8-2.
[0486] Fig. 9C The expansion of PG CAR-T cells in mice in the experiment of Example 9-1 is shown. The results show that only PG CAR-T cells were administered, and they began to expand after 1 week of reinfusion into mice, expanded to 919 cells / 100 μL peripheral blood after 2 weeks, and rapidly dropped to 204 cells / 100 μL peripheral blood at 3 weeks; when PG CAR-T cells were combined with different doses of PG antibodies of 0.3 mg / kg, 1 mg / kg and 3 mg / kg, the peak expansion level of PG CAR-T cells in vivo reached 4380 cells / 100 μL peripheral blood, 8049 cells / 100 μL peripheral blood and 3347 cells / 100 μL peripheral blood after 2 weeks, and remained at a high level after 3 weeks, which were 2475 cells / 100 μL peripheral blood, 4121 cells / 100 μL peripheral blood and 1969 cells / 100 μL peripheral blood, respectively, which was much higher than the group not given antibodies in the same period. In addition, the traditional Blue21 CAR-T cells used as a positive control also expanded to reach a peak level (76,836 cells / 100 μL peripheral blood) 2 weeks after being infused back into the mice, and still maintained a high level (36,328 cells / 100 μL peripheral blood) 3 weeks later.
[0487] Example 10. Anti-tumor effects of different doses of PG CAR-T cells combined with PG antibodies in vivo
[0488] (10-1) Mouse tumor inoculation and treatment
[0489] Resuspend H929 cells in 1× PBS to prepare a cell concentration of 5×10 6 NOG mice (aged 4-6 weeks, weighing 15-17 g, female) were shaved on the right back and injected subcutaneously with H929 cell suspension at a volume of 0.2 mL / mouse, i.e., an inoculum of 1×10 6 cells / mouse. Nine days after tumor cell inoculation, the tumor volume of mice ranged from 59.50 to 105.82 mm 3 The mice were divided into 7 groups, namely vehicle group, PG Ab group, PG CAR-T group, PG Ab+PG CAR-T group, 10×10 6 Group, PGAb+PG CAR-T, 1×10 6 Cell group, PG Ab+PG CAR-T, 0.1×10 6 Cell groups and PG Ab+PG CAR-T, 0.01×10 6There were 7 mice in each group. The antibody concentration was 0.3 mg / mL. After grouping, the antibody was administered on the 9th day. The volume of each mouse was 10 mL / kg. The administration frequency was once a week and the administration method was intraperitoneal injection. The CAR-T cells prepared by donor 4 were resuspended in 1×PBS to prepare CAR + The cells are 50×10 6 The cell suspension was prepared by 10-fold serial dilution to prepare 5×10 6 , 0.5×10 6 and 0.05×10 6 The cells were suspended at 100 μg / mL and injected into the tail vein at 0.2 mL / mouse on day 9. The body weight, maximum long axis (L) and maximum wide axis (W) of the tumor tissue were monitored twice a week.
[0490] Fig. 10A The results showed that the therapeutic effect of PG antibody combined with different doses of PG CAR-T cells was shown in immunodeficient tumor-bearing mice subcutaneously inoculated with human H929 tumor cells. 6 In the case of CAR-T cells alone, CAR-T cells produced an anti-tumor effect similar to that of PG antibody alone, with TGIs of 49% and 50%, respectively. Increasing the CAR-T cell dose to 0.1×10 6 , 1×10 6 , 10×10 6 The anti-tumor effect induced by CAR-T cells and PG CAR-T cells was significantly increased, with TGI of 91%, 104%, and 103%, respectively. No anti-tumor effect was shown when CAR-T cells were administered alone.
[0491] (10-2) In vivo CAR-T cell detection: The method is the same as Example 8-2.
[0492] Fig. 10B The results show that the proliferation of PG CAR-T cells in mice in the experiment of Example 10-1. The results show that CAR-T cells infused back into mice began to proliferate under the induction of PG antibodies in one week, and the proliferation reached a peak level after two weeks, and remained at a high level after three weeks. In addition, when combined with PG antibodies, the proliferation of CAR-T cells in vivo depends on the dose of CAR-T cells. Mice in the higher CAR-T dose group have a higher level of CAR-T cell proliferation, 0.01×10 6 , 0.1×10 6 , 1×10 6 , 10×10 6The peak expansion levels of the CAR-T cell dose groups were 6 cells / 100 μL peripheral blood, 338 cells / 100 μL peripheral blood, 3640 cells / 100 μL peripheral blood, and 12895 cells / 100 μL peripheral blood, respectively.
[0493] Example 11: Study on the anti-tumor effect of PG CAR-T cells combined with PG antibodies at different administration frequencies in vivo
[0494] (11-1) Mouse tumor inoculation and treatment
[0495] Resuspend H929 cells in 1× PBS to prepare a cell concentration of 5×10 6 NOG mice (aged 4-6 weeks, weighing 15-17 g, female) were shaved on the right back and injected subcutaneously with H929 cell suspension at a volume of 0.2 mL / mouse, i.e., an inoculum of 1×10 6 cells / mouse. Seven days after tumor cell inoculation, the tumor volume of mice ranged from 51.25 to 94.97 mm 3 The mice were divided into 7 groups, including vehicle group, PG CAR-T group, PG Ab+PG CAR-T, Q3 / 4×2 group, PG Ab+PGCAR-T, QW×4 group, PG Ab+PG CAR-T, Q2W×2 group, PG Ab+PG CAR-T, Q3W×2 group and traditional CAR-T group, with 7 mice in each group. PG Ab antibody was prepared at a concentration of 0.1 mg / mL. After grouping, the antibody was administered, with a volume of 10 mL / kg per mouse, and the administration method was intraperitoneal injection. The CAR-T cells prepared by donor 4 were resuspended in 1×PBS to prepare CAR + Cells 10×10 6 The cell suspension was 0.2 mL / mouse per tail vein injection. The body weight, maximum long axis (L) and maximum wide axis (W) of the tumor tissue were monitored twice a week.
[0496] Fig.11A The dosing frequency of PG antibody in the experiment of Example 11-1 is shown. Q3-4D×2: PG antibody is administered twice in the first week with a 4-week cycle, and the dosing interval is 3-4 days; Q3W×2: PG antibody is administered twice, and the dosing frequency is 3 weeks / time; Q2W×2: PG antibody is administered twice, and the dosing frequency is 2 weeks / time; QW×4: PG antibody is administered 4 times, and the dosing frequency is 1 week / time.
[0497] Fig. 11BThe results showed that in immunodeficient tumor-bearing mice inoculated subcutaneously with human H929 tumor cells, the therapeutic effect of different dosing frequencies of PG antibody when combined with PG CAR-T cells was induced by different dosing frequencies of PG antibody when combined with PG CAR-T cells to produce significant anti-tumor effects, and the anti-tumor effect induced by PG CAR-T cells increased significantly with increasing the dosing frequency of PG antibody. The anti-tumor effect induced by CAR-T cells in the QW×4 group was the most significant, showing the same anti-tumor effect as traditional Blue21 CAR-T cells.
[0498] (11-2) In vivo CAR-T cell detection: The method is the same as Example 8-2.
[0499] Fig. 11C The expansion of PG CAR-T cells in mice in the experiment of Example 11-1 is shown. The results show that when PG CAR-T cells are used in combination, the CAR-T cell expansion dynamics are similar under different dosing frequencies of PG antibodies. CAR-T cells begin to expand in the body of mice 1 week after being reinfused, and the expansion reaches a peak level after 2 weeks, and drops to the baseline level after 3 weeks. In addition, traditional Blue21 CAR-T cells also expand to a peak level 2 weeks after being reinfused into mice, and remain at a high level after 3 weeks.
[0500] Example 12: Study on the anti-systemic tumor effect of PG CAR-T cells combined with different doses of PG antibodies in vivo
[0501] (12-1) Mouse tumor inoculation and treatment
[0502] First, H929-luc cells were prepared. Specifically, H929 cells (purchased from Nanjing Kebai Biotechnology Co., Ltd.) were used to package lentivirus containing the GFP-luciferase gene, and the obtained lentivirus was used to infect H929 cells, and then flow cytometry sorting was performed to obtain a H929-luc cell line with dual expression of GFP and luciferase.
[0503] Then, resuspend the H929-luc cells in 1× PBS to prepare a cell concentration of 25×10 6 / mL cell suspension. NOG mice (age 4-6 weeks, weight 15-17g, female) were injected with H929-luc cell suspension via tail vein, with an injection volume of 0.2mL / mouse. 14 days after tumor cell inoculation, substrate D-Luciferin (15mg / mL) was injected intraperitoneally, with an injection volume of 10mL / kg / mouse. IVIS spectrum imaging was used for analysis 10 minutes after substrate injection. The fluorescence signal was set at 1.17×10 7 ~1.43×10 8The mice with photons / sec were divided into 7 groups, namely vehicle group, PG Ab, 0.3 mg / kg group, PG Ab, 3 mg / kg group, PGCAR-T group, PG Ab+PG CAR-T, 0.3 mg / kg+2×10 6 Group, PG Ab+PG CAR-T, 3mg / kg+2×10 6 The CAR-T cells prepared by donor 4 were resuspended in 1×PBS to prepare CAR + Cells 10×10 6 On the 7th day, 0.2 mL of cell suspension was injected into the tail vein of each mouse.
[0504] Fig. 12A Fluorescence images showing the therapeutic effects of different doses of PG antibody combined with PG CAR-T cells in immunodeficient tumor-bearing mice inoculated with human H929-luc tumor cells in the tail vein. The results showed that in the systemic tumor model, PG antibody combined with PG CAR-T cells also produced significant anti-tumor effects. On the 18th day, the fluorescence distribution and fluorescence intensity of mice in the PG antibody 0.3 mg / kg combined with PG CAR-T cell group were significantly reduced compared with the control group. At the same time, there was no obvious fluorescence signal in the mice in the PG antibody 3 mg / kg combined with PG CAR-T cell group, while there was still a large amount of fluorescence distribution in the traditional Blue21 CAR-T treatment group, indicating that the PG CAR-T cell group induced anti-tumor effects faster than Blue21 CAR-T; there was no obvious fluorescence signal in the PG antibody 3 mg / kg combined with PG CAR-T cell group until the 56th day, and some mice tumors showed slight fluorescence signals on the 63rd day, while at this time, more than half of the mice in the Blue21CAR-T treatment group had obvious recurrence and metastasis to the peritoneal cavity, indicating that PG CAR-T cells combined with PG antibodies produced a more lasting anti-tumor effect.
[0505] Fig. 12BThe therapeutic effects of different doses of PG antibody combined with PG CAR-T cells were shown in immunodeficient tumor-bearing mice inoculated with human H929-luc tumor cells in the tail vein. The results showed that when PG antibody was administered at 0.3 mg / kg, PG CAR-T cells produced a certain anti-tumor effect. When the dose of PG antibody was increased to 3 mg / kg, the anti-tumor effect induced by PG CAR-T cells increased significantly, and the anti-tumor effect was maintained for a longer time. After stopping the administration of PG antibody, tumor growth began to recur in about 4 weeks, while the tumor recurred faster after the same cell dose of traditional Blue21 CAR-T, showing that PG CAR-T cells have a more lasting anti-tumor effect than traditional Blue21CAR-T. The PG CAR-T cell group and the PG antibody group only did not show obvious anti-tumor effects.
[0506] Fig. 12C The results show that the weight of mice in each treatment group increased steadily during the treatment period, indicating that different doses of PG antibody combined with PG CAR-T cell treatment did not induce significant toxicity in the blood tumor model.
[0507] Example 13: In vivo toxicology study of PG CAR-T cells combined with PG antibodies
[0508] (13-1) Mouse tumor inoculation and treatment
[0509] Resuspend H929 cells in 1× PBS to prepare a cell concentration of 5×10 6 NOG mice (aged 4-6 weeks, weighing 15-17 g, female) were shaved on the right side of their backs and injected subcutaneously with 5×10 6 H929 cell suspension was injected at a volume of 0.2 mL / mouse. Six days after tumor cell inoculation, the tumor volume of mice ranged from 38.49 to 104.77 mm 3 The mice were divided into 8 groups, as shown in Table 11, including the vehicle group without tumor, PG Ab+PG CAR-T, 10 mg / kg+10×10 6 group; and the vehicle group, PG CAR-T group, PG Ab group, PG Ab+PG CAR-T, 10 mg / kg+10×10 6 Group, PG Ab+PG CAR-T, 3mg / kg+10×10 6 Group and PG Ab+PG CAR-T, 3mg / kg+1×10 6Groups, 24 mice in each group. Antibodies were prepared at concentrations of 1 mg / mL and 0.3 mg / mL, respectively. After grouping, antibodies were administered, with a volume of 10 mL / kg per mouse, once a week, 3 times, and intraperitoneal injection. One day after the first antibody administration, CAR-T cells prepared by donor 4 were resuspended in 1×PBS to prepare CAR + Cells 50×10 6 / mL and 5×10 6 / mL cell suspension. 0.2mL / mouse cell suspension was injected into the tail vein. The body weight of mice, the maximum long axis (L) and the maximum wide axis (W) of tumor tissue were monitored twice a week. Peripheral blood was collected before the first antibody administration, after CAR-T infusion, before the third antibody administration and at the end of the experiment, with 4 mice in each group, for hematological and blood biochemical tests.
[0510] Table 11 Treatment and dosage of each group
[0511]
[0512]
[0513] Fig.13A The results showed that the therapeutic effect of PG antibody combined with PGCAR-T cells was shown in immunodeficient tumor-bearing mice subcutaneously inoculated with human H929 tumor cells. The results showed that the PG antibody combined with PG CAR-T cell treatment group produced significant anti-tumor effects, while the anti-tumor effect of mice treated with only PG antibody was weak, and the administration of PG CAR-T alone did not produce an anti-tumor effect.
[0514] Fig. 13B The results show that the weight of mice in the tumor-bearing and non-tumor-bearing groups increased steadily during the treatment period, and there was no significant change in weight compared with the control mice, indicating that different doses of PG antibodies combined with different doses of PGCAR-T cells did not induce obvious toxic reactions.
[0515] Fig. 13C and Fig.13D The results of hematological and blood biochemical tests of mice in the above experiment are shown. The results showed that during the treatment period, the hematological and blood biochemical indicators of mice in the tumor-bearing and non-tumor-bearing treatment groups did not change significantly compared with those of the control mice, indicating that the PG antibody combined with PG CAR-T cell therapy did not produce toxic reactions.
[0516] Example 14: Clinical study
[0517] 1. Test drugs and other drugs:
[0518] The active components of the test drug described in this example are: P329G BCMA antibody (ADI-38497 PG antibody, which comprises the heavy chain variable region shown in SEQ ID NO: 2 and the heavy chain constant region shown in SEQ ID NO: 5, and the light chain variable region shown in SEQ ID NO: 3 and the light chain constant region shown in SEQ ID NO: 6) and P329G CAR-T cells (CAR-T cells obtained by transforming the patient's autologous PBMC cells).
[0519] The formulation of P329G BCMA antibody is 20.0mg / ml P329G BCMA antibody, 0.76mg / ml histidine,
[0520] 1.08 mg / ml histidine hydrochloride, 50.00 mg / ml sorbitol, 0.20 mg / ml polysorbate 80, pH 6.0; specification of P329GBCMA antibody: 60 mg (3 mL) / bottle.
[0521] Specifications of P329G CAR-T cells: Each bag contains 90-140×10 dissolved in 5%-7.5% DMSO cryoprotectant. 6 CAR-positive cells against P329G Fc fragment; the manufacturer of P329G CAR-T cells is Innovent Biologics (Suzhou) Co., Ltd.
[0522] Hereinafter, the drug combination comprising ADI-38497 PG antibody and P329G CAR-T cells will be referred to as BCMA-CAR-PG.
[0523] 2. Inclusion / Exclusion Criteria
[0524] Inclusion Criteria
[0525] 1) 18 years old and above, regardless of gender.
[0526] 2) According to the International Myeloma Working Group (IMWG) diagnostic criteria for multiple myeloma, there is evidence of initial diagnosis of multiple myeloma.
[0527] 3) After at least 3 anti-myeloma treatment regimens (previous treatment included proteasome inhibitors and immunomodulators), including continuous induction chemotherapy, stem cell transplantation and maintenance therapy, if there is no disease progression during treatment, it is considered as 1 treatment regimen; disease progression with examination data occurred during or within 12 months after the most recent anti-myeloma treatment (according to IMWG criteria).
[0528] 4) The presence of measurable lesions at screening as determined by any of the following criteria:
[0529] ① The proportion of monoclonal plasma cells in bone marrow cytology, bone marrow biopsy or flow cytometry is ≥5%;
[0530] ② Serum monoclonal protein (M-protein) level ≥ 0.5 g / dL;
[0531] ③ Urine M protein level ≥ 200 mg / 24 hours;
[0532] ④ Light chain multiple myeloma with no measurable lesions in serum or urine: serum immunoglobulin free light chains ≥ 10
[0533] mg / dL and abnormal serum immunoglobulin kappa / lambda free light chain ratio.
[0534] 5) ECOG score is 0 or 1.
[0535] 6) Expected survival time ≥ 12 weeks.
[0536] Exclusion criteria:
[0537] 1) Patients with graft-versus-host disease (GVHD) or those who need to use immunosuppressants.
[0538] 2) Patients who had received autologous hematopoietic stem cell transplantation (ASCT) within 12 weeks before PBMC collection or had previously received allogeneichematopoietic stem cell transplantation (allo-HSCT).
[0539] 3) No non-mobilized mononuclear cells can be collected for CAR-T cell production.
[0540] 4) Previously received the following anti-tumor treatments:
[0541] ① Treatment with cytotoxic or proteasome inhibitors within 14 days before mononuclear cells can be collected, or;
[0542] ② receiving systemic steroid treatment within 7 days before mononuclear cells can be collected, or;
[0543] ③ Use of monoclonal antibodies to treat multiple myeloma within 21 days before mononuclear cells can be collected, or;
[0544] ④Received immunomodulatory therapy within 7 days before mononuclear cells can be collected, or;
[0545] ⑤ Those who have received targeted therapy, epigenetic therapy, or used invasive experimental medical devices within 14 days before mononuclear cells can be collected, or;
[0546] ⑥ Radiotherapy within 14 days before mononuclear cells can be collected. However, if the radiation field covers ≤5% of the bone marrow reserve,
[0547] Subjects were eligible to participate in the study regardless of the radiotherapy end date, or;
[0548] ⑦ Undergo leukocyte apheresis within 7 days before mononuclear cells can be collected.
[0549] 5) Subjects who are determined by the investigator to require long-term use of systemic steroids during treatment (except for inhaled or topical use, with a dose of <10 mg / day).
[0550] 6) Patients with a history of hypertension that cannot be controlled by drug treatment (blood pressure ≥ 140 / 90 mmHg).
[0551] 7) Severe heart disease: including but not limited to unstable angina, myocardial infarction (within 6 months before screening), congestive heart failure (New York Heart Association [NYHA] classification ≥ III), and severe arrhythmia.
[0552] 8) Systemic diseases judged by the investigator to be unstable: including but not limited to severe liver, kidney or metabolic diseases requiring drug treatment.
[0553] 9) Patients with malignant tumors other than multiple myeloma within 5 years before screening, except for fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, and breast ductal carcinoma in situ after radical surgery.
[0554] 10) Those with a history of solid organ transplantation.
[0555] 11) Patients with a history of T-cell-mediated autoimmune diseases (such as type 1 diabetes, multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus). If the researchers determine that the patient may have the above-mentioned T-cell-mediated autoimmune disease indications before enrollment, relevant disease tests are required to exclude the above-mentioned autoimmune diseases before enrollment.
[0556] 12) Patients suspected of or with symptoms of central nervous system invasion by plasma cell tumors.
[0557] 13) Stroke or seizure occurred within 6 months before signing the ICF.
[0558] 14) Suffering from plasma cell leukemia at the time of screening (according to domestic standards, the plasma cells in the peripheral blood leukocyte classification are greater than 20% or the absolute value of plasma cells is ≥2.0×10 9 / L), Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal proteinopathy, and skin changes), or primary systemic light-chain amyloidosis (AL).
[0559] 15) Patients who have received live attenuated vaccines within 4 weeks before mononuclear cell collection.
[0560] 16) Subjects who have undergone major surgery within 2 weeks before mononuclear cell collection, or are planning to undergo surgery within 2 weeks after mononuclear cell collection or after the first administration of study treatment (Note: Subjects who are planning to undergo surgery under local anesthesia can participate in this study).
[0561] 17) Participating in other interventional clinical studies when signing the ICF.
[0562] 18) Active infection or uncontrolled infection requiring systemic treatment within 7 days before mononuclear cell collection (CTCAE
[0563] Grade 1 genitourinary tract infection and upper respiratory tract infection are excluded).
[0564] 3. Dosage method and process
[0565] The enrolled subjects will undergo peripheral blood mononuclear cell (PBMC) apheresis (D-33 to D-26 (-33 days to -26 days)), and then use the subjects' own T cells to prepare P329G CAR-T cell preparations (hereinafter referred to as P329G CAR-T cells). After the successful preparation of P329G CAR-T cells, the subjects will first receive a lymphoproliferative conditioning regimen of cyclophosphamide and fludarabine (D-5 to D-3 (-5 days to -3 days)); after two days of rest after the pretreatment, they will receive a dose of P329G BCMA antibody (also known as ADI-38497 PG antibody) infusion (D1); after the completion of the P329G BCMA antibody infusion, they will receive P329G CAR-T cell infusion within 1 to 2 hours or on the next day (D2); thereafter, starting from the day of P329GBCMA antibody infusion, every 21 days will be a cycle, and ADI-38497 PG will be periodically infused (the first cycle (1st to 21st day) includes QW*3 administration and Q3W administration, and the second cycle and thereafter are all Q3W administration) until disease progression, intolerable toxicity, withdrawal of informed consent by the subject, or other reasons for stopping the study treatment (whichever occurs first).
[0566] The relevant dosing regimen is shown in the following table:
[0567]
[0568]
[0569] Dose escalation phase:
[0570] In the dose escalation phase, the classic "3+3" dose escalation method was used. ADI-38497 PG antibody has 4 dose groups: 0.1mg / kg, 0.3mg / kg, 1mg / kg, 3mg / kg; P329G CAR-T cells have 2 dose groups: 2*10 6 pcs / kg and 5*10 6 First, the P329G CAR-T cell dose was fixed to fully explore the optimal dose of ADI-38497 PG, with a starting dose of 2*10 6 P329G CAR-T cells / kg and ADI-38497 PG 0.1mg / kg. If the initial dose is not tolerated, consider reducing the cell dose to 0.75*10 6 The DLT observation window is 21 days after the first dose of ADI-38497 PG antibody. If the above BCMA-CAR-PG dose does not reach the maximum tolerated dose (MTD), the ADI-38497 PG antibody dose will be fixed and the P329G CAR-T cell dose will be increased to 5*10 6 / kg continue to explore.
[0571] In the dose-escalation phase, possible dose groups for BCMA-CAR-PG administration are as follows:
[0572] Dose group 1: 0.1mg / kg ADI-38497 PG antibody + 2*10 6 P329G CAR-T cells / kg (n=3-6);
[0573] Dose group 2: 0.3mg / kg ADI-38497 PG antibody + 2*10 6 P329G CAR-T cells / kg (n=3-6);
[0574] Dose group 3: 1mg / kg ADI-38497 PG antibody + 2*10 6 P329G CAR-T cells / kg (n=3-6);
[0575] Dose group 4: 3mg / kg ADI-38497 PG antibody + 2*10 6 P329G CAR-T cells / kg (n=3-6);
[0576] Dose group 5: 3mg / kg ADI-38497 PG antibody + 5*10 6 P329G CAR-T cells / kg (n=3~6)
[0577] Exploration dose group: For example: 1mg / kg ADI-38497 PG antibody + 5*10 6 P329G CAR-T cells / kg (n=3-6) or an exploratory dose group selected after full discussion between the investigator and the sponsor based on previous observation data.
[0578] The relevant dosages of P329G CAR-T cells and P329G BCMA antibodies are shown in the following table:
[0579]
[0580] 4. Experimental Results
[0581] The meanings of the indicators of the experimental results are as follows
[0582]
[0583]
[0584] 1. Efficacy:
[0585] The C-BCMA-CAR-PG-01 and C-BCMA-CAR-PG-02 regimens are summarized as follows:
[0586]
[0587] C-BCMA-CAR-PG-Y001: A total of 6 subjects were enrolled, including 3 in the 0.3mg / kg dose group and 3 in the 1mg / kg dose group. According to the researchers' evaluation, a total of 3 subjects had a PR in their best tumor assessment results. In the 0.3mg / kg dose group, one subject achieved a PR in the best tumor assessment result, which lasted for 7 months before disease progression; in the 1mg / kg dose group, two subjects achieved a PR in the best tumor assessment result, and one of them had disease progression after 2 months (such as Fig.14 shown).
[0588] C-BCMA-CAR-PG-Y002: A total of 5 subjects were enrolled, including 1 in the 0.1mg / kg dose group, 3 in the 0.3mg / kg dose group, and 1 in the 1mg / kg dose group. According to the investigator's evaluation, 1 subject in the 0.1mg / kg dose group achieved the best tumor assessment result VGPR (very good partial response) 3 months after reinfusion, and continued VGPR in the most recent 6-month visit. 1 subject in the 0.3mg / kg dose group achieved the best tumor assessment result PR (such as Fig.15 shown).
[0589] 2. Cell PK:
[0590] C-BCMA-CAR-PG-01: The median (range) time to peak cell proliferation (Tmax) of the 0.3 mg / kg (N=3) and 1 mg / kg (N=3) dose groups were 20 (14-33.8) days and 13.8 (9.71-26.8) days, respectively; the geometric mean (coefficient of variation) of the peak cell proliferation (Cmax) was 1.01*10^4 (148.6%) and 10.3*10^4 (50.6%) copies / μg DNA, respectively; the geometric mean (coefficient of variation) of the cell AUC0-21d was 4.24*10^4 (145%) and 17.4*10^4 (89.4%) day*copies / μg DNA, respectively.
[0591] C-BCMA-CAR-PG-02: The median (range) time to peak cell proliferation (Tmax) of the 0.1 mg / kg (N=1), 0.3 mg / kg (N=3) and 1 mg / kg (N=1) dose groups were 20.9 days, 16 (12.9-17.9) days and 20.9 days, respectively; the geometric mean (coefficient of variation) of the peak cell proliferation (Cmax) was 7*10^4 (NaN), 3.27*10^4 (85.1%) and 1.66*10^4 (NaN) copies / μg DNA, respectively; the geometric mean (coefficient of variation) of the cell AUC0-21d was 47.1*10^4 (NaN), 19.1*10^4 (69.4%) and NaN (NaN) day*copies / μg DNA, respectively.
[0592] 3. Antibody PK
[0593] C-BCMA-CAR-PG-01: The geometric mean (coefficient of variation) of peak drug concentration (Cmax) in the 0.3 mg / kg (N=3) and 1 mg / kg (N=3) dose groups were 4.88 (97.2%) and 9.89 (71.9%) μg / mL, respectively; the geometric mean (coefficient of variation) of the area under the plasma concentration-time curve (AUC0-last) were 200 (132.4) and 117.6 (127%) μg·h / mL, respectively; the geometric mean (coefficient of variation) of clearance (CL) were NaN (NaN) and 0.000671 (104.9%) L / h / kg, respectively; the geometric mean (coefficient of variation) of half-life (t1 / 2) were NaN (NaN) and 88.9 (133.6%) h, respectively. Within the dose range of 0.3 to 1 mg / kg, target-mediated drug elimination dominated and ADI-38497 PG antibody was rapidly cleared.
[0594] C-BCMA-CAR-PG-02: The geometric mean (coefficient of variation) of peak drug concentration (Cmax) in the 0.1 mg / kg (N=1), 0.3 mg / kg (N=3) and 1 mg / kg (N=1) dose groups were 1.95 (NaN), 3.99 (58.1%) and 7.83 (NaN) μg / mL, respectively; the geometric mean (coefficient of variation) of the area under the plasma concentration-time curve (AUC0-last) were 20.2 (NaN), 23.8 (82.4%) and 30 (NaN) μg·h / mL, respectively; the geometric mean (coefficient of variation) of clearance (CL) were 0.00439 (NaN), NaN (NaN) and NaN (NaN) L / h / kg, respectively; the geometric mean (coefficient of variation) of half-life (t1 / 2) were 9.79 (NaN), NaN (NaN) and NaN (NaN) h, respectively. Within the dose range of 0.1 to 1 mg / kg, target-mediated drug elimination dominated and ADI-38497 PG antibody was rapidly cleared.
[0595] At the current dose, the target-mediated drug elimination effect is obvious. Based on this, it is recommended that the QW dosing frequency of antibodies in the first cycle will be more conducive to maintaining effective antibody concentrations.
[0596] 4. Safety data:
[0597] In the C-BCMA-CAR-PG-01 study, 5 subjects experienced treatment related adverse events (TRAEs). The most common TRAEs were decreased neutrophil count (5 cases, 83.3%), decreased lymphocyte count (5 cases, 83.3%), decreased white blood cell count (5 cases, 83.3%), and decreased platelet count (5 cases, 83.3%).
[0598] In the C-BCMA-CAR-PG-02 study, TRAEs occurred in 5 subjects, with the most common TRAEs being decreased neutrophil count (5 cases, 100%), decreased white blood cell count (5 cases, 100%), decreased platelet count (5 cases, 100%), and anemia (5 cases, 100%).
[0599] Based on the above non-clinical study results, mechanism of action, previous clinical research experience of similar drugs and preliminary clinical safety data, it is proved that the product of the present invention achieves a relatively good effect in terms of safety:
[0600] (1) CRS: As of the data cutoff date, in the two studies, 5 of the 11 subjects developed CRS of varying degrees, with a CRS incidence of 45.5%, which is lower than that of existing BCMA-CART products. Under the current circumstances, the CRS that have occurred are relatively controllable, and the subjects have improved or been cured after treatment;
[0601] (2) ICANS (immune effector cell-associated neurotoxicity syndrome): As of the data cutoff date, no neurological toxicity events were observed in the two studies. Overall, BCMA-CAR-PG has good safety and tolerability, and the incidence of CRS and ICANS is lower than that of existing products.
[0602] (3)(3) Clinical results show that CART cells in the bodies of subjects who have been administered this product can be maintained for a longer period of time, which has certain guiding significance for the clinical treatment effect.
[0603] Example 15. Typical case
[0604] Typical case 1: C-BCMA-CAR-PG-02 subject, female, 46 years old, IgG-κ multiple myeloma, DS stage III, no extramedullary lesions, previously received 7 chemotherapy regimens including proteasome inhibitors, immunomodulators, and glucocorticoids. The baseline bone marrow plasma cell ratio was 31%. The patient signed the informed consent form on June 16, 2022, and received 0.1 mg / kg of antibody and 2*10 cells. 6 / kg dose group. Mononuclear cells were collected on June 27, 2022, and the first antibody and cell transfusion was performed on August 9, 2022. The second and third antibody administrations of the first cycle were performed on August 16 and 23, 2022, respectively; the second and third antibody administrations were performed on August 30, 2022 and September 20, 2022; the fourth and fifth cycles were missed due to the epidemic; the sixth cycle was administered on November 28, 2022; the seventh and eighth cycles were missed due to the epidemic; the ninth and tenth cycles were administered on February 3, 2023 and February 23, 2022. The patient's tumor evaluation result at 1 month was PR, and the tumor evaluation results at 3 months and 6 months were VGPR, and the patient is in sustained remission. The patient's cell PK results are as follows Fig.18 , D15 reached the peak of amplification, the level was 10 5 The patient's CAR-T persistence was good, and CAR-T could still be detected half a year after the reinfusion, with a level of 10 3 About 10 days after cell transfusion, the patient's cytokines, including IL-6, IL-10, IL-2R, and TNF-α, showed a significant peak, and then dropped to the normal range around 15 days. The patient developed grade 1 CRS on the 9th day after transfusion, which lasted for 6 days before remission.
[0605] Typical case 2: C-BCMA-CAR-PG-01 subject, male, 43 years old, with κ light chain multiple myeloma, DS stage III-A, and extramedullary lesions. The proportion of bone marrow plasma cells at baseline was 0.5%. The patient signed the informed consent form on April 27, 2022, and received 0.3 mg / kg of antibody and 2*10 cells. 6 The patient received mononuclear cells on May 11, 2022, the first antibody infusion on June 20, 2022, and the cell infusion on June 21, 2022. The antibody was subsequently administered every three weeks, for a total of 9 cycles of antibody administration. The patient's tumor evaluation result was SD 3 weeks after administration, and the efficacy evaluation was PR 9 weeks after administration. The disease progressed after PR lasted for 7 months. The patient's cell PK results are as follows Fig. 20 , D15 reached the peak of amplification, the level was 10 5 About 10 days after cell transfusion, the cytokines, including IL-6, IL-10, and TNF-α, showed a significant peak, and then dropped to the normal range around 15 days later ( Fig.21 ).
[0606] The exemplary embodiments of the present invention are described above, and it should be understood by those skilled in the art that these disclosures are only exemplary, and various other substitutions, adaptations and modifications can be made within the scope of the present invention. Therefore, the present invention is not limited to the specific embodiments listed herein.
[0607] Exemplary sequences
[0608]
[0609]
[0610]
[0611]
Claims
1. A method of treating multiple myeloma in an individual, comprising administering to the individual a drug combination comprising (i) T cells expressing a molecular switch-regulated CAR polypeptide, i.e., CAR-T cells, wherein the CAR polypeptide comprises a humanized anti-P329G mutant scFv sequence that is capable of specifically binding to an antibody Fc domain comprising a P329G mutation, but is unable to specifically bind to an unmutated parent antibody Fc domain; (ii) an antibody or antigen-binding fragment that specifically binds to a BCMA molecule comprising a P329G mutation, wherein the P329G mutant antibody comprises a mutant Fc domain, wherein the amino acid at position P329 according to EU numbering is mutated to glycine (G); Among them, about 0.5×10 6 cells / kg body weight - approximately 5×10 6 The CAR-T cells are administered at a dosage unit of about 0.1-3 mg / kg body weight, and the antibody or antigen-binding fragment is administered in a dosage unit of about 0.1-3 mg / kg.
2. The method of claim 1, comprising administering CAR-T cells and the antibody or antigen-binding fragment thereof in a dosage regimen as follows: In the first cycle, the antibody or antigen-binding fragment thereof is administered on the first day, and the CAR-T cells are administered at an interval of 1-5 hours or the CAR-T cells are administered on the second day (e.g., at an interval of 24 hours); and the antibody or antigen-binding fragment thereof is administered every 1 week (QW), 2 weeks (Q2W), or every 3 weeks (Q3W) starting from the first day; and Optionally, the second cycle to the nth cycle: in each cycle, the antibody or antigen-binding fragment thereof is administered every three weeks (Q3W), wherein n=2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 or more.
3. The method of claim 2, wherein each administration cycle is 21 days or 28 days.
4. The method of any one of claims 1 to 3, wherein the CAR-T cells are present at approximately 0.75×10 6 cells / kg body weight, 1×10 6 cells / kg body weight, 1.5×10 6 cells / kg body weight, 2×10 6 cells / kg body weight, 2.5×10 6 cells / kg body weight, 3×10 6 cells / kg body weight, 3.5×10 6 cells / kg body weight, 4×10 6 cells / kg body weight, 4.5×10 6 cells / kg body weight, 5×10 6 The cells / kg body weight are administered to the subject, preferably in a single administration.
5. The method of any one of claims 1-4, wherein the antibody or antigen-binding fragment thereof is administered in a single dose unit of about 0.1 mg / kg, 0.2 mg / kg, 0.3 mg / kg, 0.4 mg / kg, 0.5 mg / kg, 1 mg / kg, 1.5 mg / kg, 2 mg / kg, 2.5 mg / kg, 3 mg / kg.
6. The method of any one of claims 1-5, wherein the CAR-T cells and the antibody or antigen-binding fragment thereof are administered intravenously.
7. The method of any one of claims 1-6, wherein the individual undergoes a lymphodepletion regimen prior to administration of the antibody or antigen-binding fragment thereof.
8. The method of claim 7, wherein the lymphodepleting regimen comprises administration of cyclophosphamide and fludarabine.
9. The method of claim 7 or 8, wherein the lymphodepletion regimen is initiated between 3-5 days prior to administration of the antibody or antigen-binding fragment thereof.
10. The method of any one of claims 7 to 9, wherein the lymphodepletion regimen lasts for about 1 to 5 days, such as about 3 days.
11. The method of any one of claims 1-10, wherein the antibody or antigen-binding fragment that specifically binds to the BCMA molecule comprising the P329G mutation comprises a heavy chain variable region and a light chain variable region, wherein The heavy chain variable region comprises CDRH1 shown by the amino acid sequence SSSYYWT (SEQ ID NO:25) according to the Kabat numbering; CDR H2 shown by the amino acid sequence SISIAGSTYYNPSLKS (SEQ ID NO:26); and CDR H3 shown by the amino acid sequence DRGDQILDV (SEQ ID NO:27); the light chain variable region comprises CDR L1 shown by the amino acid sequence RASQSISRYLN (SEQ ID NO:28) according to the Kabat numbering; CDR L2 shown by the amino acid sequence AASSLQS (SEQ ID NO:29); and CDR L3 shown by the amino acid sequence QQKYFDIT (SEQ ID NO:30).
12. The method of claim 11, wherein The heavy chain variable region comprises the sequence of SEQ ID NO:2, or a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, and the light chain variable region comprises the sequence of SEQ ID NO:3, or a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.
13. The method of claim 12, wherein The heavy chain variable region comprises or consists of the sequence of SEQ ID NO:2, and the light chain variable region comprises or consists of the sequence of SEQ ID NO:
3.
14. The method of any one of claims 11 to 13, wherein the Fc domain is selected from the Fc domain of IgG1, IgG2, IgG3 or IgG4, such as the Fc domain of IgG1.
15. The method of claim 14, wherein the Fc domain comprises the amino acid sequence of SEQ ID NO: 10, or has at least 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity thereto and comprises a P329G mutation.
16. The method of any one of claims 1-15, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain constant region comprising the amino acid sequence shown in SEQ ID NO:5, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto and wherein the amino acid at position P329 according to EU numbering is mutated to G.
17. The method of any one of claims 1-16, wherein the antibody or antigen-binding fragment thereof comprises a light chain constant region comprising the amino acid sequence shown in SEQ ID NO:6 or a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.
18. The method of claim 17, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain constant region and a light chain constant region, wherein the heavy chain constant region comprises or consists of the amino acid sequence shown in SEQ ID NO:5, and the light chain constant region comprises or consists of the amino acid sequence shown in SEQ ID NO:
6.
19. The method of any one of claims 1-18, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence shown in SEQ ID NO:34, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto and wherein the amino acid at position P329 according to EU numbering is mutated to G.
20. The method of any one of claims 1-19, wherein the antibody or antigen-binding fragment thereof comprises a light chain comprising the amino acid sequence shown in SEQ ID NO:35, or a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.
21. The method of claim 20, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain and a light chain, wherein the heavy chain comprises or consists of the amino acid sequence shown in SEQ ID NO:34, and the light chain comprises or consists of the amino acid sequence shown in SEQ ID NO:
35.
22. The method of any one of claims 1-21, wherein the molecular switch-regulated CAR polypeptide comprises a humanized anti-P329G mutant scFv sequence, wherein the scFv sequence comprises (i) a heavy chain variable region comprising a (a) CDR H1 represented by the amino acid sequence RYWMN (SEQ ID NO: 19); (b) CDR H2 represented by the amino acid sequence EITPDSSTINYAPSLKG (SEQ ID NO: 20); and (c) CDR H3 represented by the amino acid sequence PYDYGAWFAS (SEQ ID NO: 21); and (ii) a light chain variable region comprising a (d) CDR L1 represented by the amino acid sequence RSSTGAVTTSNYAN (SEQ ID NO: 22); (e) CDR L2 represented by the amino acid sequence GTNCRAP (SEQ ID NO: 23); and (f) CDR L3 represented by the amino acid sequence ALWYSNHWV (SEQ ID NO: 24).
23. The method of claim 22, wherein the scFv comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises the sequence of SEQ ID NO: 12, or a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, and the light chain variable region comprises the sequence of SEQ ID NO: 13, or a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.
24. The method of claim 23, wherein the heavy chain variable region comprises or consists of the sequence of SEQ ID NO: 12, and the light chain variable region comprises or consists of the sequence of SEQ ID NO:
13.
25. The method of any one of claims 1-24, wherein the CAR polypeptide comprises: (1) a hinge region / spacer region selected from (i)(G4S) n 、(SG4) n or G4(SG4) n A peptide linker, wherein "n" is an integer from 1 to 4, such as the sequence shown in SEQ ID NO: 14; (ii) the CD8α hinge region sequence shown in SEQ ID NO: 18 or a variant thereof having one amino acid modification; (2) a transmembrane region (TM) selected from the CD8 transmembrane domain shown in SEQ ID NO: 15 or a variant thereof having one amino acid modification; (3) a co-stimulatory signaling domain (CSD) selected from the 4-1BB co-stimulatory domain shown in SEQ ID NO: 16 or a variant thereof having one amino acid modification; (4) a stimulatory signaling domain (SSD) selected from the CD3δ signaling domain shown in SEQ ID NO: 17 or a variant thereof having one amino acid modification, The amino acid modification is the addition, deletion or substitution of amino acids.
26. The method of any one of claims 1-25, wherein the molecular switch-regulated CAR polypeptide further comprises a signal peptide sequence located at the N-terminus, for example, the signal peptide sequence shown in SEQ ID NO:
11.
27. The method of any one of claims 1-26, wherein the molecular switch-regulated CAR polypeptide has an amino acid sequence as shown in SEQ ID NO: 1 or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto.
28. The method of any one of claims 1-27, wherein the CAR-T cell comprises a nucleic acid molecule encoding the CAR polypeptide.
29. The method of any one of claims 1-28, wherein the multiple myeloma is refractory multiple myeloma.
30. The method of any one of claims 1-28, wherein the multiple myeloma is relapsed multiple myeloma.
31. The method of any one of claims 1-28, wherein the multiple myeloma is refractory and relapsed multiple myeloma.
32. The method of any one of claims 1-31, wherein the individual has been through at least three prior therapies for multiple myeloma.
33. The method of any one of claims 1-32, wherein the individual has been treated with at least three prior therapies for multiple myeloma including treatment with a proteasome inhibitor and an immunomodulatory agent.
